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INTRODUCTION
Synchronous, coordinate contraction of the ventricles, as established by normal conduction in
healthy hearts, is important for good cardiac pump function. Under physiological circumstances,
the electrical impulse originating from the sinus node in the right atrium passes the
atrioventricular (AV) node, and is then rapidly conducted via the specialized His-Purkinje
conduction system to both ventricles simultaneously. This results in almost synchronous electrical
activation and, consequently, in a coordinate contraction of the myocytes.
Dyssynchrony may deteriorate cardiac function
In hearts with a partially disrupted conduction system, as well as in ventricularly paced hearts,
the physiological pattern of electrical ventricular activation is adversely affected. The delayed left
ventricular (LV) electrical activation in left bundle branch block (LBBB) is accompanied by
abnormal dyssynchronous mechanical interactions within the LV.1, 2 The sequence of activation
in conventional, right ventricular (RV), pacing resembles the pattern as in LBBB.3 Both, intrinsic
and pacing-induced LBBB, are associated with impairment of LV function, structural remodelling
of the LV, and an increased risk for heart failure.4-9 Efforts should be made to better treat, as well
as to prevent, cardiac deterioration originating from either intrinsic or pacing-induced
dyssynchrony.
Cardiac resynchronization therapy
Cardiac resynchronization therapy (CRT) aims to reverse the deleterious effects that may originate
from LV dyssynchrony, by restoration of a more coordinated contraction pattern by means of
biventricular (BiV) pacing. Biventricular pacing improves clinical presentation, reduces mortality,
reverses LV remodeling and improves LV function in the majority of patients with severe LV
dysfunction and severe clinical heart failure associated with either LBBB,10-15 or RV pacing-induced
dyssynchrony.16, 17 Consequently, CRT is nowadays incorporated in the management of severe LV
dysfunction and clinical heart failure associated with dyssynchrony. However, the individual
response to CRT varies widely between patients, with inadequate response in up to 30-50% of
the patients receiving CRT. The proportion of these ‘non-responders’ may be diminished by
individual optimization of CRT-delivery and better pre-implant selection of CRT-candidates. At
the other hand, also patients with less severe heart failure might benefit from CRT, but they do
currently not fulfill the criteria to receive this therapy. Conceivably the question may arise
whether the indication criteria for CRT should be extended. In deduction, several aspects of CRT
should be optimized to increase the overall success rate and the individual benefits of CRT.
General Introduction
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Chronic ventricular pacing for complete atrioventricular block
In patients with congenital or acquired complete atrioventricular (AV) block, ventricular pacing is
indicated to increase heart rate. An important side effect of ventricular pacing is the induction of
abnormal electrical activation patterns, which may cause mechanical dyssynchrony. In contrast to
adults with intrinsic LBBB, the objective in pediatric patients with isolated AV block should be to
prevent pacing-induced dyssynchrony, rather than to treat dyssynchrony. Conventionally,
ventricular pacemaker leads are positioned in or at the RV. Chronic RV pacing is associated with
an acute and chronic impairment of LV function, structural remodeling of the LV, and increased
risk of heart failure.8, 18-22 Overt heart failure is reported in about 7%, and impaired LV function
in up to 13% of the chronically RV-paced pediatric patients after follow-up for about one
decade.19, 23-25 The actual incidence of ventricular dysfunction in relation to chronic RV pacing
may in fact be higher for life-long follow-up. Therefore, in children requiring chronic ventricular
pacing, the prevention of pacing-induced functional and structural deterioration should be a
major aim. 
AIM OF THE THESIS
The general aim of the research presented in this thesis is to improve pacing therapy in adults
and children to better treat electromechanical ventricular dyssynchrony and to avoid pacing-
induced cardiac deterioration. 
Toward optimization of CRT to better treat dyssynchrony 
To improve treatment of dyssynchrony, optimization of CRT should be achieved in several
perspectives. First of all, in the broad perspective of ‘optimization of CRT’, it may be beneficial to
refine indication-criteria for CRT. We sought therefore to investigate the effect of BiV pacing in
patients who may benefit from (re)synchronization of electrical activation, but who do not meet
current indication criteria for CRT. Secondly, benefits induced by CRT may be improved by
tailoring of device-settings to the individual patient.26-29 However, procedures to optimize
device-settings, as well as measurements to guide these optimization procedures, are still under
debate. We sought for a patient-friendly non-invasive measurement to guide optimization
procedures.
Toward prevention of pacing-induced deterioration: ‘optimal-site pacing’
Especially in children the preservation of cardiac function during chronic ventricular pacing
should take high priority, because they have a perspective of life-long pacing. The awareness of
the potentially deleterious effects of conventional pacing has initiated the search for alternative
approaches for chronic ventricular pacing. The degree of pacing-induced dyssynchrony seems to
be a major determinant of cardiac pump function and appears to vary between the different
Chapter 1
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pacing sites.30-34 Aiming at the prevention of pacing-associated functional and structural
deterioration, we sought therefore to define strategies for ‘optimal’ chronic ventricular pacing in
the young.
OUTLINE OF THE THESIS
The general background and introduction to the studies presented in this thesis are given in
chapter 2. Herein, the importance of the sequence of activation and the pathophysiology of
ventricular pacing are elucidated. 
Pertaining to the aim to improve treatment of dyssynchrony, our research on the optimization of
CRT in adult patients is presented in chapters 3 and 4. In the perspective that CRT may also be
beneficial in patients with mild forms of dyssynchrony-associated LV dysfunction, we investigated
the effects of permanent BiV pacing and RV pacing in a cross-over study in previously chronically
RV paced patients with mild cardiomyopathy (chapter 3). With respect to optimization of CRT,
great clinical need exits for a harmless, patient friendly and easy-to-use technique suitable for
being applied in individual optimization procedures. We investigated whether Nexfin CO-Trek®
(BMEYE B.V., Amsterdam, Netherlands), a non-invasive method to continuously monitor
hemodynamics using a finger sensor, reliably measures beat-to-beat changes in stroke volume, as
well as immediate effects of CRT at various AV-delays and, hence, whether its use is feasible in the
individual optimization of CRT (chapter 4).
The studies with the objective to define better pacing-strategies aiming at prevention of pacing-
induced cardiac deterioration in children are presented in chapters 5-8. Given the acute
beneficial hemodynamic effects of single-site LV pacing shown by earlier studies of our group,32,
34, 35 we investigated whether chronic LV pacing is superior to RV pacing in children with
structurally normal hearts. A small pilot study is presented in which we surveyed LV function in
children with isolated AV block, undergoing chronic epicardial pacing at either the RV or LV
(chapter 5). Subsequently, influences of chronic ventricular pacing in children with isolated AV
block were retrospectively, as well as cross-sectionally, evaluated in a large observational multi-
center study (chapters 6 and 7). In patients with transposition of the great arteries treated by
atrial redirection surgery, we investigated the acute hemodynamic effects of conventional non-
systemic ventricular pacing, systemic ventricular pacing, and biventricular pacing (chapter 8).
In the last chapter of this thesis (chapter 9), the findings of above-mentioned studies are linked
and put in broader perspective. The first part of the general discussion concerns optimization of
CRT. In the second part, several sites for chronic ventricular pacing are reviewed and clinical
implications of these sites are discussed. 
General Introduction
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CONSEQUENCES OF ABNORMAL VENTRICULAR ELECTRICAL ACTIVATION
Normal electrical activation of the ventricles
In the normal heart coordinated mechanical contraction of the ventricular myocytes enables
pump function to circulate the blood through the lungs and body. Coordinate mechanical
contraction is induced by synchronous electrical activation of the myocardium via the specialized
cardiac conduction system. Under physiological circumstances, the electrical impulse originating
from the sinus node in the right atrium passes the atrioventricular (AV) node, and is then rapidly
conducted via the specialized His-Purkinje conduction system to both ventricles simultaneously.
This results in almost synchronous electrical activation and, consequently, in a coordinate
contraction of the myocytes. During normal activation, synchrony is observed between the
ventricles (interventricular synchrony) and within each ventricle (intraventricular synchrony).*
Left-intraventricular electrical synchrony during normal activation is illustrated by the left upper
panel of Figure 1. Intraventricular and interventricular synchrony may be disturbed by
pathological alterations in the sequence of electrical activation. These alterations may be induced
either intrinsically by ventricular pre-excitation or disruptions of the conduction system, or
artificially by ventricular stimulation (i.e., ventricular pacing). 
* Literally, “synchronous activation” denominates simultaneous activation of all ventricular
myocytes, which is not achieved under physiological circumstances. Despite the rapid
propagation (3-4 m/s) of the electrical impulse through the conduction tissue, activation of the
ventricular myocardium occurs over a certain amount of time. Normally, electrical activation
starts at the endocardium of the apex and progresses toward the epicardium, as well as
upwards to the base, resulting in a coordinated and energetically efficient mechanical
contraction, which is crucial for optimal left ventricular performance. Therefore, the term
“euchrony” would more correctly describe the normal timing and sequence of ventricular
activation under physiological conditions. However, “electrical synchrony” and “synchronous
activation” are generally used in the literature to denominate the physiological timing and
sequence of electrical activation and are accordingly used throughout this thesis.
Background of the Thesis
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Asynchronous electrical activation
In hearts with ventricular pacing for complete AV block, as well as in hearts with a partially
disrupted conduction system (e.g., left bundle branch block, LBBB), the initiation and the
sequence of electrical ventricular activation are different from those in normal physiology. In the
above-mentioned pathological circumstances, electrical activation of one or both ventricle(s)
occurs exclusively through the slowly transmitting myocardium, instead of also through the
rapidly conducting specialized conduction system. Slow cell-to-cell transmission of the electrical
impulse results in asynchrony of electrical ventricular activation, with early activation of the
myocytes close to the site where activation starts and delayed activation of the cells in remote
regions (Figure 1, right upper panel). Consequently, early systolic shortening of the early-
Chapter 2
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Figure 1 
Left ventricular endocardial activation in canine hearts
Electrical activation mapping using a left ventricular (LV) intraventricular mapping catheter in canine
experiments (described by Verbeek et al. JACC 2003),56 during normal activation, and while pacing from
the right ventricular (RV) apex, LV free wall, and LV apex, respectively. The electrical activation maps are
presented as bull’s eye plots with the inner disk representing the LV apex and the outer disk representing
the LV base. The letters A, P, S, and L indicate the anterior, posterior, septal, and lateral wall, respectively.
Electrical activation of the LV is fast and synchronous during normal activation. During ventricular pacing,
the region in the proximity of the pacing-site is early-activated, whereas myocardium remote from the
pacing site is late-activated. In LV apical pacing, electrical activation is circumferentially synchronous. * =
ventricular pacing-site.  
activated myocytes results in stretch of late-activated myocytes, rather than that it results in the
onset of the ejection phase. When myocytes in remote regions are subsequently activated and
start to contract, they contract even more powerfully due to the early systolic pre-stretching
(known as the local Frank-Starling mechanism).1, 2 Hence, electrical asynchrony, induced either
by intrinsic conduction delays or by ventricular pacing, results in a ‘dyssynchronous’ contraction
pattern, which is associated with a reduction in left ventricular (LV) pump function and an
asymmetric redistribution of mechanical workload in the myocardium. The latter results in a
redistribution of oxygen demand and perfusion, as well as in asymmetrical hypertrophy.1, 3-6
However, the extent and importance of mechanical dyssynchrony are dependent on the pattern of
electrical activation.2, 7
Right ventricular pacing, as well as intrinsic left bundle branch block, results
in ventricular dyssynchrony and is associated with cardiac deterioration
Traditionally, ventricular pacemaker leads are positioned at the right ventricle (RV), since the RV
apex and free wall are easily accessible, either at the epicardium via a surgical implantation or at
the endocardium by means of a transvenous approach. These RV pacing sites are readily
identified and associated with stable lead position and reliable capture. In hearts with normal
left-right anatomy, RV pacing results in an LBBB-pattern of activation.2, 8, 9 In both intrinsic and
RV pacing-induced LBBB-pattern the activation pattern is characterized by early activation of the
RV and septum and delayed activation of the LV lateral wall, implicating electrical and
mechanical asynchrony between the ventricles (interventricular asynchrony), as well as within
each ventricle (intraventricular asynchrony). When the RV free wall starts to contract before the
interventricular septum and the LV free wall, RV pressure increases before LV pressure is built up.
As a consequence of this abnormal early systolic pressure gradient over the interventricular
septum, the septum bulges into the LV, which can be observed as paradoxical movement of the
septum.10 Mechanical dyssynchrony resulting from either intrinsic or pacing-induced LBBB, is
associated with acute and chronic impairment of LV function, structural remodeling of the LV,
and increased risk of heart failure.2, 8, 11-17 Additionally, the adverse relation between LBBB-
dyssynchrony and cardiac function is illustrated by the findings that morbidity and mortality are
higher in chronic RV pacing when compared with atrial pacing only,18-21 and that prognosis is
worse for heart failure patients with LBBB than for those without.22 Above-mentioned
observations underline the importance of the efforts that should be made toward treatment and
prevention of dyssynchrony originating from either intrinsic or pacing-induced LBBB.
Toward treatment of dyssynchrony: cardiac resynchronization therapy 
Like normal patterns, adverse ventricular activation patterns can be manipulated by artificial
ventricular stimulation. Ventricular pacing in order to induce a more synchronous pattern of
activation in patients with dyssynchrony, is regularly referred to as ‘cardiac resynchronization
Background of the Thesis
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therapy’ (CRT). By restoring a more coordinated contraction pattern by artificial stimulation prior
to activation by means of abnormal intrinsic conduction, CRT aims to prevent adverse
dyssynchronous contraction patterns. Typically, CRT is achieved by means of biventricular (BiV)
pacing. The concept of electrical resynchronization is schematically represented in Figure 2. The
first full paper reporting clinical benefit of CRT was published by Cazeau et al. in 1994.23
Subsequently, beneficial effects of BiV pacing in severe heart failure patients with wide QRS
complex have consistently been reported by several clinical studies.24-26 Shortly after BiV pacing
has been approved for clinical application (United States Food and Drug Administration in 2001),
CRT has been recommended as an additional therapy for the treatment of patients with heart
failure in the 2002 update of the American College of Cardiology/American Heart
Association/North American Society of Pacing and Electrophysiology (ACC/AHA/NASPE).27
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Figure 2
Schematic pathway of ventricular activation fronts
Schematic pathway of different ventricular activation fronts during normal conduction, left bundle branch
block (LBBB) and LBBB with biventricular pacing. During normal conduction (left), activation of right
ventricle (RV) and left ventricle (LV) occurs through intrinsic activation, and the time of activation (TRV and
TLV) is similar. During LBBB (middle), activation to the LV lateral wall (TLV) is delayed because it occurs only
by slow myocardial conduction (TRV–LV). During biventricular (BiV) pacing (right) RV and LV lateral wall can
be activated by a pacing stimulus (TA–RVpace and TA–LVpace, respectively) if this stimulation occurs before
intrinsic activation. (After Vernooy et al. Heart Rhythm. 2007 Jan;4(1):75-82., with permission).57
Nowadays, CRT constitutes an established way of treatment for patients suffering from severe
heart failure associated with conduction disturbances. Biventricular pacing improves LV function
and reverses LV remodeling, as well as it improves clinical presentation and reduces mortality28
in the majority of patients with severe LV dysfunction and severe clinical heart failure associated
with either LBBB25,26, 29-32 or RV pacing-induced dyssynchrony.33-35 Therefore, BiV pacing is
strongly recommended in patients with severe LV dysfunction (LV ejection fraction (LVEF) <35%)
and moderate to severe clinical heart failure (NYHA classification III-IV) associated with
ventricular dyssynchrony (QRS >120ms).36 Based on the basic principle of CRT to prevent the
heart from adverse dyssynchronous contraction patterns, CRT may also be beneficial in patients
with milder forms of dyssynchrony-associated LV dysfunction (chapter 3). 
Although collective benefit of CRT has been proven, appropriate individual response to CRT in terms
of increase in LVEF and substantial reduction of LV dilatation appears to be absent in up to 30-50%
of patients in whom CRT is applied.37 Individual response to CRT, and thus indirectly the overall
success rate of CRT, could be improved by optimization of device settings. Ever since the first
applications, devices for CRT have become significantly more sophisticated and include nowadays the
capability to independently program atrioventricular (AV) and interventricular (ventriculo-ventricular;
VV) stimulation timing intervals. It has been shown that alterations in AV- or VV intervals acutely and
significantly influence cardiac function.38-41 Although tailoring the AV-delay and VV-interval to the
individual patient may increase the haemodynamic improvement and long-term benefits brought by
CRT, the best way to guide, as well as to perform, optimization of these device settings is still under
debate. Besides the need for an evidence-based protocol for optimization, there is great clinical need
for a harmless, patient friendly and easy-to-use technique, suitable to guide individual optimization of
CRT (chapter 4). 
Toward prevention of pacing-induced dyssynchrony: optimal-site pacing
In patients with complete AV block and bradycardia, ventricular pacing is indicated to increase
heart rate, rather than to ‘resynchronize’ electrical activation. In addition to the obvious
beneficial effects of the restoration of heart rate, chronic ventricular pacing cures the risk of
sudden cardiac death and LV failure associated with untreated complete heart block.42, 43
Therefore, AV block associated with symptomatic bradycardia is a class I indication for ventricular
pacing therapy.44 Conventional RV pacing, however, induces an abnormal electrical activation
pattern which causes mechanical dyssynchrony and is associated with impairment of pump
function, LV remodeling, and increased risk of heart failure.2, 8, 13, 14, 16, 17, 45 Right ventricular
pacing, rather than etiology of AV block, has even been identified as an independent risk factor
for the development of LV dilatation and dysfunction following chronic pacing.46, 47
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Prevention of mechanical dyssynchrony, and thus prevention of functional as well as structural
deterioration, seems a new major challenge in patients that require chronic ventricular pacing.
Above and beyond total activation time, the pattern of electrical activation is described by the
sequence of activation in apex-base, left-right and endocard-epicard directions. This activation-
pattern seems to be a major determinant for cardiac pump function.2, 48 During LV pacing in
structural normal hearts, the LV lateral wall is activated prior to the septum and RV lateral wall,
preventing the septum from paradoxical movements and resulting in superior hemodynamic
performance as compared to RV pacing.10 On top of that, a physiological apex-to-base sequence
of activation is induced by LV apical pacing, which results in synchronous electrical activation and
contraction at the circumferential level of the LV (Figure 1, lower panels).49, 50 In the acute setting
of animal experiments and explorations in children undergoing cardiac surgery, LV apical pacing
increases pump function when compared with RV pacing.51 In adult patients, single-site LV
pacing has been shown to induce improvement in LV function comparable to the improvement
by BiV pacing.52-54 Moreover, in a young child with severe LV failure following chronic RV pacing,
impressive improvement of LV function and diameter was observed during chronic LV pacing.55
In deduction, the LV seems to provide promising alternative sites for chronic ventricular pacing
(chapter 5-7).  
Chapter 2
26
REFERENCES
1. Delhaas T, Arts T, Prinzen FW, Reneman RS. Regional fibre stress-fibre strain area as an estimate
of regional blood flow and oxygen demand in the canine heart. J Physiol 1994; 477 ( Pt 3):481-
496.
2. Prinzen FW, Peschar M. Relation between the pacing induced sequence of activation and left
ventricular pump function in animals. Pacing Clin Electrophysiol 2002; 25(4 Pt 1):484-498.
3. Prinzen FW, Augustijn CH, Arts T, Allessie MA, Reneman RS. Redistribution of myocardial fiber
strain and blood flow by asynchronous activation. Am J Physiol 1990; 259(2 Pt 2):H300-308.
4. van Oosterhout MF, Prinzen FW, Arts T, Schreuder JJ, Vanagt WY, Cleutjens JP, Reneman RS.
Asynchronous electrical activation induces asymmetrical hypertrophy of the left ventricular wall.
Circulation 1998; 98(6):588-595.
5. Prinzen FW, Hunter WC, Wyman BT, McVeigh ER. Mapping of regional myocardial strain and
work during ventricular pacing: experimental study using magnetic resonance imaging tagging.
J Am Coll Cardiol 1999; 33(6):1735-1742.
6. van Oosterhout MF, Arts T, Bassingthwaighte JB, Reneman RS, Prinzen FW. Relation between local
myocardial growth and blood flow during chronic ventricular pacing. Cardiovasc Res 2002;
53(4):831-840.
7. Prinzen FW, Van Oosterhout MF, Vanagt WY, Storm C, Reneman RS. Optimization of ventricular
function by improving the activation sequence during ventricular pacing. Pacing Clin Electrophysiol
1998; 21(11 Pt 2):2256-2260.
8. Karpawich PP. Chronic right ventricular pacing and cardiac performance: the pediatric perspective.
Pacing Clin Electrophysiol 2004; 27(6 Pt 2):844-849.
9. Manolis AS. The deleterious consequences of right ventricular apical pacing: time to seek alternate
site pacing. Pacing Clin Electrophysiol 2006; 29(3):298-315.
10. Little WC, Reeves RC, Arciniegas J, Katholi RE, Rogers EW. Mechanism of abnormal interventricular
septal motion during delayed left ventricular activation. Circulation 1982; 65(7):1486-1491.
11. Prinzen FW, Cheriex EC, Delhaas T, van Oosterhout MF, Arts T, Wellens HJ, Reneman RS.
Asymmetric thickness of the left ventricular wall resulting from asynchronous electric activation:
a study in dogs with ventricular pacing and in patients with left bundle branch block. Am Heart
J 1995; 130(5):1045-1053.
12. Karpawich PP, Mital S. Comparative left ventricular function following atrial, septal, and apical
single chamber heart pacing in the young. Pacing Clin Electrophysiol 1997; 20(8 Pt 1):1983-1988.
13. Moak JP, Barron KS, Hougen TJ, Wiles HB, Balaji S, Sreeram N, Cohen MH, Nordenberg A, Van
Hare GF, Friedman RA, Perez M, Cecchin F, Schneider DS, Nehgme RA, Buyon JP. Congenital heart
block: development of late-onset cardiomyopathy, a previously underappreciated sequela. J Am
Coll Cardiol 2001; 37(1):238-242.
Background of the Thesis
27
14. Tantengco MV, Thomas RL, Karpawich PP. Left ventricular dysfunction after long-term right
ventricular apical pacing in the young. J Am Coll Cardiol 2001; 37(8):2093-2100.
15. Vernooy K, Verbeek XA, Peschar M, Prinzen FW. Relation between abnormal ventricular impulse
conduction and heart failure. J Interv Cardiol 2003; 16(6):557-562.
16. Thambo JB, Bordachar P, Garrigue S, Lafitte S, Sanders P, Reuter S, Girardot R, Crepin D, Reant P,
Roudaut R, Jais P, Haissaguerre M, Clementy J, Jimenez M. Detrimental ventricular remodeling in
patients with congenital complete heart block and chronic right ventricular apical pacing.
Circulation 2004; 110(25):3766-3772.
17. Janousek J, Tomek V, Chaloupecky V, Gebauer RA. Dilated cardiomyopathy associated with dual-
chamber pacing in infants: improvement through either left ventricular cardiac resynchronization
or programming the pacemaker off allowing intrinsic normal conduction. J Cardiovasc
Electrophysiol 2004; 15(4):470-474.
18. Andersen HR, Nielsen JC, Thomsen PE, Thuesen L, Mortensen PT, Vesterlund T, Pedersen AK.
Long-term follow-up of patients from a randomised trial of atrial versus ventricular pacing for
sick-sinus syndrome. Lancet 1997; 350(9086):1210-1216.
19. Nielsen JC, Andersen HR, Thomsen PE, Thuesen L, Mortensen PT, Vesterlund T, Pedersen AK.
Heart failure and echocardiographic changes during long-term follow-up of patients with sick
sinus syndrome randomized to single-chamber atrial or ventricular pacing. Circulation 1998;
97(10):987-995.
20. Wilkoff BL, Cook JR, Epstein AE, Greene HL, Hallstrom AP, Hsia H, Kutalek SP, Sharma A. Dual-
chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the
Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA 2002; 288(24):3115-3123.
21. Sweeney MO, Hellkamp AS, Ellenbogen KA, Greenspon AJ, Freedman RA, Lee KL, Lamas GA.
Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with
normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction.
Circulation 2003; 107(23):2932-2937.
22. Zannad F, Huvelle E, Dickstein K, van Veldhuisen DJ, Stellbrink C, Kober L, Cazeau S, Ritter P,
Maggioni AP, Ferrari R, Lechat P. Left bundle branch block as a risk factor for progression to heart
failure. Eur J Heart Fail 2007; 9(1):7-14.
23. Cazeau S, Ritter P, Bakdach S, Lazarus A, Limousin M, Henao L, Mundler O, Daubert JC, Mugica
J. Four chamber pacing in dilated cardiomyopathy. Pacing Clin Electrophysiol 1994; 17(11 Pt
2):1974-1979.
24. Leclercq C, Cazeau S, Le Breton H, Ritter P, Mabo P, Gras D, Pavin D, Lazarus A, Daubert JC. Acute
hemodynamic effects of biventricular DDD pacing in patients with end-stage heart failure. J Am
Coll Cardiol 1998; 32(7):1825-1831.
25. Cazeau S, Leclercq C, Lavergne T, Walker S, Varma C, Linde C, Garrigue S, Kappenberger L,
Haywood GA, Santini M, Bailleul C, Daubert JC. Effects of multisite biventricular pacing in patients
with heart failure and intraventricular conduction delay. N Engl J Med 2001; 344(12):873-880.
Chapter 2
28
26. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, Kocovic DZ, Packer M, Clavell
AL, Hayes DL, Ellestad M, Trupp RJ, Underwood J, Pickering F, Truex C, McAtee P, Messenger J,
the MSG. Cardiac Resynchronization in Chronic Heart Failure. N Engl J Med 2002; 346(24):1845-
1853.
27. Gregoratos G, Abrams J, Epstein AE, Freedman RA, Hayes DL, Hlatky MA, Kerber RE, Naccarelli
GV, Schoenfeld MH, Silka MJ, Winters SL, Gibbons RJ, Antman EM, Alpert JS, Gregoratos G,
Hiratzka LF, Faxon DP, Jacobs AK, Fuster V, Smith SC, Jr. ACC/AHA/NASPE 2002 guideline update
for implantation of cardiac pacemakers and antiarrhythmia devices: summary article: a report of
the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
(ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). Circulation 2002;
106(16):2145-2161.
28. Linde C, Abraham WT, Gold MR, St John Sutton M, Ghio S, Daubert C. Randomized trial of cardiac
resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with
left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol 2008;
52(23):1834-1843.
29. St John Sutton MG, Plappert T, Abraham WT, Smith AL, DeLurgio DB, Leon AR, Loh E, Kocovic DZ,
Fisher WG, Ellestad M, Messenger J, Kruger K, Hilpisch KE, Hill MR. Effect of cardiac
resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation
2003; 107(15):1985-1990.
30. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L. The effect
of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005;
352(15):1539-1549.
31. Daubert JC, Leclercq C, Donal E, Mabo P. Cardiac resynchronisation therapy in heart failure:
current status. Heart Fail Rev 2006; 11(2):147-154.
32. Donal E, Leclercq C, Linde C, Daubert JC. Effects of cardiac resynchronization therapy on disease
progression in chronic heart failure. Eur Heart J 2006; 27(9):1018-1025.
33. Leclercq C, Cazeau S, Lellouche D, Fossati F, Anselme F, Davy JM, Sadoul N, Klug D, Mollo L,
Daubert JC. Upgrading from single chamber right ventricular to biventricular pacing in
permanently paced patients with worsening heart failure: The RD-CHF Study. Pacing Clin
Electrophysiol 2007; 30 Suppl 1:S23-30.
34. Laurenzi F, Achilli A, Avella A, Peraldo C, Orazi S, Perego GB, Cesario A, Valsecchi S, De Santo T,
Puglisi A, Tondo C. Biventricular upgrading in patients with conventional pacing system and
congestive heart failure: results and response predictors. Pacing Clin Electrophysiol 2007;
30(9):1096-1104.
35. Shimano M, Tsuji Y, Yoshida Y, Inden Y, Tsuboi N, Itoh T, Suzuki H, Muramatsu T, Okada T, Harata
S, Yamada T, Hirayama H, Nattel S, Murohara T. Acute and chronic effects of cardiac
resynchronization in patients developing heart failure with long-term pacemaker therapy for
acquired complete atrioventricular block. Europace 2007; 9(10):869-874.
Background of the Thesis
29
36. Vardas PE, Auricchio A, Blanc JJ, Daubert JC, Drexler H, Ector H, Gasparini M, Linde C, Morgado
FB, Oto A, Sutton R, Trusz-Gluza M. Guidelines for cardiac pacing and cardiac resynchronization
therapy. The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European
Society of Cardiology. Developed in collaboration with the European Heart Rhythm Association.
Europace 2007; 9(10):959-998.
37. Young JB, Abraham WT, Smith AL, Leon AR, Lieberman R, Wilkoff B, Canby RC, Schroeder JS, Liem
LB, Hall S, Wheelan K. Combined cardiac resynchronization and implantable cardioversion defibrillation
in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA 2003; 289(20):2685-2694.
38. Auricchio A, Stellbrink C, Block M, Sack S, Vogt J, Bakker P, Klein H, Kramer A, Ding J, Salo R,
Tockman B, Pochet T, Spinelli J. Effect of pacing chamber and atrioventricular delay on acute
systolic function of paced patients with congestive heart failure. The Pacing Therapies for
Congestive Heart Failure Study Group. The Guidant Congestive Heart Failure Research Group.
Circulation 1999; 99(23):2993-3001.
39. Auricchio A, Stellbrink C, Sack S, Block M, Vogt J, Bakker P, Huth C, Schondube F, Wolfhard U,
Bocker D, Krahnefeld O, Kirkels H. Long-term clinical effect of hemodynamically optimized cardiac
resynchronization therapy in patients with heart failure and ventricular conduction delay. J Am Coll
Cardiol 2002; 39(12):2026-2033.
40. Whinnett ZI, Davies JE, Willson K, Manisty CH, Chow AW, Foale RA, Davies DW, Hughes AD, Mayet
J, Francis DP. Haemodynamic effects of changes in atrioventricular and interventricular delay in
cardiac resynchronisation therapy show a consistent pattern: analysis of shape, magnitude and
relative importance of atrioventricular and interventricular delay. Heart 2006; 92(11):1628-1634.
41. Perego GB, Chianca R, Facchini M, Frattola A, Balla E, Zucchi S, Cavaglia S, Vicini I, Negretto M,
Osculati G. Simultaneous vs. sequential biventricular pacing in dilated cardiomyopathy: an acute
hemodynamic study. Eur J Heart Fail 2003; 5(3):305-313.
42. Udink ten Cate FE, Breur JM, Cohen MI, Boramanand N, Kapusta L, Crosson JE, Brenner JI, Lubbers
LJ, Friedman AH, Vetter VL, Meijboom EJ. Dilated cardiomyopathy in isolated congenital complete
atrioventricular block: early and long-term risk in children. J Am Coll Cardiol 2001; 37(4):1129-1134.
43. Michaelsson M, Riesenfeld T, Jonzon A. Natural history of congenital complete atrioventricular
block. Pacing Clin Electrophysiol 1997; 20(8 Pt 2):2098-2101.
Chapter 2
30
44. Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA, 3rd, Freedman RA, Gettes LS, Gillinov AM,
Gregoratos G, Hammill SC, Hayes DL, Hlatky MA, Newby LK, Page RL, Schoenfeld MH, Silka MJ,
Stevenson LW, Sweeney MO, Smith SC, Jr., Jacobs AK, Adams CD, Anderson JL, Buller CE, Creager
MA, Ettinger SM, Faxon DP, Halperin JL, Hiratzka LF, Hunt SA, Krumholz HM, Kushner FG, Lytle
BW, Nishimura RA, Ornato JP, Page RL, Riegel B, Tarkington LG, Yancy CW. ACC/AHA/HRS 2008
Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American
College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing
Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac
Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American
Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol 2008;
51(21):e1-62.
45. Kim JJ, Friedman RA, Eidem BW, Cannon BC, Arora G, Smith EO, Fenrich AL, Kertesz NJ.
Ventricular function and long-term pacing in children with congenital complete atrioventricular
block. J Cardiovasc Electrophysiol 2007; 18(4):373-377.
46. Karpawich PP, Rabah R, Haas JE. Altered cardiac histology following apical right ventricular pacing
in patients with congenital atrioventricular block. Pacing Clin Electrophysiol 1999; 22(9):1372-
1377.
47. Gebauer RA, Tomek V, Salameh A, Marek J, Chaloupecky V, Gebauer R, Matejka T, Vojtovic P,
Janousek J. Predictors of left ventricular remodelling and failure in right ventricular pacing in the
young. Eur Heart J 2009; 30(9):1097-1104.
48. Puggioni E, Brignole M, Gammage M, Soldati E, Bongiorni MG, Simantirakis EN, Vardas P, Gadler
F, Bergfeldt L, Tomasi C, Musso G, Gasparini G, Del Rosso A. Acute comparative effect of right
and left ventricular pacing in patients with permanent atrial fibrillation. J Am Coll Cardiol 2004;
43(2):234-238.
49. Wyman BT, Hunter WC, Prinzen FW, Faris OP, McVeigh ER. Effects of single- and biventricular
pacing on temporal and spatial dynamics of ventricular contraction. Am J Physiol Heart Circ Physiol
2002; 282(1):H372-379.
50. Peschar M, de Swart H, Michels KJ, Reneman RS, Prinzen FW. Left ventricular septal and apex
pacing for optimal pump function in canine hearts. J Am Coll Cardiol 2003; 41(7):1218-1226.
51. Vanagt WY, Verbeek XA, Delhaas T, Mertens L, Daenen WJ, Prinzen FW. The left ventricular apex
is the optimal site for pediatric pacing: correlation with animal experience. Pacing Clin
Electrophysiol 2004; 27(6 Pt 2):837-843.
52. Auricchio A. Pacing the left ventricle: does underlying rhythm matter? J Am Coll Cardiol 2004;
43(2):239-240.
53. Etienne Y, Mansourati J, Gilard M, Valls-Bertault V, Boschat J, Benditt DG, Lurie KG, Blanc JJ.
Evaluation of left ventricular based pacing in patients with congestive heart failure and atrial
fibrillation. Am J Cardiol 1999; 83(7):1138-1140, A1139.
Background of the Thesis
31
54. Touiza A, Etienne Y, Gilard M, Fatemi M, Mansourati J, Blanc JJ. Long-term left ventricular pacing:
assessment and comparison with biventricular pacing in patients with severe congestive heart
failure. J Am Coll Cardiol 2001; 38(7):1966-1970.
55. Vanagt WY, Prinzen FW, Delhaas T. Reversal of pacing-induced heart failure by left ventricular
apical pacing. N Engl J Med 2007; 357(25):2637-2638.
56. Verbeek XA, Vernooy K, Peschar M, Cornelussen RN, Prinzen FW. Intra-ventricular
resynchronization for optimal left ventricular function during pacing in experimental left bundle
branch block. J Am Coll Cardiol 2003; 42(3):558-567.
57. Vernooy K, Verbeek XA, Cornelussen RN, Dijkman B, Crijns HJ, Arts T, Prinzen FW. Calculation of
effective VV interval facilitates optimization of AV delay and VV interval in cardiac
resynchronization therapy. Heart Rhythm 2007; 4(1):75-82.
Chapter 2
32
Background of the Thesis
33
Irene E. van Geldorp 1,2
Kevin Vernooy 1,2
Tammo Delhaas 1,3
Martin H. Prins 4
Harry J.G.M. Crijns 1
Frits W. Prinzen 2
Barbara Dijkman 1
From the Departments of 1Cardiology and 2Physiology, Cardiovascular Research Institute
Maastricht (CARIM), Maastricht University Medical Center, Maastricht, The Netherlands;
3Department of Pediatrics, Maastricht University Medical Center, Maastricht, The Netherlands;
4Departments of Clinical Epidemiology and Medical Technology Assessment (KEMTA), Maastricht
University Medical Center, Maastricht, The Netherlands.
Europace 2010; 12(2):223-229
3B
en
ef
ic
ia
l E
ff
ec
ts
 o
f 
B
iv
en
tr
ic
u
la
r 
Pa
ci
n
g
 in
 
C
h
ro
n
ic
al
ly
 R
ig
h
t 
V
en
tr
ic
u
la
r 
Pa
ce
d
 P
at
ie
n
ts
 
w
it
h
 M
ild
 C
ar
d
io
m
yo
p
at
h
y
ABSTRACT
Aims: To investigate whether cardiac resynchronisation therapy (CRT) by means of biventricular
(BiV) pacing can improve left ventricular (LV) function, remodelling and clinical status in
chronically right ventricular (RV) paced patients with mild cardiomyopathy. 
Methods: Thirty-six chronically (10±7years) RV paced patients with left ventricular ejection
fraction (LVEF)<40% or LVEDD>55mm, without an established indication for CRT, were
subjected to 6 months RV and BiV pacing in a patient-blinded, randomized crossover design.
Treatment-effects of BiV pacing were evaluated for LV function, LV remodelling and clinical
status. 
Results: As compared with RV pacing, BiV pacing significantly improved LV function (LVEF
46±12% vs. 39±12% and LVFS 24±7% vs. 21±7%) and reduced LV end-diastolic and end-
systolic diameters and volumes (LVEDD 56±8mm vs. 59±8mm, LVESD 43±8mm vs. 47±9mm,
LVEDV 132±65ml vs.144±62ml and LVESV 77±56ml vs. 92±55ml, respectively). In 19 patients
(53%) response to BiV pacing was clinically relevant, defined as LVESV reduction >15%. BiV
pacing also significantly improved NYHA classification. 
Conclusion: BiV pacing following chronic RV pacing may improve LV function and reverse LV
remodelling in patients with relatively mild LV dysfunction or remodelling. Hence, upgrade to BiV
pacing might be considered in chronically RV paced patients with mild cardiomyopathy.
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INTRODUCTION
In right ventricular (RV) pacing, the sequence of electrical activation resembles the activation
pattern as in left bundle branch block (LBBB).1 This asynchronous electrical pattern is
accompanied by abnormal dyssynchronous mechanical interactions within the left ventricle
(LV).2, 3 Evidence is increasing that LBBB as well as RV pacing, are associated with impairment of
LV function, structural remodelling of the LV, and an increased risk for heart failure.4-9 Cardiac
resynchronisation therapy (CRT) by means of biventricular (BiV) pacing, aims to reverse the
deleterious effects that may originate from LV dyssynchrony. In the majority of patients with
severe LV dysfunction and severe clinical heart failure associated with either LBBB,10-15 or RV
pacing induced dyssynchrony,16, 17 BiV pacing improves clinical presentation, reduces mortality,
reverses LV remodelling and improves LV function. Therefore, BiV pacing is nowadays strongly
recommended in patients with ventricular dyssynchrony (QRS >120ms), severe LV dysfunction (LV
ejection fraction (LVEF) <35%) and moderate to severe clinical heart failure (NYHA classification
III-IV).18 The purpose of the present study was to investigate whether BiV pacing can improve LV
function and can reverse LV remodelling in chronically RV paced patients with mild
cardiomyopathy. The second aim was to investigate whether BiV pacing could improve, or at
least maintain, clinical performance in those patients without severe heart failure.
METHODS
Study population and inclusion criteria
From a database with ±1000 pacemaker patients in the Maastricht University Medical Centre, all
patients with permanent pacemaker stimulation were screened for inclusion. Criteria for
inclusion in the study were permanent RV pacing (>95% paced beats) accompanied with
echocardiographic signs of LV remodelling (defined as LV end-diastolic diameter (LVEDD)
>55mm) or LV dysfunction (defined as LVEF <40%). At least one of these echocardiographic
signs had to be present despite stable pharmacological treatment and pacemaker programming
aimed at maximal ventricular filling and minimal ventricular pacing. Inclusion was regardless of
clinical symptoms of heart failure. Nevertheless, patients with severe LV dysfunction in
combination with moderate to severe heart failure symptoms (i.e. LVEF <35% and NYHA III-IV,
respectively) were excluded from the current study, as they had an established indication for
CRT.18 Other criteria for exclusion were myocardial infarction or cardiac surgery within the
previous six months, or non-cardiac conditions that could limit exercise capacity and life
expectancy (within the duration of the study).
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Study protocol 
The Institutional Review Board approved the protocol and all patients provided written informed
consent at enrolment in the study (for study design see Figure 1). Patients underwent an upgrade
to a BiV pacing device and had routine post-implant pacemaker evaluations. Post-implant all
patients were BiV paced to detect and solve possible problems with pacing leads or pacemaker
systems within the run-in period. Two to four weeks after implantation patients were randomly
assigned to either RV or BiV pacing. At the same time-point individual optimization of the
pacemaker settings was performed using echocardiography. The atrioventricular-delay in both
RV and BiV pacing was optimized to the shortest delay that still provided maximal ventricular
filling, assessed using pulsed Doppler analysis of the transmitral flow. Patients with permanent
atrial fibrillation were exempt from the atrioventricular-delay procedure. Optimal interventricular-
interval in BiV pacing was determined by maximizing the aortic velocity-time-integral. After 6
months of either BiV pacing or RV pacing, patients crossed over to the other pacing
configuration for which the same optimization procedure was performed as at randomization.
Thereafter, they were paced in the other pacing configuration for another 6 months. Patients
were blinded for pacemaker configurations. Changes in pacing mode were performed by an
independent physician, using an external programmer. Clinical and echo-cardiographic
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Figure 1 - Study design. 
Subsequent to inclusion and baseline evaluation after chronic right ventricular (RV) pacing, patients
underwent an upgrade procedure to a biventricular (BiV) pacing device and a run-in period before
optimization of pacing settings. Thereafter patients were randomized to either BiV pacing or RV pacing,
followed by a crossover to the other mode. At the end of each 6 months pacing period left ventricular (LV)
function, LV remodelling and clinical status were evaluated.
evaluations were performed before enrolment in the study (prior to upgrade procedure;
measurement 1), and after the first and second phases (6 and 12 months after randomization;
measurement 2 and 3, respectively).
Clinical evaluation 
Symptoms of heart failure were classified according to the NYHA classification for heart failure.
For further assessment of clinical status, a 12-lead electrocardiogram and an exercise tolerance
test (i.e. treadmill-test, 6 min hall-walk distance, or bicycle-test) were performed. Approximate
oxygen cost during exercise testing was derived from the peak work rate achieved by the patient
and was defined in metabolic equivalents (METs).19 The self-administered “Minnesota Living with
Heart Failure Questionnaire” was used for scoring the quality-of-life on a scale from 0 (best) to
105 (worst).20
Echocardiographic evaluation
All measurements were performed according to the guidelines of the American Society of
Echocardiography. An experienced physician performed the echocardiographic evaluation using
Philips Sonos 5500 or Philips iE 33 (Philips Medical Systems, The Netherlands) with 1.8-3.5-MHz
transducers. Standard 2D and Doppler data from three consecutive beats were digitally stored for
offline analysis with a customized software package (Xcelera, Philips Medical Systems, The
Netherlands). During post-processing a single reviewer (K.V.) systematically measured LV end-diastolic
(LVEDD) and LV end-systolic diameters (LVESD) in parasternal long-axis views. End-diastolic and end-
systolic LV volumes (LVEDV and LVESV, respectively) and LVEF were calculated from the apical two-
and four-chamber images with Simpson’s biplane method.21 Additionally, LV fractional shortening
(LVFS) was used as a parameter for LV pump function [LVFS=(LVEDD-LVESD)/LVEDD]. Using color-flow
Doppler in the apical four-chamber view, mitral regurgitation was assessed and its severity was semi-
quantitatively graded on a scale from 0 (no regurgitation) to 4 (severe regurgitation).22 The time delay
between the onset of aortic and pulmonic flow was used to define interventricular asynchrony. The
time difference in onset of systolic motion between septum and LV lateral wall, determined using
pulse wave tissue Doppler, was used as a measure of intraventricular dyssynchrony.
Pacemaker implantation
All patients were implanted with Guidant (St.Paul, MN, USA) BiV pacemaker systems (B.D.). When
indicated an implantable cardioverter-defibrillator (ICD) with an additional LV pacing lead was
implanted. LV pacing leads were inserted by a transvenous approach via the coronary sinus into
either the lateral or postero-lateral vein whenever possible. Well functioning right atrial and apical
RV leads of the prior pacemaker system were used for the upgraded system. In case of ICD
implantation an RV coil lead was placed in the RV apex. After the upgrade procedure, lead positions
of RV- and LV leads were determined from chest X-ray films (posterior-anterior and lateral view). 
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Statistical analysis
Statistical data-analysis was performed (M.P., I.v.G.) using SPSS version 16.0 (SPSS Inc., Chicago,
IL, USA). A two-tailed P-value of <0.05 was considered significant. Reduction in LVESV was
considered as major efficacy variable for the study. The smallest difference with clinical
significance was considered to be a change in LVESV of >10% with BiV pacing as compared to
RV pacing. To reach over 80% power with an estimated 10% loss of patients during follow up,
the study had to include 37 patients (type 1 error: 0.05, 2-tailed; and type 2 error: 0.10). Baseline
characteristics at study enrolment were assessed. Comparisons of baseline characteristics
between both randomization groups were performed using either unpaired Student t-test for
continuous or X2 test for discrete variables. The efficiency (described in terms of treatment-
effects) of BiV pacing treatment as compared to RV pacing, was assessed from crossover data
using one-way analysis of variance (ANOVA) for repeated measures. The stimulation mode (RV
versus BiV pacing) was defined as within-subjects factor. To allow for testing on treatment-period
interaction (carry-over effect), the randomization sequence (RV→BiV versus BiV→RV) was
entered as a between-groups factor. Responders were defined as patients with an LVESV-
difference (RV paced LVESV versus BiV paced LVESV) >15% in favour of BiV pacing, since this
degree of LVESV reduction has been used as a cut-off value for response in other trials.23-26
Comparison between responders and non-responders was performed with the use of unpaired
Student t-test or X2 test. Pearson’s product-moment correlation coefficient was used to measure
the strength of relationship between treatment-effects and baseline LVEF, LVESV, interventricular
asynchrony and intraventricular dyssynchrony during RV pacing, the duration of RV pacing prior
to, and the age at upgrade. Additionally, to detect possible predictors for the response to BiV
pacing analysis of covariance (ANCOVA) was performed on the treatment-effect of BiV pacing
on LVESV. In this ANCOVA analysis NYHA classification at inclusion, QRS duration in RV pacing,
LV lead position, and baseline echocardiographic characteristics were defined as covariates
(independent variables).
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RESULTS
Study population
From the entire pacemaker population 706 patients were paced in VVI or DDD mode. Within this
group 93 patients were eligible. However, eleven of them had an indication for CRT following
the guidelines and were therefore excluded from this study. Two patients recently suffered
myocardial infarction, and in 31 patients exercise capacity and life expectancy were limited due
to non-cardiac causes. Among the remaining 49 patients matching all study-criteria, 40 patients
provided written informed consent. Thereafter, one patient was withdrawn from the study, as he
preferred to have no replacement and upgrade of his pacemaker system prior to end-of-life of
the system. Two patients were excluded from the study because transvenous LV lead
implantation failed and surgical intervention was unfavourable. In the period between October
2004 and October 2006, 37 patients were enrolled after successful implantation of a BiV pacing
device (ICD; n=12). After the upgrade procedure and the run-in period, 18 patients were
randomized to receive RV pacing in the first 6 months (group A) and to crossover to BiV pacing
for the second period of 6 months. The other 19 patients (group B) were randomized to both
pacing treatments in reversed order (BiV pacing first and RV pacing thereafter). In one patient
from group A, LV function and remodelling worsened considerably during RV pacing in the first
period. Within three months after programming to BiV pacing he died from end-stage heart
failure. Since paired data (BiV versus RV) from this patient were not available, this case was
excluded from analysis. From the patients included, nineteen patients met both echocardio -
graphic inclusion criteria (LVEF <40% and LVEDD >55mm). The other patients had
echocardiographic signs of either remodelling (LVEDD >55mm (n=13)), or impaired LV function
(LVEF <40% (n=4)). All subject characteristics at study enrolment are summarized in Table 1. On
average, patients had relatively mild LV dysfunction (LVEF 36±10%) and they were without
severe symptoms of heart failure after chronic RV pacing (10±7years). Patient characteristics
were not significantly different between both randomization groups. 
Complications 
In one patient the LV lead was placed epicardially via a minimal invasive thoracotomy after
transvenous implantation of the lead failed. In another patient the initial procedure was
discontinued because of a coronary sinus dissection, and re-intervention was performed one
month later. In three other patients re-intervention was needed because of, stimulation of the
diaphragm by the LV lead, RV lead dislodgement (n=1) or impending LV lead dislodgement (n=1).
Minor complications were pocket haematoma (n=3) and temporary stimulation of the diaphragm
(n=1). All complications mentioned were solved before pacemaker optimization and
randomization. 
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Table 1 - Patient characteristics at baseline
Total Group A Group B p-value
(n = 36) (n = 17) (n = 19)
Gender (M/F) 28 / 8 13 / 4 15 / 4 0.858
Age (years) 65±10 67±10 64 ±11 0.374
History of RV pacing (years) 10±7 9±7 11 ±7 0.562
Aetiology of pacing indication 0.790
- Spontaneous AV-block, n (%) 17 (47%) 7 (41%) 10 (53%)
- Surgically induced AV-block, n (%) 3 (8%) 2 (12%) 1 (5%)
- His-ablation (in permanent atrial fibrillation), n (%) 11 (31%) 6 (35%) 5 (26%)
- Brady/Tachy syndrome (in atrial fibrillation), n (%) 5 (14%) 2 (12%) 3 (16%)
Co-morbidity
- Coronary artery disease, n (%) 13 (36%) 8 (47%) 5 (26%) 0.196
- Atrial fibrillation (permanent), n (%) 19 (15) (53%) 7 (7) (41%) 12 (8) (63%) 0.187
- Hypertension, n (%) 6 (17%) 4 (24%) 2 (11%) 0.296
- Diabetes mellitus, n (%) 3 (8%) 1 (6%) 2 (11%) 0.615
NYHA classification 0.617
- Class I, n (%) 9 (25%) 4 (24%) 5 (26%)
- Class II, n (%) 19 (53%) 10 (59%) 9 (47%)
- Class III, n (%) 8 (22%) 3 (18%) 5 (26%)
RV paced QRS duration (ms) 195±26 196±29 193 ±23 0.078
LVEDD (mm) 60±7 59±7 60 ±7 0.698
LVESD (mm) 48±8 48±8 48 ±9 0.984
LVEDV (ml) 155±72 147±63 163 ±80 0.520
LVESV (ml) 104±64 98±61 109 ±69 0.633
LVEF (%) 36±10 36±11 36 ±9 0.938
LVFS (%) 20±6 20±6 21 ±6 0.552
AV-block = atrioventricular block; LVEDD and LVESD = left ventricular end-diastolic and end-systolic diameter, respectively; LVEDV
and LVESV = left ventricular end-diastolic and end-systolic volume; LVEF = left ventricular ejection fraction; LVFS = left ventricular
fractional shortening; RV = right ventricular. 
Biventricular pacing improves left
ventricular function and reverses left
ventricular remodelling 
There was no significant effect of the treatment
sequence (RV→BiV vs. BiV→RV), as no
interaction between randomization sequence
and within-subjects factor could be detected for
any of the parameters evaluated (no carry-over
effect). Thus, treatment-effects of BiV pacing
could be calculated from the BiV paced and RV
paced measurements previous to and 6 months
after cross-over (baseline measure-ments are not
included in this analysis). Figure 2 shows the
results on echocardio-graphic measurements of
6 months BiV pacing versus 6 months RV pacing.
The positive treatment-effects of BiV pacing in
LVEF (+7%; p<0.001) and LVFS (+3%; p=0.001)
are indicative for a significantly better LV
function with BiV pacing as compared to RV
pacing. LV dilatation was significantly less in BiV
pacing as compared to RV pacing, as expressed
by smaller diameters and volumes in BiV pacing
as compared with RV pacing (LVEDD: -4%,
p<0.001; LVESD: -8%, p<0.001; LVEDV: -9%,
p=0.001; LVESV: -19%, p<0.001, respectively).
The severity-grade of mitral regurgitation was
similar in both pacing configurations (1.3±0.9
and 1.1±0.7 during RV and BiV pacing,
respectively; p=0.107). In 19 patients (53%) the
LVESV-difference (RV paced LVESV vs. BiV paced
LVESV) was >15% in favour of BiV pacing. These
patients are referred to as ‘responders’. Only one
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Figure 2 - Left ventricular function and remodelling. 
Comparison of left ventricular (LV) function (A) and LV remodelling (B) after 6 months biventricular (BiV)
pacing vs. 6 months right ventricular (RV) pacing. LVEF = LV ejection fraction; LVFS = LV fractional
shortening; LVEDD = LV end-diastolic diameter; LVESD = LV end-systolic diameter; LVEDV = LV end-diastolic
volume; LVESV = LV end-systolic volume.
patient (3%) was defined as an ‘adverse-responder’ as in this patient the LVESV difference between
both pacing-modes was >15% in favour of RV pacing. In 20 patients (56%) BiV pacing was
beneficial for LV function indicated by a positive treatment-effect in LVEF >5%. In none of the
patients, LVEF was adversely influenced >5% by BiV pacing. In the responders the mean LVESV
reduction (LVESV treatment-effect: -32±10%) was paralleled by a significantly larger treatment-
effect in LVEF as compared with non-responders (+9±7% vs. +4±5%, respectively; p=0.030) and
the number of patients with LVEF-treatment-effect >5% was 14 (74%) in the responder-group. 
Clinical outcome 
NYHA classification was significantly better (p=0.007) after BiV pacing as compared with RV pacing
(Table 2). In six (17%) patients NYHA classification was one class less in BiV pacing (NYHA II vs.
NYHA III  (n=2) and NYHA I vs. NYHA II (n=4) for BiV vs. RV pacing, respectively). In one patient
(3%) the difference was even two NYHA classification levels in favour of BiV pacing (NYHA I in BiV
pacing vs. NYHA III in RV pacing). The mean LVESV reduction in all these seven patients was
19±22%; four patients were responders (LVESV reduction >15%) and one patient was the
‘adverse-responder’ (LVESV increase >15%). Quality-of-life-scores and quantity of METs as
derivative of performance on exercise testing were not significantly different during BiV pacing and
RV pacing (Table 2). 
Determinants of response to biventricular pacing 
No evident determinant for the response to BiV pacing was found. The degree of difference between
RV paced and BiV paced LVESV was neither affected by baseline LVESV (Pearson’s R=-0.5, ANCOVA
p=0.163), nor by baseline LVEF (R=0.3; p=0.506) (Figure 3). Also, the duration of chronic RV pacing
(10±7years) prior to enrolment in the current study (R=0.1; p=0.777), and patients’ age at upgrade
(R<0.1; p=0.308) did not affect the treatment-effect on LVESV. LV lead-tips were located at the lateral
free wall (n=17), posterior free wall (n=10), anterior free wall (n=2), lateral-base (n=2), posterior-base
(n=3) and anterior-base (n=2). The position of the LV lead-tip was not a significant covariate for the
response to BiV pacing (p=0.596). The duration of the QRS complex was significantly shorter (-16%,
p<0.001) during BiV pacing than during RV pacing (163±19ms, range 130-200ms vs. 195±26ms,
range 140-240ms). However, baseline QRS duration and measurements of interventricular- and LV
intraventricular dyssynchrony could not predict the response to BiV pacing (R=0.2 and p=0.802; R=-
0.2 and p=0.633; and R=-0.1 and p=0.523, respectively). The response to BiV pacing was not
influenced by the NYHA classification at baseline (p=0.271), nor by the presence of atrial fibrillation
as a comorbidity (p=0.501).
Patients in NYHA I and II, subgroup analysis
In patients with mild symptoms of heart failure (NYHA I and II, n=28) the treatment-effects of BiV
pacing were similar to compared with the entire study cohort. In this subgroup, mean LVESV
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Table 2 - Clinical outcome
RV pacing BiV pacing p-value
NYHA classification 0.007
- Class I, n (%) 11  (31%) 16  (44%)
- Class II, n (%) 18  (50%) 16  (44%)
- Class III, n (%) 7  (19%) 4  (11%)
Quality-of-life score (total) 30 ± 24 27 ±23 0.427
Exercise test (METs) 9 ± 4 10 ±3 0.205
BiV = biventricular; METs = metabolic equivalents; RV = right ventricular. 
Figure 3 - Response to biventricular pacing. 
Percentage reduction in left ventricular end-systolic volume (LVESV) after biventricular pacing plotted
against the baseline LVESV (A) and baseline left ventricular ejection fraction (LVEF) (B). 
reduction was 19% (p<0.001) and LVESV reduction was >15% in 15 patients (54%). All
parameters of remodelling were smaller in BiV pacing as compared with RV pacing: LVEDD
56±7mm vs. 58±7mm (4%, p=0.002), LVESD 43±8mm vs. 46±9mm (8%, p<0.001), LVEDV
124±53ml vs. 134±49ml (8%, p=0.025) and LVESV 68±47ml vs. 83±47ml (19%, p<0.001). Also
regarding LV function, BiV pacing was better in comparison with RV pacing, indicated by a
higher mean LVEF (48±12% vs. 41±12%, p<0.001) and higher LVFS (24±7% vs. 21±8%,
p=0.004). In 16 patients (57%) from this subgroup the difference between RV and BiV paced
LVEF was >5% in favour of BiV pacing.
DISCUSSION
The present study shows that BiV pacing following chronic RV pacing improves LV function,
reverses LV remodelling and improves NYHA classification in patients with cardiomyopathy
associated with RV pacing, although not having an established indication for CRT.  
Biventricular pacing in asymptomatic and mildly symptomatic patients with
relatively mild left ventricular dysfunction 
On average, patients from this study had less severe LV dysfunction and LV remodelling, as well
as fewer clinical symptoms of heart failure, as compared with patients in other studies on CRT.
Even though patients in the present study had these better conditions, response to BiV pacing
was evident with clinically relevant reverse remodelling (LVESV reduction >15%) in 53% of the
patients, and improvement in LV function in the majority of them. The finding that BiV pacing is
beneficial in mildly symptomatic and even in asymptomatic patients (NYHA I-II subgroup) is
supported by earlier investigations.27-29 The present study shows that improvement of LV
function and reversion of LV remodelling after BiV pacing may even occur in patients with less
severe LV dysfunction (LVEF 36±10%) as compared with other studies (i.e., REVERSE study LVEF
27±7%).27-29 Furthermore, the response to BiV pacing does not seem to be related to the
severity of either LV dysfunction or LV remodelling.
Biventricular pacing and clinical status
In patients with severe heart failure BiV pacing has been shown to be beneficial regarding clinical
status by many studies.13, 16, 17 The present study shows no evident benefit of BiV pacing in
exercise performance or quality of life, despite significant beneficial treatment-effects of BiV pacing
on LV function and remodelling. This finding might be explained by the fact that the parameters
used were probably too rough to define modest benefits in those patients with a good clinical
condition, leaving not much room for clinical improvement. Nevertheless, NYHA classification was
improved by BiV pacing. Though, the clinical benefit of BiV pacing was not always paralleled by
echocardiographic benefit.
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Biventricular pacing in patients with a history of chronic right ventricular
pacing
Although in most studies benefits of CRT are shown in patients with dyssynchrony due to an
‘intrinsic’ LBBB (ischemic or idiopathic), in the current study beneficial treatment-effects of BiV
pacing are shown in patients with RV pacing-induced dyssynchrony (paced LBBB). Improvement
in LV function and reversion of LV remodelling are described for BiV upgrade in chronically RV
paced patients by other studies too,2, 16, 17, 30 but the history of chronic RV pacing was longer in
the current study (10±7years). Delnoy et al. have shown similar clinical and echocardiographic
improvement when CRT was applied in patients with preceding chronic RV pacing compared
with patients with native LBBB.31 In the current study the response to BiV pacing does not seem
to be related to the number of years of chronic RV pacing prior to the upgrade. To appreciate
these findings, it is important to keep in mind that also in LBBB patients, dyssynchrony may have
existed for several years before the presence of symptoms becomes the final indication for ‘de
novo CRT’. As CRT restores LV electrical and mechanical synchrony, and therefore improves LV
function, it seems reasonable that response may be independent of aetiology and time-span of
the underlying dyssynchronous activation pattern.
Implications of results 
To date, the presence of severe LV dysfunction (LVEF <35%) and moderate to severe clinical heart
failure (NYHA classification III-IV) are widely used as criteria for CRT. Although the new American
guidelines are less tenacious to the presence of clinical heart failure symptoms, severe LV
dysfunction is still a strict criterion: it is advised to consider CRT in slightly symptomatic patients
(NYHA II) only if LVEF <35%.32 Improvement of clinical condition and improvement in
echocardiographic parameters in patients with mild heart failure suggest that CRT prevents or
slows the progression to severe heart failure. In the prevention of LV dysfunction, LV remodelling
and heart failure, it might be valuable to start BiV pacing in patients with an indication for
permanent ventricular stimulation. However, the complication rate and unnecessary costs are
important issues in a mildly symptomatic patient cohort and make (upgrade to) BiV pacing in
every patient with a conventional pacemaker indication or an LBBB unfavourable. Nevertheless,
our suggestion is to monitor LV function routinely and to carefully consider (upgrade to) BiV
pacing from the moment that echocardiographic signs of remodelling or deterioration of LV
function occur, whereas disregarding NYHA classification in this concern. 
Limitations of the study  
As this was a single-centre study, the study was limited to a relatively small number of patients.
Nonetheless, in a crossover-design every patient acts as his/her own control, so paired analysis
can be performed and fewer patients are needed to reach a powered level of significance. Using
a crossover-design, placebo effects of study-inclusion and pacemaker upgrade to a BiV device
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can be excluded, because data from the crossover-phase were used for the assessment of
treatment-effects. Furthermore, patients were blinded for pacemaker configurations. Conversely,
in a single blind trial unintended bias by investigators cannot be totally excluded. To minimize
this bias the investigators were unaware of the results of previous measurements in the
individual patient.
CONCLUSION
We conclude that BiV pacing following chronic RV pacing may improve LV function and reverse LV
remodelling even in patients with relatively mild LV dysfunction or remodelling, and no severe
clinical symptoms of heart failure. In addition, in these patients clinical status can be improved by
BiV pacing. Hence, upgrade to BiV pacing might be considered in patients with mild cardio-
myopathy associated with chronic RV pacing, even though they have no established indication for
CRT following current guidelines.
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ABSTRACT
Aims: We investigated the accuracy and feasibility of a non-invasive arterial pulse contour
technique for continuous measurement of stroke volume (SV) in optimization of atrioventricular
(AV) delay in cardiac resynchronization therapy (CRT), by comparing SV changes assessed by
Nexfin CO-Trek® (Nexfin) and echo Doppler aortic velocity-time-integral (VTIao). Furthermore, we
investigated whether AV-delay optimization increases the effect of CRT when compared with a
default AV-delay (120ms).
Methods and results: In 23 CRT patients, biventricular pacing (BiVP) was applied at various AV-
delays, while recording 10 beats preceding BiVP (baseline) and the first 10 BiVP beats, for both
methods in parallel. Agreement between Nexfin and VTIao measurements was evaluated (Bland-
Altman) on beat-to-beat changes in SV, as well as on effects of BiVP (averaged over 8 beats) at
various AV-delays. Individual optimal AV-delays, for Nexfin (AVopt-n) and VTIao (AVopt-ao), were
derived from the second-order polynomial fitted to the effect measurements of 20 patients. In
252 episodes assessed, the difference between measurements (=Nexfin–VTIao)  was -0.6±8.1%
for beat-to-beat SV-changes and -1.3±7.3% for effects of BiVP. Optimal AV delays for Nexfin
were well related to AVopt-ao (R2=0.69). The effect (%) of BiVP at the optimal AV-delay was
significantly larger than at the default AV-delay: median difference (range) being +6.3% (0.1-
14.4%; p<0.001) for VTIao and +4.7% (0.0-14.0%; p<0.001) for Nexfin.
Conclusions: Individual AV-optimization increases the effect of CRT. Nexfin is a promising tool
in individual CRT optimization, as Nexfin agrees with VTIao on measuring beat-to-beat SV-
changes and on assessing relative effects of BiVP on SV at various AV-delays.
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INTRODUCTION
Cardiac resynchronization therapy (CRT) improves left ventricular (LV) pump function and
reverses LV remodelling through the restoration of synchrony in LV electrical activation in patients
in a wide spectrum of mild to severe heart failure and prolonged QRS duration. The substantial
evidence that CRT improves clinical status and that it reduces morbidity as well as mortality, has
resulted in the incorporation of CRT in the management of dyssynchrony associated heart
failure. Devices for CRT have become significantly more sophisticated, including the capability to
independently program atrioventricular (AV) and interventricular (VV) stimulation timing
intervals, which has been shown to acutely significantly influence cardiac function.1-4 Although
tailoring the AV-delay and VV-interval to the individual patient could further increase the
haemodynamic improvement and long term benefits brought by CRT, the best way to guide the
optimization of these device settings is still under debate. Since CRT has been shown to acutely
improve haemodynamic status,1 AV-delay and VV-interval might be optimized by haemodynamic
monitoring. Gold standards for the measurement of haemodynamic status are the estimation of
LV contractility by measuring the maximum rate of rise of LV pressure and the measurement of
cardiac output by thermodilution or conductance catheter. These invasive methods, however, are
not suitable for routine use in CRT optimization as they require cardiac catheterization, and thus
impose significant biological and interventional risk to patient as well as add significant financial
and human resource burden. Although echocardiographic assessment of the velocity-time-
integral of the aorta (VTIao) has been shown to be a good surrogate for stroke volume (SV),5, 6
this measurement may be challenging in some patients due to limited or poor acoustic window.
Furthermore, it is very time-consuming to obtain a reliable set of data over a series of heart beats
for device optimization. Summarizing, there is great clinical need for a harmless, patient friendly
and easy-to-use technique for (continuous) haemodynamic monitoring, suitable for being
applied in individual optimization of CRT. A non-invasive method to continuously monitor
haemodynamics, using a finger sensor, is provided by Nexfin® (BMEYE B.V., Amsterdam,
Netherlands). We investigated whether Nexfin reliably measures beat-to-beat changes as well as
immediate relative effects on SV induced by CRT at various AV-delays and, hence, whether the
use of Nexfin is feasible in the individual optimization of CRT. The second aim was to investigate
whether benefit of CRT is increased with AV-delay optimization when compared with a default
AV-delay.
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METHODS
Subjects
From the cardiology departments of Maastricht and Lugano, 23 outpatients (5 females; 22%)
were enrolled 2.9±2.6 years after implantation of a biventricular pacemaker or biventricular
defibrillator for refractory heart failure and left bundle branch block (LVEF<35% and
QRS>130ms). Patient characteristics at implantation: QRS-duration 161±25ms; LVEF 25±7%;
median NYHA functional class 3 (range: 2-4); heart failure aetiology: ischaemic n=11, non-
ischaemic n=12. Exclusion criteria for the current study were atrial fibrillation, non-optimal
echocardiographic image-quality of the LV outflow tract which did not permit to assess VTIao
(known from previous examinations), as well as the presence of moderate to severe aortic valve
stenosis or regurgitation. At inclusion in the study, patient characteristics were: age 69±8 years;
paced QRS-duration 137±31ms; LVEF 35±11%; median NYHA classification 2 (range: 1-3).
Patients gave informed consent for this study, which was approved by the institutional review
boards of both centres. 
Study protocol 
In order to investigate the reliability of Nexfin CO-Trek in measuring SV changes, we compared
relative SV changes assessed by Nexfin with relative changes in VTIao on the same beats. Stroke
volume changes were induced by biventricular pacing (BiVP) at various AV-delays. The pacing
protocol was initiated after the patient being in supine position for 15 minutes. To exclude
haemodynamic variability induced by spontaneous changes in heart rate, and to increase the
probability of a more pronounced peak in the immediate haemodynamic responses to CRT at the
various AV-delays at higher heart rates,7 we enforced a constant heart rate by atrial overdrive
pacing (90bpm). The protocol consisted of a baseline without ventricular pacing, alternated with
atrial-based BiVP at various AV-delays in episodes of ~30 seconds (Figure 1). Starting at an AV-
delay of 60ms for the first BiVP intervention, the AV-delay was increased in 20ms steps until
either complete ventricular sensing occurred or until a maximum AV-delay of 340ms. 
Measurements and data acquisition
During the entire protocol, arterial pressure and SV were continuously and non-invasively
recorded by Nexfin. Nexfin uses an inflatable cuff that is placed around the mid-phalanx of the
middle finger, which contains a built-in photo-electric plethysmograph. By a volume-clamp
circuit combined with the Physiocal® method,8, 9 the finger arteries under the cuff are
dynamically clamped to their unloaded volume, and the pressure used is determined and tracked
over time, resulting in a dynamic and calibrated measurement of finger arterial pressure. The
finger arterial pressure is automatically reconstructed into the brachial arterial pressure waveform.8-
10 Stroke volume is automatically computed from the systolic area under the brachial arterial
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pressure pulse contour. Patient’s age, gender, height, and weight are important input parameters for
the patient individualization of the SV measurement using the Nexfin CO-Trek® algorithm.10
Simultaneously, ECG signal was recorded with the ECG module of Nexfin. Offline, data on SV as
measured by Nexfin from the last 10 individual heartbeats preceding BiVP (baseline beats) and the
first 10 beats during BiVP (registration in black, Figure 1) were selected and exported using
customized software based on the Matlab platform (MathWorks, Natick, MA, USA) after conversion
by FrameInspector (version 1.22.0.0, BMEYE) to a format compatible with Matlab (.bin). In parallel
with the Nexfin recordings, continuous wave Doppler echocardiography (Vivid 7, General
Electric, Milwaukee, WI, USA) of the aorta was performed on the same beats (10 baseline beats
+ 10 BiVP beats). The echo Doppler recordings were stored and the VTIao was manually
measured offline using EchoPAC post-processing software (Dimension BT08, General Electric).
Stroke volume can directly be derived from the VTIao, by multiplying the VTIao with the aortic
Figure 1. Study design
Along a baseline (BL) of constant heart rate enforced by atrial overdrive pacing without ventricular pacing,
SV changes were induced by episodes of biventricular pacing (BiVP) at various AV delays in the range of 60-
340ms (AV xx). Nexfin continuously recorded ECG and blood pressure, and computed beat-to-beat. In
parallel, for each intervention echo Doppler investigation of the LV outflow tract was performed on at least
the final 10 baseline beats and the first 10 BiVP beats. Off line the velocity-time-integral was manually
estimated (for this example, SV was calculated from the velocity-time-integral and cross sectional area of
the aorta).
cross sectional area. Though, since this study focuses on the comparison of relative changes in
SV, we did not calculate absolute SV for echo measurements. 
Statistical methods
Comparison of Nexfin and echo Doppler: on the assessment of beat-to-beat
stroke volume changes and on the estimation of the effect on stroke volume
as induced by biventricular pacing
To allow pooling of the data of the various episodes and different patients, the mean values of
each of the baselines, for both Nexfin and VTIao, served as a reference (0% level in Figure 2,
upper panel). Then, the relative deviation (RD, %) from the reference of the episode was
calculated for each of the 20 beats in that episode, for both Nexfin and VTIao (RDSVn and
RDSVao, respectively; Figure 2, upper panel). The first objective was to identify the agreement of
Nexfin and echo Doppler on the measurement of beat-to-beat SV changes due to either
spontaneous variability or artificially induced variability by BiVP. For this purpose, the differences
between the measurements of Nexfin and VTIao on relative beat-to-beat SV changes were
calculated (Figure 2, lower panel) and evaluated according to the suggested method of analysis
by Bland and Altman.11 In this method, the mean difference between the methods is defined as
‘bias’. The upper and lower limits of agreement are defined as ‘bias ± 1.96 x SD of the difference
between the methods’. The second step in the comparison of Nexfin and echo Doppler was to
investigate the agreement of the methods on the assessment of the effect on SV as induced by
BiVP at the various AV-delays. Because SV is strongly affected by changes in RR-intervals due to
either lengthening or shortening of the AV-delay (see also the example given in Figure 1),
premature and post-premature beats, as well as the first and the second beats after transition
were excluded. Subsequently, we assessed the relative effect of BiVP on SV for each AV-delay by
calculating the mean relative SV increase or decrease over the BiVP beats (= mean RDSVao and
RDSVn over BiVP beats) and defined these as ‘effect-SVao’ and ‘effect-SVn’, for echo Doppler
VTIao and Nexfin, respectively (Figure 2, upper panel). The Bland-Altman analysis was performed
on effect-SVao and effect-SVn, to identify the agreement between Nexfin and echo Doppler on
the assessment of the relative effects on SV induced by BiVP at various AV-delays. 
Atrioventricular-optimization curves for Nexfin and echo Doppler
Individual optimization curves for echo Doppler and Nexfin were obtained by a second-order
polynomial curve fitted to the data on the relative effects, effect-SVao and effect-SVn,
respectively (Figure 4). The AV-delay at the location of the maximal effect (peak of the curve) was
defined as the optimal AV-delay (AVopt-ao and AVopt-n, for echo Doppler and Nexfin
respectively). The difference in effect-SVao at AVopt-n and at AVopt-ao, was used as a measure
of the haemodynamic relevance of the discrepancy between AVopt-n and AVopt-ao. For both
echo Doppler and Nexfin, the range of optimal AV-delays was defined as the part of the curve
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where the relative effect was less than 2%-points lower than the effect at the optimal AV-delay.
Lastly, the maximal relative effect was compared with the relative effect at a default AV-delay of
120 ms to investigate whether individual AV-delay optimization is beneficial. 
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Figure 2. Statistical design
In each episode, the relative deviation from the mean of the baseline beats was calculated for stroke
volume measured by Nexfin as well as for stroke volume (SV) derived from echo Doppler investigation
(RDSVn and RDSVao, respectively) for each of the 20 beats in that episode (upper panel). For each AV delay
we assessed the relative effect of biventricular pacing (BiVP) on SV, by calculating the mean relative SV
increase or decrease over the BiVP beats (= mean RDSVao and RDSVn over BiVP beats, excluding the first
and second beats after transition) and defined these as ‘effect SVao’ and ‘effect SVn’, for echo Doppler
velocity-time-integral (VTIao) and Nexfin, respectively (upper panel). The differences between RDSVn and
RDSVao (lower panel), as well as the differences between the effect-measurements were calculated for
subsequent analysis on the agreement of Nexfin and echo Doppler.
RESULTS
Protocol complications
In 23 patients, a total of 252 BiVP episodes at various AV-delays were assessed with an average
of 11±3 interventions for each individual patient. In one patient, from an AV-delay of 200ms
onwards, the device (St. Jude Medical Systems; Promote RF 3213-36) could not be programmed
in 20ms steps, therefore the AV-delays tested were subsequently 225, 250, 275, 300 and
350ms. In three patients the protocol was performed using overdrive pacing at a rate of 75 bpm
(n=1) or 80 bpm (n=2), since progressive AV-conduction disturbances occurred at higher rates. 
Agreement between Nexfin and echo Doppler; on the assessment of relative
beat-to-beat stroke volume changes and on the estimation of the effect on
stroke volume as induced by biventricular pacing
For a total of 5028 beats, measurements by both Nexfin and echo Doppler were available. From
the Bland-Altman analysis on the beat-to-beat relative deviations (step1), the observed variance
(SD) on the measurement differences between the methods (=RDSVn-RDSVao) was ±8.1%
around a mean bias of -0.6% (limits of agreement: ±15.9%). The inter-beat variability on
baseline beats (n=2422 after exclusion of premature and post-premature beats), was ±4.7% for
RDSVn and ±6.3% for RDSVao. The second step in the comparison of Nexfin with echo Doppler
was the use of the Bland-Altman analysis for the evaluation of the agreement between the
methods on the assessment of the relative effect of BiVP on SV when compared with baseline
(‘effect-SVao’ and ‘effect-SVn’, as visualized in Figure 3). By means of the Bland-Altman analysis,
the difference between Nexfin and echo Doppler (effect-SVn–effect-SVao) was -1.3±7.3% (limits
of agreement: ±14.3%). The variances (SD) observed on the measurement differences between
the methods, as well as the limits of agreement (bias ± 1.96 x SD), are indicative for a good
agreement between the methods and suggest that Nexfin CO-Trek is reliable in the
measurement of SV changes (the reliability of Nexfin is further exemplified in the ‘Discussion’
section). 
Atrioventricular-optimization curves for Nexfin and echo Doppler
In the third step of the comparison of Nexfin and echo Doppler in CRT optimization, optimization
curves for both Nexfin and echo Doppler could be obtained for 20 individual patients. (One
patient was excluded for this analysis, because the occurrence of multiple premature beats in each
episode implicated that the measurements on relative effects were not representative and thus
not useful for optimization. In two patients optimization curves couldn’t be fitted to the individual
data because of a large ‘back and forth variation’ between the settings). Regarding the shape of
the curves and their fit to the individual effect measurements, variation between patients was
observed. Figure 4 demonstrates four different explicative examples, all with a good agreement
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between Nexfin and echo Doppler on the individual effect values (limits of agreement for the
individual patients are respectively, A: ±17.6%; B: ±11.0%; C: ±13.9%; and D: ±11.8%). The
optimization curves in panel A show a positive effect of BiVP for all AV-delays tested. The curves
well fit the individual effect-values (echo: R2=0.93 and Nexfin: R2=0.80) and AVopt-n (258ms) is
close to AVopt-ao (270ms). In the example shown in panel B, the optimization curve for echo
Doppler fits the individual points only moderately (R2=0.51). Nevertheless, AVopt-ao (260ms) and
AVopt-n (257ms) are almost similar. In the patient presented in panel C optimization curves have
a good fit to the individual data points (echo: R2=0.84 and Nexfin: R2=0.82), but there is less
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Figure 3. Agreement between Nexfin and echo Doppler on the assessment of the relative effect
on stroke volume as induced by biventricular pacing
The relative effect on stroke volume induced by biventricular pacing at various AV delays, as measured by
Nexfin (effect SVn) is plotted against the relative effect measured with the use of echo Doppler (effect
SVao) (A). The difference between effect SVn and effect SVao is displayed against the average of both
measurements (B). 
agreement between Nexfin and echo Doppler on the optimal AV-delay (186ms and 260ms for
AVopt-n and AVopt-ao, respectively). In the patient presented in panel D, the accordances of the
curves with the individual data and consensus of the optimal AV-delay derived from Nexfin and
echo Doppler are poor (281ms and 211ms for AVopt-n and AVopt-ao, respectively). On average,
the correlation of the fitted optimization curves and the individual effect-data was similar for
Nexfin (R2=0.63±0.24) and echo Doppler (R2=0.68±0.27). The averaged maximum effect as
derived from the Nexfin optimization curves was 4.3±5.4%, which was significantly smaller than
the maximal effect as derived from the echo curves (7.2±7.7%; p=0.008). Optimal AV delay for
Nexfin and AVopt-ao were well correlated, as is shown in Figure 5 (Patients A-D are
corresponding to the patients in Figure 4). The absolute difference in AV-delay (ms) between
AVopt-n and AVopt-ao was ≤20ms for 13 out of 20 patients (65%), indicating (almost) similarity
of AVopt-n and AVopt-ao in these patients (Figure 5). In the majority of the patients (80%;
n=16), the difference in relative effect by BiVP as measured with echo at the AVopt-ao and at
AVopt-n was <1%-points (difference in the effect of total population: median 0.2%-points;
range 0.0-5.2%-points). This might be clinically even more important than an exact similarity of
AVopt-n and AVopt-ao, as the small difference in effect indicates just only a minimal
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Figure 4. Individual curves for AV optimization 
A, B, C and D are four different explicative examples of individual optimization curves as derived from the
measurements of relative effect on stroke volume induced by biventricular pacing at various AV delays, as
assessed by Nexfin and echo Doppler. The AV delay corresponding to the maximal relative effect (top of the
curve) was defined as the optimal AV delay (AVopt-ao and AVopt-n, for echo Doppler and Nexfin, respectively). 
haemodynamic relevance of the discrepancy between AVopt-n and AVopt-ao. For both echo
Doppler and Nexfin, a range of optimal AV-delays was defined as the part of the curve where the
relative effect was <2%-points lower than the effect (%) at the optimal AV-delay. The width of
this range of optimal AV-delays was 110±34ms for Nexfin and 97±47ms for echo, suggesting
that there may be a broad range of AV-delays leading to (almost) optimal effects. Furthermore,
there was a great similarity for Nexfin and echo Doppler in this optimal range, as indicated by
73±21% overlap of the Nexfin optimal range with the optimal range of echo Doppler. The
relative effect as achieved by optimizing the AV-delay was significantly larger than the effect
using a default (“out-of-the-box”) AV-delay of 120ms: 7.2±7.7% versus 0.6±9.4% (median
difference in effect +6.3%; range 0.1-14.4%; p<0.001) as estimated by echo Doppler and
4.3±5.4% versus -0.6±7.2% (median difference +4.7%; range 0.0-14.0%; p<0.001) by Nexfin.
DISCUSSION
In the current study, we investigated the accuracy and feasibility of continuous non-invasive SV
measurements by Nexfin CO-Trek in CRT optimization, by comparing Nexfin with echo Doppler
at three levels: the measurement of beat-to-beat changes in SV, the assessment of relative effects
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Figure 5. Correlation of individual optimal AV delays assessed using Nexfin and optimal AV-
delays assessed using echo Doppler
AVopt-n: optimal atrioventricular (AV) delay as defined with the use of Nexfin; AVopt-ao: optimal AV delay
as assessed with echo Doppler. (The indices for the individual cases A, B, C, and D correspond to the
selected patients for figure 4).
of BiVP at various AV-delays, and the determination of the optimal AV-delay. The most important
findings are that Nexfin has a good agreement with VTIao by echo Doppler on the measurement
of changes in SV due to either physiological beat-to-beat alterations or to changes induced by
BiVP, and that in individual optimization both methods Nexfin and VTIao determine similar AV-
delays as the optimal AV-delay. Additionally, our data suggest that individual optimization of the
AV-delay leads to better haemodynamic improvement of CRT than programming a default AV-
delay of 120ms.
Reliability of Nexfin in the assessment of acute haemodynamic changes
To investigate the reliability of Nexfin CO-Trek on the assessment of acute haemodynamic
changes, we used the VTIao assessed by echo Doppler to compare Nexfin CO-Trek with, as this
method provides a validated non-invasive measurement of (changes in) SV.5, 6 Optimizing the
VTIao is also one of the recognized and accurate methods for CRT optimization.12 The variance
(±SD) on the measurement differences between Nexfin and echo Doppler, was ±8.1% for the
measurement of beat-to-beat changes. This observed variance can be entirely explained by the
summation of the variability in each of the methods, since by analysing exactly the same beats
for both methods, physiological variability is excluded as a confounding factor. The measurement
variability for each method separately can be hypothesized from the equation for combined
variances [combined variance = √(variance A 2 + variance B 2)].13 If the measurement variabilities
on SV changes of echo Doppler and Nexfin are assumed to be equal, these variabilities would be
5.7% [√(5.72+5.72)=8.1]. If the measurement variability of echo Doppler is assumed to be
higher, the precision of Nexfin would even be better: for the theoretical example that the
measurement variability for echo Doppler is 7.0%, the variability of Nexfin would be 4.1%
[√(7.02+4.12)=8.1]. When compared with the available haemodynamic measurements, a method
with a ~5% inconsistency in the assessment of beat-to-beat SV changes may be considered to be
very precise.14-16 In clinical practice, haemodynamic measurements are usually performed on
multiple beats. Therefore, it seems more appropriate to judge the reliability of Nexfin based on
the variance on the difference between the effect-measurements of Nexfin and echo Doppler
(derived from averages of multiple beats), which was the second step in our comparison. The
variance on these measurement differences was ±7.3%. Consequently, if the measurement
variability on the assessment of the effect on SV by BiVP are assumed to be equal for echo
Doppler and Nexfin, these variabilities would be 5.2% [√(5.22+5.22)=7.3].
From Figure 3A and B (trendline), as well as from the finding that the optimal effect was smaller
when measured with Nexfin (4.3±5.4%) when compared with echo Doppler (7.2±7.7%), it can
be deduced that using Nexfin, changes in SV are estimated to be smaller than that using echo
Doppler. This may also explain the smaller inter-beat variance on baseline beats for Nexfin
(±4.7%) when compared with echo Doppler (±6.3%). These findings appear to be in keeping
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with observations of Butter et al.17 that finger blood pressure measurements underestimate
haemodynamic changes, but also that these measurements provide highly specific predictions of
positive and negative changes in aortic pulse pressure. Moreover, the reliability of an effect
measurement is influenced by the size of the effect and the standard error of the mean effect
(SEM). In the current study, the SEM can be derived from the inter-beat variance (combination of
physiological inter-beat variability and measurement error on each beat), divided by the square
root of the number of beats on which the effect is determined (n=8). The ratio between the
effect and SEM may be used as a measure for reliability of the effect measured [averaged optimal
effect / SEM]. For the averaged optimal effect on SV by BiVP this ratio was 2.6 [4.3% / (4.7%/√8)
=2.6] for Nexfin, and even a little better for echo Doppler [7.2% / (6.3%/√8) =3.2]. However, it
should be kept in mind that for the effect measurements in the present study, VTIao tracing was
performed using careful off-line analysis of 8 paced heart beats (in comparison with 10 baseline
beats), whereas in clinical practice, often only 1-3 beats are used. By virtue of this lower number
SEM will increase and reliability will therefore decrease, and will decrease even more if the beats
are not randomly spread over the respiratory cycle. 
Defining the optimal atrioventricular-delay using individual optimization
curves
There was no clinically relevant difference between the AV-delays corresponding to the peaks of
the individual optimization curves of Nexfin and echo Doppler, since there was a good
correlation between the optimal AV-delays and a great overlap of the ranges of optimal AV-
delays (where the effect of BiVP was not relevantly different from the effect of BiVP at the
optimal AV-delay). These findings suggest that Nexfin reliably defines the best AV-delay setting
in accordance with echo Doppler VTIao. These optimal AV-delays were identified from individual
optimization curves for echo Doppler and Nexfin as obtained by a second order polynomial fitted
to the data on effect-SVao and effect-SVn (Figure 4). Whinnett et al. demonstrated that the
curve of response to BiVP at various AV-delays fits closely to a second order polynomial.3 In our
study the fit of the optimization curves with the data was not as good as in the study by
Whinnett et al., as reflected by lower mean R-values for both Nexfin and echo Doppler. This
discrepancy may be explained by the inclusion of shorter AV-delays (40ms) by Whinnett,
resulting in extreme worsening of haemodynamics, and therefore improving the correlation
coefficient. An additional explanation may be that Whinnett et al. used repeated measurements
on the effect of BiVP for each AV-setting. This was not practical in our study, because this was
not the first aim of our study and would have increased the duration of the patient protocol
significantly, due to the time consuming echo Doppler measurements. If only Nexfin would be
used, measurements can be performed repeatedly in order to achieve more accurate
optimization curves.
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Clinical implications 
Cardiac resynchronization therapy is shown to be beneficial and is broadly applied in heart failure
patients, though up to 30% of the patients are not fully responding to CRT. Some of the under-
responders may turn into responders by better application of CRT. Despite proven acute
haemodynamic benefits of individual optimization of AV-delay and VV-intervals,2, 3 it is not yet
proven whether or not CRT optimization significantly reduces the number of non-responders or
has important impact on patient prognosis. Interestingly, preliminary results of the CLEAR study
report that AV-delay optimization using an accelerometer substantially increases the number of
patients responding to CRT, and reduces the number of major clinical events including
hospitalization for heart failure and death.18, 19 The benefit of individual optimization of the AV-
delay is also indicated by our data as the optimal AV-delay varied between patients and as the
relative effect on SV was significantly better at the optimal AV-delay than at a default AV-delay
of 120ms. Long term effects of CRT cannot be directly predicted from the immediate
haemodynamic effects achieved in optimization procedures. Nevertheless, improvements in
haemodynamics have been shown to persist over time20 and have been associated with
diminished energy costs,21 indicating improvement of mechanical efficiency which may last on
the long term and may increase cardiac reserve.22 Additionally, in a recent study using invasive
pulse-contour measurements,23 patients in whom an acute SV increase of >5% by optimized
CRT was achieved, showed a better clinical as well as echocardiographic response at 6-8 weeks
follow-up, when compared with patients in whom <5% acute SV increase was achieved. Nexfin
immediately and automatically computes SV and, as showed in our study, is reliable in the
assessment of SV changes. In contrast to other haemodynamic measurement techniques in CRT
optimization procedures, Nexfin is non-invasive, patient friendly, and does not require great skill. 
As the main purpose of this study was to evaluate the reliability of Nexfin in the optimization of
CRT and, hence, a steady and high heart rate was preferred,7 we performed (overdrive)pacing.
In clinical practice, however, it would be important to also determine the optimal AV-delay for
atrial sensed ventricular pacing, as this may better reflect physiological circumstances. Moreover,
it would be interesting to optimize even at various heart rates and during exercise.24, 25 One of
the major advantages of using Nexfin above using echocardiography is that it can easily be
applied in different body positions and even during exercise. Another advantage of the simple
application of Nexfin is that optimization procedures can easily be repeated multiple times over
longer time course, as it is likely that on the long term and/or in real life the optimal CRT settings
will change.26
Prospective randomized studies are needed to clarify the real clinical impact of CRT
optimization on the patients course. In this regard, the method for optimization may be of
critical importance. Echocardiography is the most common approach to optimize AV- and VV-
timing,27 yet it is a time-consuming approach and uses significant human resources. Thus, there
is the quest for an alternative, inexpensive and highly reliable method which can be included as
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part of routine device follow-up. With the easy and relatively inexpensive use of Nexfin, all
patients could undergo individual optimization. 
Study limitations 
The Bland-Altman evaluation of agreement assumes independent observations.28 Contrary to
this assumption, we used multiple measurements on SV within each subject, where the true
value varies due to (spontaneous or artificially induced) changes in haemodynamics. Variances on
the biases and intervals within the limits of agreement were observed between the subjects
(mean interval within the limits of agreement: 15.6±5.5%; mean bias -0.6±2.6%) which may
implicate that the interval between the observed limits of agreement for the total study group
might be narrower than it should be, but probably only slightly.28 Measurements on the effect of
BiVP were performed once for each AV-delay, since repetition was not feasible in our protocol
with the parallel echocardiographic data acquisition. Nevertheless, for each AV-delay effect-
measurements should be performed repeatedly to define the individual optimal AV-delay more
reliably. In the current study it was practically not feasible to perform both AV- and VV
optimization (due to the parallel assessment of SV changes by Nexfin and VTIao). Because the
results of our study indicate that Nexfin is reliable in the assessment of SV changes, we feel that
parallel assessment of VTIao, next to Nexfin, is not longer necessary in subsequent studies.
CONCLUSIONS
Individual optimization of the AV-delay may increase the beneficial response to CRT. Nexfin CO-
Trek provides an easy, non-invasive and patient friendly method to evaluate changes in SV due
to either beat-to-beat alterations or to different settings of AV-delays. As Nexfin has a good
precision on the measurement of beat-to-beat SV changes, the assessment of relative effects
induced by BiVP and on the determination of the optimal AV-delay, we judge Nexfin as a
promising tool in the individual optimization of CRT.
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ABSTRACT
Background: Chronic right ventricular (RV) pacing can induce structural and functional cardiac
deterioration. Because animal studies showed benefit of left ventricular (LV) over RV pacing, this
study compared the effects of chronic RV and LV pacing in children. 
Methods: Retrospectively, echocardiographic data were evaluated from 18 healthy children
(control subjects) and from children undergoing chronic epicardial RV pacing (7 RVP) or LV pacing
(7 LVP). Assessment included LV end-diastolic wall thickness (LVEDWT) and end-systolic wall
thickness (LVESWT) as well as LV end-diastolic diameter (LVEDD) and x-systolic diameter (LVESD).
The shortening fraction (SF) and eccentricity index (=LV diameter/2 ´ LV wall thickness) were
calculated as measures of LV function and eccentricity, respectively. Duration of QRS and septal-
posterior-wall-motion-delay (SPWMD) were used as measures of electrical and mechanical
dyssynchrony, respectively. A p value less than 0.05 determined significance.
Results: LVEDD, LVESD, LVEDWT, and LVESWT were not significantly different between the
groups. The shortening fraction was significantly lower in the RVP (21.7±6.0%) than in the LVP
(32.2±5.2%) or control (29.3±4.3%) children. The systolic LV eccentricity index was significantly
larger in the RVP (1.8±0.2) than in the LVP (1.4±0.1) or control (1.4±0.2) children. The SPWMD
was significantly larger in the RVP (338±20ms) than in the LVP (-16±14ms) or control (-5±35ms)
group, whereas QRS-duration was similarly prolonged in the RVP (157±10ms) and LVP
(158±22ms) groups than in the control group (69±7ms).
Conclusion: Left ventricular function in children may be preserved by chronic pacing at the LV
lateral wall.
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INTRODUCTION
In children and adults with congenital or acquired atrioventricular (AV) block, the ventricular
pacing lead is traditionally positioned at the right ventricle (RV).1, 2 However, RV apex pacing
causes an acute decrease in left ventricular (LV) function in animals,3 adults4 and children.5, 6
During chronic RV pacing in children, LV function, morphology7, 8 and histology9 are at risk for
deterioration over time (for review see Karpawich).1 Chronic RV pacing can eventually result in
cardiac failure, which occurs in 6% to 7% of children.10-12 Also, in adults, chronic RV apex pacing
has deleterious effects (for review see Manolis)2 and increases the risk of heart failure.13, 14
Recognition of the possible harmful effects from RV apex pacing initiated the search for
alternative ventricular pacing sites including the RV outflow tract, His bundle, LV wall, and
biventricular pacing. Pacing at the His bundle is likely the superior approach,15 but appears
technically difficult, especially in children. Right ventricular outflow tract pacing does not
provide a consistent beneficial hemodynamic effect compared with RV apex pacing.4 During
pacing at different RV septal sites, hemodynamic function varies widely, and the location of the
RV septal site that leads to the less pronounced decrease in pump function also varies between
hearts in canine experiments.16 In adults with heart failure, both LV lateral wall pacing17, 18 and
biventricular (RV apex + LV lateral wall) pacing18 acutely results in a better functional outcome
than RV apex pacing. Also in adults, LV pacing alone seems to be as effective as biventricular
resynchronization therapy, both in the acute situation19 and after 6 months of pacing.20 The
current study aimed to investigate the long-term functional and structural outcome of epicardial
RV and LV pacing in children. The study was performed retrospectively on echocardiographic and
electrocardiographic (ECG) data from children undergoing chronic RV or LV pacing and from
healthy children (control subjects). 
METHODS
Study population and pacing characteristics 
All children with normal cardiac anatomy and a ventricular pacemaker in the database of the
Children’s University Hospital in Zurich (Switzerland) were considered for inclusion. The study
included all children with congenital or acquired AV block (except for cardiomyopathy)
undergoing chronic epicardial RV or LV pacing for rate control (minimum of 95% paced beats)
for whom echocardiographic and ECG data were available. Data were acquired during the most
recent outpatient clinic visit of children with chronic RV pacing (RVP, n = 7) or LV pacing (LVP, n
= 7) and evaluated retrospectively. For the children who underwent a pacing lead replacement,
the last echocardiography and ECG data before the replacement were evaluated to exclude
effects of changes in the pacing site between the initiation of pacing and the moment the data
were obtained. In addition, for a small number of patients (3 RVP and 4 LVP), the
Chronic RV and LV Pacing in Children
77
echocardiographic preimplantation data were of sufficient quality for assessment and are
presented to provide an estimation of the baseline characteristics. Bipolar steroid-eluting pacing
leads (Medtronic CapSure Epi 10366 or 4968; Medtronic Inc., Minneapolis, MN, USA) were
implanted in all children and connected to various pulse generators. Pacemaker lead positioning
was purely determined by the surgical approach preferred by surgeons.21 Through a sternotomy
or using a subxyphoidal approach, RV pacing leads were implanted and positioned at the RV
apex (n=6) or RV free wall (n=1). Left ventricular pacing leads were implanted through a left
lateral thoracotomy and placed at the LV mid lateral wall.21 Table 1 depicts the characteristics of
the paced children. Before pacemaker implantation and during the follow-up, none of the
patients had clinical symptoms of heart failure, received any cardiovascular drugs, or had
echocardiographic signs of cardiac failure. The control group consisted of 18 healthy children
who visited the outpatient clinic for an innocent cardiac murmur. This retrospective study was
approved by the local ethics committee and performed according to their guidelines. 
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Table 1: Patient and pacemaker characteristics
Patient Sex Pacing indication SPWMD (ms) Shortening Pacing Pacing Age at end
(M/F) prepacing Fraction (%) mode Duration (y) of study (y)
prepacing
RVP-1 F C-AVB III DDD 6.9 8.7
RVP-2 M C-AVB III 70 28 DDD 2.2 9.4
RVP-3 F C-AVB III (Mat. SLE) VVI 6.3 6.3
RVP-4 F A-AVB II 65 38 DDD 2.5 4.3
RVP-5 F C-AVB III DDD 2.3 4.4
RVP-6 F C-AVB II 10 40 DDD 2.5 8.4
RVP-7 F C-AVB III (Mat. SLE) VVI 4.9 4.9
LVP-1 M C-AVB III VVI 5.5 6.8
LVP-2 F A-AVB III -5 40 DDD 1.5 11.1
LVP-3 F C-AVB II, long QT DDD 4.8 4.4
LVP-4 M AVB II, SSS 45 35 DDD 3.3 7.4
LVP-5 M C-AVB III 20 39 DDD 2.5 3.7
LVP-6 F C-AVB III 35 33 DDD 6.3 10.6
LVP-7 M C-AVB III (Mat. SLE) VVI 2.8 2.8
II = 2nd degree, III = 3rd degree, A-AVB = acquired AV block, C-AVB = congenital AV block, DDD = atrial and ventricular sensing
and pacing, F = female, LVP = left ventricular pacing group, M = male, Mat. SLE = maternal systemic lupus erythematosus, RVP =
right ventricular pacing group, SPWMD = septal-to-posterior wall motion delay, SSS = sick sinus syndrome, VVI = ventricular
sensing and pacing. 
Available shortening fraction and SPWMD data before pacemaker implantation are presented. 
Echocardiographic evaluation
Echocardiographic data were obtained in the standard precordial positions with appropriate
transducers (7.5-, 5.0-, 3.5-, and 2.5-MHz; Vivid 7; General Electric Healthcare, UK; or Philips Sonos
5500; Philips, Best, The Netherlands). Data were stored either digitally or on VHS videotapes, then
subsequently digitized offline. End-diastolic and end-systolic frames of the parasternal short-axis
views were further analyzed using Matlab software (The Mathworks Inc., Natick, MA, USA). Two
observers, blinded to the study group of the patient, each performed three independent
measurements in random order for every patient. The average of the measurements performed by
the two observers was used for further analysis. A representative example of a processed
echocardiographic image is depicted in Figure 1. Body surface area was calculated using the
formula of Du Bois and Du Bois22: Body surface area (m2) = 0.20247 x length (m)0.725 x weight
(kg)0.425 Left ventricular end-diastolic diameter (LVEDD) and LV end-systolic diameter (LVESD) were
measured bidirectionally (Figure 1) and averaged to minimize over- or underestimation in case of
an asymmetric mechanical activation pattern. To estimate the degree of LV dilatation and to
compare between patients of different ages and weights, LVEDD was expressed as a z-score of
normal.23 Shortening fraction (SF) as a measure of cardiac function was defined as: SF (%) =
(LVEDD – LVESD) / LVEDD x 100. Regional changes in LV wall thickness were assessed by measuring
the LV wall in six consecutive regions at end-diastole and end-systole on short-axis views (Figure 1).
The mean of these six regions was used as the mean LV end-diastolic wall thickness (LVEDWT) and
mean LV end-systolic wall thickness (LVESWT). Again, LVEDWT was expressed as z-score of normal.
The eccentricity index of the LV (as a measure of fiber stress) was calculated as follows: LV
eccentricity index = LV diameter / (2 x mean LV wall thickness). Septal-to-posterior wall motion
delay (SPWMD), as a measure of intraventricular mechanical synchrony, was obtained from short-
axis M-mode echocardiographic images and defined as the time delay between the earliest peak
of systolic inward movement of the septum and the opposite LV posterior wall.24-26
Electrocardiographic evaluation
Duration of QRS was assessed from the surface ECG during sinus rhythm (control group), RV
pacing (RVP group), and LV pacing (LVP group) and used as a measure for synchrony of electrical
ventricular activation. 
Statistical analysis
Statistical analysis was performed using one-way analysis of variance (ANOVA) on every
parameter. Only if ANOVA showed a significant difference was further analysis with Tukey
comparison used to identify statistical differences between the different study groups. A p value
less than 0.05 determined statistical significance. Data are presented as mean ± standard
deviation. For echocardiographic measures, the interobserver correlation (r value) was assessed
using Pearson product-moment correlation. 
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RESULTS
Study population
The characteristics of the RVP and LVP groups are presented in Table 1. Unless specified, the
etiology of the AV block was not identified. Age and body surface area were not significantly
different between the groups (RVP group: 6.6 ± 2.2 years and 0.9 ± 0.2 m2, respectively; LVP
group: 6.7 ± 3.3 years and 0.9 ± 0.3 m2; control group: 4.8 ± 3.7 years and 0.7 ± 0.3 m2). The
duration of ventricular pacing was not significantly different between the two paced groups
(RVP: 3.9 ± 2.1 years vs LVP: 3.8 ± 1.8 years). 
Due to the paucity of preimplantation echocardiographic data, no statistical analysis was
performed on these data. It seems likely from available preimplantation echocardiographies (3
RVP and 4 LVP) that mechanical asynchrony during AV nodal escape rhythm was irrelevant
because SPWMD was 48 ± 33 ms in the RVP group and 23 ± 22 ms in the LVP group.
Furthermore, available data suggest no preimplantation difference in shortening fraction
between the two groups (RVP: 35.4% ± 6.2% vs LVP: 36.5% ± 3.3%).   
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Figure 1: Representative echocardiographic short-axis view. 
Six regions are indicated for wall thickness determination (arrows) and the inner diameter of the left ventricle
(LV). The LV diameter was determined bidirectionally as the mean of diameters A and B.
Structural echocardiographic outcome
Interobserver reproducibility was good for LVEDD (r = 0.96), LVESD (r = 0.95), mean LVEDWT (r
= 0.90), and mean LVESWT (r = 0.94). Among the three study groups, LVEDD, LVESD, mean
LVEDWT, and mean LVESWT did not differ significantly (Table 2). No significant differences in LV
wall thickness between different regions of the heart were observed in any of the study groups
(data not shown).
Functional echocardiographic outcome 
After chronic epicardial pacing, the shortening fraction was significantly lower in the RVP group
(21.7% ± 6.0%) than in the LVP group (32.2% ± 5.2%) or the control group (29.3% ± 4.3%,
nonsignificant difference between the control and LVP groups, Figure 2). The end-systolic LV
eccentricity index was significantly higher in the RVP group (1.8 ± 0.2) than in the LVP (1.4 ± 0.1)
and control (1.4 ± 0.2) group (nonsignificant difference between the LVP and control groups,
Figure 3). At end-diastole, the LV eccentricity index was not significantly different between the
study groups (RVP: 2.7 ± 0.3; LVP: 2.7 ± 0.6; control: 2.7 ± 0.4). The SPWMD was similar in the
control (-5 ± 35 ms) and LVP (-16 ± 14 ms) groups, with good interobserver reproducibility (r =
0.97). As compared with the control and LVP groups, the SPWMD in the RVP group (338 ± 20
ms) was significantly different (p<0.001). 
QRS-duration
The duration of QRS was 69 ± 7 ms in the control group, and significantly longer (p < 0.001) in
both paced groups (RVP: 157 ± 10 ms vs LVP: 158 ± 22 ms; nonsignificant difference between
RVP and LVP). 
Chronic RV and LV Pacing in Children
81
Table 2: Echocardiographic structural results
RV Pacing group LV Pacing group Control group
LVEDD (mm) 39.5 ± 6.8 39.4 ± 6.1 34.2 ± 6.8
z-score 0.6 ± 0.9 0.4 ± 0.7 0.0 ± 0.9
LVESD (mm) 31.0 ± 6.9 26.7 ± 4.3 24.2 ± 5.2
LVEDWT (mm) 7.4 ± 2.1 7.4 ± 1.3 6.3 ± 1.2
z-score 1.5 ± 1.4 1.3 ± 0.9 0.8 ± 0.5
LVESWT (mm) 8.7 ± 1.9 9.2 ± 1.3 8.2 ± 1.4
LV = left ventricular, LVEDD = LV end-diastolic diameter, LVEDWT = mean LV end-diastolic wall thickness, LVESD = LV end-systolic
diameter, LVESWT = mean LV end-systolic wall thickness, RV = right ventricular. 
There are no significant differences between groups.
DISCUSSION
To our knowledge, this is the first study to compare the long-term effects of RV and LV pacing in
children. The current study supports the finding of previous studies that chronic RV pacing can
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Figure 2: Shortening fraction in the study groups. 
Closed symbols represent individual data. Open symbols represent group average ± standard deviation. LVP,
left ventricular pacing group; RVP, right ventricular pacing group. 
Figure 3: End-systolic left ventricular eccentricity index in the study groups. 
For legends see Fig. 2.
be detrimental to LV function.1, 2, 7, 8 Chronic RV pacing is associated with deleterious LV
remodeling8, 9 and decreased LV function7 in the young (for a review, see Karpawich)1 and in
adults (for review see Manolis).2 More importantly, the current study shows that during chronic
epicardial LV pacing (mean duration >3½ years), LV function and structure are maintained at the
level of healthy control children. Therefore, the pacing site appears an important determinant for
cardiac function and structure in children. 
Pacing site and LV structure
Animal experiments showed asymmetrical hypertrophy during pacing,27 because early-activated
regions of the LV had low workload due to a low pressure gradient at this early activation phase.
Low workload results in hypotrophy, whereas late-activated regions hypertrophy as they are
stretched before activation and thus must perform higher myocardial work (local Frank-Starling
effect). Remarkably, we did not find differences in regional wall thicknesses during pacing,
possibly because the quality of images was not appropriate to distinct regional changes in wall
thicknesses.
Relation between pacing site and LV function 
In parallel with the acute decrease in cardiac pump function during RV pacing,5, 6 chronic RV
pacing significantly depressed shortening fraction in the current study. Furthermore, the LV
eccentricity index was significantly increased after chronic RV pacing. This eccentricity index
provides an approximation of fiber stress, since fiber stress increases proportionally to the result
of the following equation28, 29: LV pressure x (LV cavity diameter / LV wall thickness). From this
equation, it can be deduced that at similar LV pressure, an increase in LV cavity diameter or a
decrease in LV wall thickness will result in higher fiber stress. Although neither LV nor aortic pressures
were assessed for this study, the increased eccentricity index in RV-paced children may indicate
increased fiber stress. Left ventricular pacing neither increased the eccentricity index nor
decreased the shortening fraction after more than 3 years of pacing. Superior hemodynamic
performance during LV pacing compared with RV pacing probably is caused by a more favorable
balance between interventricular synchrony,30 intraventricular synchrony,6 and the sequence of
electrical ventricular activation3 during LV pacing. The idea that the sequence of activation is an
important determinant of cardiac pump function is supported by other studies as well.3, 31
During RV pacing, a left bundle branch block pattern of activation is created.1-3, 6 In the current
study, RV-paced children showed significant intraventricular mechanical dyssynchrony, with
motion of the interventricular septum toward the LV posterior wall more than 300 ms before the
first peak of inward LV posterior wall movement. This motion pattern of the interventricular
septum is caused by the pressure developments within each ventricle. If the interventricular
septum and the LV free wall are activated after the RV free wall, RV pressure increases before LV
pressure is built up. This causes early systolic bulging of the interventricular septum into the LV.32
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Cardiac resynchronization therapy with biventricular pacing increases cardiac function after
surgery for congenital heart disease compared with intrinsic activation.30, 33 Experience with
chronic biventricular pacing in children is sparse, but a multi-center study showed promising
results with regard to cardiac function after 4 months of resynchronization therapy,34 and
biventricular pacing proved effective in the treatment of six children with RV pacing-induced heart
failure.10 In adults with congestive heart failure, chronic LV lateral wall pacing (single-site, short AV
delay) can be as effective as biventricular pacing.20, 35, 36 To our knowledge, the effect of chronic
biventricular pacing in children has not been compared with LV lateral wall pacing alone.
The duration of QRS was not significantly different between the two paced groups in our
study despite the significantly different hemodynamic and mechanical performance. This is
consistent with other studies, in which QRS duration during pacing was not related to cardiac
function.6, 31, 33 It is important to bear in mind that QRS duration reflects total biventricular
activation time, whereas intraventricular mechanical synchrony and sequence of electrical
ventricular activation3 probably are more important determinants of LV function.2, 6 Given the
absence of a consistent correlation between cardiac function and QRS duration in acute and
chronic pacing studies, we discourage the use of QRS duration as a tool for the selection of an
optimal epicardial pacing site in children. 
Clinical application
We apply and advocate the use of LV pacing sites when chronic epicardial pacing is indicated in
children. We do so because chronic LV pacing has proved superior to RV pacing in terms of LV
function and relative systolic dimensions in the current study, and because in some case reports,
RV pacing-induced heart failure was successfully treated with single-site LV pacing.37-39 However,
once implantation of LV epicardial leads is started, it is of major clinical importance to know
which site, apex or free wall, should be preferred. In an acute-pacing study, LV apex pacing
increased pump function compared with RV pacing, whereas there was no benefit of LV free wall
pacing.6 Nevertheless, the current study shows that LV lateral wall pacing preserves LV function.
These findings could be explained by subtle differences in LV lateral wall pacing sites. In the
aforementioned study,6 the pacing lead was placed at the base of the LV lateral wall, whereas in
the current study, the location of the LV pacing lead was half way between the LV apex and the
base of the LV lateral wall (mid lateral wall). 
The hypothesis that the exact pacing site at the LV lateral wall influences the effect of LV
pacing is supported by the following experiment. In an established animal left bundle branch
block (LBBB) model,40, 41 we investigated the hemodynamic improvement of four epicardial LV
pacing sites. In 7 dogs with experimental LBBB, pacing was applied at four LV pacing sites: apex,
apical lateral wall, mid lateral wall and base of the lateral wall, respectively. At all sites, pacing
was performed at the same short AV delay to avoid fusion with intrinsic activation. The averaged
maximum rate of LV pressure rise (LVdP/dt|max) from all beats during one ventilation cycle,
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measured with a catheter tip manometer, was used as a measure of LV function. Compared with
LBBB, LVdP/dt|max was significantly increased by pacing at the LV apex (18% ± 11%; p = 0.005),
LV apical lateral wall (11% ± 6%; p = 0.001) and LV mid lateral wall (7% ± 6%; p = 0.020),
whereas no significant improvement in LV function occurred during pacing at the base of the LV
lateral wall (3% ± 10%; p = 0.413). 
Although pacing at the LV apex caused the most pronounced improvement in LV function,
it is not easy to come within reach of this particular pacing site using established endovenous or
minimal surgical techniques. However, pacing at epicardial LV mid lateral wall sites also resulted
in improved LV function and is easily accessible through a left lateral thoracotomy. This approach
is surgically reliable and provides excellent cosmetic and functional results in children.21
Study limitations
Although the number of patients studied in the current series was small, we consider the study
groups to be comparable because body surface area, age, and duration of pacing were similar,
and none of the patients had structural heart disease. Because echocardiographic image quality
deteriorates during long-term storage,42 we were hampered in our retrospective evaluation,
especially in the evaluation of preimplantation data. We therefore could not achieve a
longitudinal follow-up evaluation of all the patients and could not perform statistical analysis of
echocardiographic preimplantation data. Therefore, the possibility that some of the differences
between chronically RV and LV paced children were preexisting cannot entirely be excluded. The
main disadvantage of this study is its retrospective design. The positive effects of single-site LV
pacing observed in this study, as well as the practical advantages of single-site over multisite
ventricular pacing, strongly advocate further investigation on LV pacing in prospective
multicenter studies.
CONCLUSION
Left ventricular function in children is preserved by chronic pacing at the LV lateral wall, whereas
chronic RV pacing causes a decrease in shortening fraction and a higher systolic eccentricity
index. 
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ABSTRACT
Background: Chronic right ventricular (RV) pacing is associated with deleterious effects on
cardiac function. 
Objective: In an observational multicentre study in children with isolated atrioventricular (AV)
block receiving chronic ventricular pacing, the importance of the ventricular pacing-site on left
ventricular (LV) function was investigated. 
Methods: Demographics, maternal autoantibody status and echocardiographic measurements
on LV end-diastolic and end-systolic dimensions and volumes at age <18 years were
retrospectively collected from patients undergoing chronic ventricular pacing (>1 year) for
isolated AV block. LV fractional shortening (LVFS) and, if possible LV ejection fraction (LVEF) were
calculated. Linear regression analyses were adjusted for patient characteristics. 
Results: From 27 centres, 297 children were included in whom pacing was applied at the RV
epicardium (RVepi, n=147), RV endocardium (RVendo, n=113) or LV epicardium (LVepi, n=37).
LVFS was significantly affected by pacing-site (p=0.001), and not by maternal autoantibody
status (p=0.266). LVFS in LVepi (39±5%) was significantly higher than in RVendo (33±7%,
p<0.001) and RVepi (35±8%, p=0.001; no significant difference between RV-paced groups,
p=0.275). Subnormal LVFS (LVFS<28%) was observed in 16/113 (14%) RVendo-paced and
21/147 (14%) RVepi-paced children, while LVFS was normal (LVFS≥28%) in all LVepi-paced
children (p=0.049). These results are supported by the findings for LVEF (n=122): LVEF was
<50% in 17/69 (25%) RVendo- and in 10/35 (29%) RVepi-paced patients, while LVEF was ≥50%
in 17/18 (94%) LVepi-paced patients.
Conclusion: In children with isolated AV block, permanent ventricular pacing-site is an
important determinant of LV function, with LVFS being significantly higher with LV pacing than
with RV pacing. 
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INTRODUCTION
In patients with bradycardia due to complete atrioventricular (AV) block, ventricular pacing is
required to normalise heart rate. The pacing-induced activation pattern is characterised by a
prolonged total activation duration and an abnormal sequence of activation (in both longitudinal
and transverse directions). This abnormal electrical activation pattern may lead to
dyssynchronous ventricular contraction, the degree of dyssynchrony varying with the site of
pacing.1 Ventricular pacemaker electrodes are conventionally positioned either at the right
ventricular (RV) endocardium or at the RV epicardium. However, RV pacing results in a left
bundle branch block morphology and is associated with cardiac dysfunction and remodeling.2-7
The preservation of cardiac function during chronic ventricular pacing should be a high priority,
especially in paediatric patients who are usually paced from an early age and may expect lifelong
pacing. The main objective of this multicentre study was to investigate whether left ventricular
(LV) pacing sites, in comparison with RV endocardial and RV epicardial pacing sites, have fewer
adverse long-term functional and structural effects, and may prevent pacing-induced LV
dysfunction in children with isolated AV block.
MATERIALS AND METHODS
Study population
From the institutional databases of the participating 27 centres, patients with a structurally
normal heart and isolated advanced second-degree or complete AV block with chronic and
permanent ventricular pacing for rate control (minimum of 1 year follow-up, minimum of 70%
ventricular paced beats) were identified. All these patients were considered for inclusion.
Exclusion criteria were: postsurgical AV block, structural congenital heart disease and evident
cardiomyopathy due to causes other than AV block. Study end points were reached whenever
patients reached 18 years of age, underwent a change in pacing-site, received cardiac
resynchronisation therapy or cardiac transplantation for heart failure, or died. For those cases,
data from the last echocardiography before the event were used. 
Data 
Demographic data and clinical characteristics (gender, age, body surface area, aetiology of AV
block, maternal autoantibody status, year of pacemaker implantation, duration of pacing) were
collected. Parameters from the last echocardiography performed at a routine follow-up visit at
age <18 years were reviewed. In all patients, LV end-diastolic diameter (LVEDD) and end-systolic
diameter (LVESD) were assessed. The degree of LV dilatation was evaluated by adjusting LVEDD
for body size, expressed as a z-score.8 As a measure of LV function, LV fractional shortening
(LVFS) was calculated [LVFS=(LVEDD-LVESD)/LVEDDx 100%]. According to generally accepted
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criteria,8, 9 we classified LVFS as ‘normal’ (LVFS ≥28%), ‘subnormal’ (LVFS <28%) or ‘depressed’
(LVFS <25%). For the subset of patients in whom end-diastolic and end-systolic LV volumes
(LVEDV and LVESV, respectively) were assessed, LV ejection fraction (LVEF) was calculated
[LVEF=(LVEDV-LVESV)/LVEDVx 100%]. Mitral regurgitation was scored on a scale from 0 (= no
regurgitation) to 4 (= severe regurgitation). Based on the location of the tip of the ventricular
pacing electrode (the site of pacing), the cohort was divided into three groups: RV epicardium
(RVepi), RV endocardium (RVendo), or LV epicardium (LVepi). 
Statistical analysis
Comparisons between groups were performed with analysis of variance or 2 tests, as
appropriate. Linear regression analyses were used to examine whether LVFS and LVEDD z-scores
differed between the groups (i.e., between pacing-sites). These analyses were adjusted for the
following covariates: maternal autoantibody status (‘positive’, ‘negative’, or ‘unknown’), year of
pacemaker implantation, age at implantation, participating centre, and duration of pacing and
body surface area at echocardiographic follow-up. The influence of pacing-mode (VVI vs DDD)
on LVFS was investigated only in the subset of patients for whom pacing-mode at follow-up was
reported. Additionally, to carefully investigate the potential influence of maternal autoantibody
status on LV function, linear regression analyses were performed on the study population
grouped into ‘autoantibody positive’, ‘autoantibody negative’ and ‘unknown autoantibody
status’. In these analyses, ‘pacing-site’ was included as a covariate in addition to above-
mentioned characteristics. Group characteristics are expressed either as mean±SD, or as
proportion (%). Mean differences in LVFS and LVEDD adjusted for covariates are expressed as
effect sizes (ß) 95% CIs, p<0.05 = significant.
RESULTS
Study population: demographic data and clinical characteristics
A total of 297 children, from the institutional databases of the 27 participating centres, were
included in the study. Pacing-site distribution was: RVendo (n=113), RVepi (n=147), and LVepi
(n=37). Maternal autoantibody status (anti-SSA (Ro), anti-SSB (La)) was reported for 201 (68%)
of the patients. Maternal autoantibodies were present in 88 (44%) of these. Patient
characteristics summarised for each pacing-site are listed in Table 1. With the above-mentioned
numbers of patients in each group, it would be possible to detect differences in LVFS between
the pacing-site groups with a power >90% ( =5% points; SD 8% points; =0.05; unequal
groups). 
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Effect of pacing-site on left ventricular fractional shortening and dilatation score
At routine follow-up, LVFS was significantly higher in children with LVepi pacing (39±5%) than in
children with RVendo pacing (33±7%) and RVepi pacing (35±8%) (Figure 1). Pacing-site was the
solitary significant determinant (p=0.001) of LVFS (maternal autoantibody status, p=0.266;
duration of pacing, p=0.833; body surface area at follow-up, p=0.882; centre, p=0.560; year of
implantation, p=0.182; and age at implantation, p=0.809). The mean LVFS differences adjusted
for covariates (i.e., ‘effect size ß’) are reported in Table 2. In the subgroup of patients for whom
the pacing-mode (either VVI or DDD) at follow-up was reported (n=242), pacing-mode was not a
significant determinant (p=0.209) while pacing-site remained a significant determinant of LV
function (p=0.002). Differences between pacing-sites, adjusted for pacing-mode in addition to
the other covariates, were similar to the effect sizes reported in Table 2. LVEDD z-score was normal
in all groups (RVendo 0.0±1.3; RVepi 0.4±1.1; LVepi 0.3±0.9, Figure 2), and was not significantly
influenced by pacing-site (p=0.640), or by maternal autoantibody status (p=0.724) or any of the
other covariates. The adjusted means were not significantly different as presented in Table 2.
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Table 1: Patient characteristics
RV endo RV epi LV epi p-value
(n=113) (n=147) (n=37)
Gender (M/F; %) 50 / 50 44 / 56 46 / 54 0.692
Aetiology of AV block
- Congenital / infectious / unknown (%) 69 / 3 / 28 85 / 1 / 14 92 / 0 / 8 0.126
- Anti-Ro/La antibodies: +/ -/ unknown (%) 17 / 38 / 45 40 / 43 / 17 27 / 19 / 54 <0.001
Age at implantation (years) 7.9 ± 4.1 2.0 ± 2.4 2.7 ± 3.5 <0.001*
Age at follow-up (years) 13.8 ± 3.4 7.4 ± 4.2 7.3 ± 4.5 <0.001*
BSA at follow-up (m2) 1.5 ± 0.3 0.9 ± 0.3 0.9 ± 0.4 <0.001*
Duration of pacing at follow-up (years) 5.9 ± 3.4 5.4 ± 3.6 4.6 ± 3.1 0.108
Years since implantation until July 2010 8.9 ± 4.0 8.2 ± 4.5 8.1 ± 6.1 0.468
QRS duration (paced; ms) 146 ± 19 139 ± 20 148 ± 24 0.004†
Pacing mode at follow-up 
- VVI / DDD / not reported (%) 32 / 50 / 18 46 / 40 / 14 22 / 38 / 40 0.059
AV block = atrioventricular block; BSA = body surface area; LVepi = left ventricular epicardial pacing; RV endo = right ventricular
endocardial pacing; RVepi = right ventricular epicardial pacing. 
* No significant differences between RV epi and LV epi (p=0.229, p=0.809 and p=0.837 for age at implantation, age at follow-
up and BSA at follow-up, respectively)
† RV epi versus RV endo, p=0.005; RV epi vs LV epi, p=0.012; RV endo versus LV epi, p=0.545.  
Depressed LV function in ~10% of the chronically RV-paced patients
LVFS was subnormal (LVFS <28%) in 16 RVendo- (14%) and 21 RVepi-paced patients (14%). In
more detail, LVFS was depressed (LVFS <25%) in 10 (9%) of the RVendo-paced and in 17 (12%)
of the RVepi-paced patients. In contrast, LVFS was normal (LVFS ≥28%) in all patients in whom
LV pacing was applied (p=0.049, X2 test). In the subset of patients for whom we could calculate
LVEF (n=122), LVEF was <50% in 17/69 (25%) RVendo-paced and in 10/35 (29%) RVepi-paced
patients, whereas this was only the case in one of the 18 (6%) LVepi-paced patients.  
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Figure 1. Left ventricular fractional shortening after chronic ventricular pacing. 
Left ventricular fractional shortening (LVFS), a measure of LV function, was significantly (*) higher in
children being paced at the LV epicardium (LVepi) than in children being paced at the RV epicardium (RVepi)
or RV endocardium (RVendo). Box plots represent 25th, 50th, and 75th percentiles. Whiskers represent the
minimal and maximal values within the range of [25th percentile - 1.5*IQR] and [75th percentile + 1.5*IQR],
respectively. Dots display mean values.
Mitral regurgitation
Distribution of mitral regurgitation scores was significantly different between the pacing-site
groups (p=0.032, X2 test). Mitral regurgitation was mild (score 1) in 42(29%) RVepi-paced and
in 19(17%) RVendo-paced patients, but only in three (8%) LVepi-paced patients. Score ‘2’ was
reported for four patients (RVepi n=1; RVendo n=2, LVepi n=1), while none of the patients had
moderate to severe mitral regurgitation (scores 3 and 4). 
Influence of maternal autoantibody status
As shown by the analyses grouped by pacing-site, LVFS was significantly affected by pacing-site
(p=0.001), while maternal autoantibody status did not affect LVFS, or LVEDD z-score (p=0.266 and
p=0.724, respectively). These results were confirmed when analyses were performed on the same
population grouped by maternal autoantibody status. For the three groups, mean LVFS and LVEDD
z-scores were comparable: 34±8% and 0.4±1.3 for ‘positive’, 35±7% and 0.1±0.9 for ‘negative’,
and 34±8% and 0.1±1.3 for ‘unknown’ maternal autoantibody status (LVFS and LVEDD z-score,
respectively). Maternal autoantibody status was not a significant determinant of either LVFS
(p=0.386) or LVEDD z-score (p=0.901), while pacing-site remained a significant determinant of
LVFS (p=0.013).
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Table 2: Mean differences in left ventricular fractional shortening and dilatation score
Effect size ß 95% CI p-value
LVFS
LVepi vs RVepi + 4.7 %-points 1.9 %  to 7.5 %-points 0.001*
LVepi vs RVendo + 6.1 %-points 2.9 %  to 9.3 %-points < 0.001*
RVepi vs RVendo + 1.4 %-points -1.1 %  to 3.9 %-points 0.275
LVEDD z-score
LVepi vs RVepi - 0.1 - 0.5   to 0.3 0.579
LVepi vs RVendo - 0.3 - 0.8   to 0.2 0.268
RVepi vs RVendo - 0.2 - 0.5   to 0.2 0.428
Effect size ß = mean difference between groups, adjusted for covariates. 
* Significant mean difference between the groups.
LVEDD = left ventricular end-diastolic diameter; LVepi = left ventricular epicardial pacing; LVFS =  left ventricular fractional
shortening; RVendo = right ventricular endocardial pacing; RVepi = right ventricular epicardial pacing.
DISCUSSION
This multicentre study retrospectively surveys LV function and dimensions in 297 children with
structurally normal hearts and chronic ventricular pacing for isolated AV block. In these patients,
requiring lifelong chronic ventricular pacing, preservation of cardiac functional and structural
integrity is a major challenge. This study indicates that pacing-site significantly influences LVFS,
with better LVFS in LVepi-paced patients than in RVepi-paced or RVendo-paced patients. 
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Figure 2. Left ventricular dilatation-score after chronic ventricular pacing
The z-score for left ventricular end-diastolic diameter (LVEDD z-score), a measure of left ventricular
dilatation, was not significantly influenced by the site of pacing. LVEDD z-score was normal for all groups
and differences between the pacing groups were not significant. Box plots represent 25th, 50th, and 75th
percentiles. Whiskers represent the minimal and maximal values within the range of [25th percentile -
1.5*IQR] and [75th percentile + 1.5*IQR], respectively. Dots display mean values.
Pacing-site influences left ventricular function 
In this survey, LV function was found to be subnormal (LVFS <28%) in 14%, and depressed (LVFS
<25%) in ~10% of the RVepi- and endo-paced patients. Our findings on LVFS are supported by
those in the subset of patients for whom we were able to calculate LVEF: the proportion of
patients with subnormal LVEF (LVEF <50%) was for each pacing-group comparable to the
proportion of patients with subnormal LVFS. Several other studies report that, within less than a
decade of pacing, 7-10% of chronically RV-paced patients develop heart failure and that up to
13% have depressed LV function combined with LV dilatation.2, 10, 11 Chronic RV pacing, rather
than the aetiology of AV block, has been identified as an independent risk factor for
development of LV dilatation and dysfunction.11, 12 This study indicates that it is predominantly
the pacing-site that affects LV function, as reflected by (1) a higher LVFS in the LV-paced group
than in the RV-paced groups; (2) pacing site being the only significant factor influencing LVFS;
and (3) dissimilar incidence of patients with LVFS<28% between the pacing-site groups.
Moreover, maternal autoantibody status did not significantly influence LV function or LV
dilatation score. Though it appears that there are relevant proportions of patients who do not
tolerate RV pacing, the reasons are not elucidated in this retrospective study. Chronic LV pacing,
however, seems to be well tolerated by all patients, as suggested by absence of LV dysfunction
in the LV-paced group. From the latter finding we hypothesise that pacing-induced LV failure in
children with structurally normal hearts might be prevented by LV pacing. 
Potential reasons for preservation of LV function by LV pacing 
We postulate that, above and beyond synchrony (reflected by the total duration of activation), the
sequence of activation is a major determinant of cardiac pump function.1, 13 In LV pacing the pattern
of activation and mechanical contraction pattern may be more favourable than patterns induced by
RV pacing. During LV (free wall) pacing, the total duration of activation is prolonged similarly to that
during RV free wall pacing, reflected by a similar QRS duration.14 However, in contrast to RV pacing,
LV pacing leads to activation of the LV lateral wall before the septum and RV lateral wall, preventing
paradoxical septal movement and resulting in better haemodynamic performance than with RV
pacing.1, 15 Furthermore, LV apical pacing induces physiological apex-to-base activation, which results
in synchronous electrical activation and contraction around the circumference of the LV.16, 17 These
remarks are supported by the observation of Gebauer et al., that LV apical pacing preserves septal-to-
lateral LV mechanical synchrony as well as systolic function.18 Also, experimental studies have shown
that LV apical pacing is better than pacing at other sites and that it maintains cardiac function at a
normal level.19, 20
Single-site left ventricular pacing versus biventricular pacing
Biventricular pacing is often used to resynchronise electrical activation in patients with either
intrinsic or pacing-induced dyssynchrony and LV dysfunction. Biventricular pacing (following
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chronic RV pacing) improves pump function and reverses ventricular remodelling in children at
least as effectively as in adults with heart failure.21-23 Although single-site LV pacing and
biventricular pacing have not yet been compared in children, single-site LV pacing in adult
patients with heart failure results in the same improvement in LV function as acute or chronic
biventricular pacing.24-26 Also, animal experiments have indicated that single-site LV apical and
LV septal pacing maintain cardiac function and efficiency at least as well as biventricular
pacing.19 The use of a single optimal ventricular pacing-site provides advantages over
biventricular pacing, such as lower pacemaker battery usage and a reduction in the number of
surgical access routes required and consequent scar tissue formation.
Clinical implications of the results from the current study
Since paediatric patients with AV block are usually paced from an early age and require lifelong
pacing, preservation of cardiac function during chronic ventricular pacing is important. This study
indicates that LV pacing may be better than RV pacing if LV function is concerned. In the
individual patient, depressed LV function (as seen in ~10% of the RV-paced patients) may
indicate that chronic pacing is not well tolerated and that there may be a higher risk for pacing-
induced heart failure. The median follow-up of pacing in this study, as in other studies, was less
than a decade, which is a mere fraction of the lifelong follow-up expectancy of a child receiving
ventricular pacing for complete AV block. The (very) long-term outcome of either RV or LV pacing
beginning in childhood is still unknown. Considering the findings of this and other studies,14, 27,
28 we suggest the use of a single LV apex or LV free wall site for chronic ventricular pacing in
children with AV block and structurally normal hearts. Unfortunately, as each ventricle brings a
continuum of possible pacing-sites, and accuracy of (retrospective) determination of the precise
site is limited, this survey has not provided exact data to reliably test which spot on the left
ventricle would be the best, or whether certain sites within the right ventricle may be better than
others.7 It is important not to simply extrapolate the results of this study to children with
structural congenital heart disease. Nevertheless, the results are likely to be applicable to patients
with a systemic left ventricle, in absence of intrinsic RV activation delay.
Practical considerations
Surgical access for LV pacing via a left lateral thoracotomy is minimal, easy and safe, though
invasive.29 In small children, the LV apex can easily be reached by a sub-xiphoidal approach,
thereby avoiding a lateral thoracotomy, and with reasonable cosmetic results. Acknowledging
the potential surgical complications, we particularly suggest implantation of electrodes at the LV
epicardium if there are also other indications for a surgical approach.30 In larger children, single-
site epicardial LV pacing may also be achieved by a transvenous approach via the coronary sinus.
In the near future, endocardial pacing in the systemic ventricle may become feasible through the
application of ‘wireless pacing’. However, in practice, the routine transvenous approach seems
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justifiable in young adults, as RV apical pacing is well tolerated by most patients.10, 31 Regular
follow-up with echocardiography to detect LV deterioration at an early stage is warranted in all
paced patients receiving chronic ventricular pacing. Changing to either biventricular or single-site
pacing at the systemic ventricle should be considered when echocardiography discloses signs of
progressive ventricular dysfunction.21, 22, 32-34
Study limitations 
The retrospective design of the study is a disadvantage, mainly because it hampers the use of
sophisticated echocardiographic parameters. The shortening fraction is a limited marker for
systolic function, and it may be affected by intraventricular asynchrony. Nevertheless, it was
chosen as a main outcome parameter, as it is the most consistently measured variable in this
population. Data on LVFS in the entire study population were supported by data on LVEF in those
patients for whom LV volumes were available. The possibility of unintended bias for the effect of
pacing from the various sites cannot totally be excluded since measurements were not
performed blinded to the pacing-site. However, at the time of the echocardiographic
examination, there was no intention to compare the effects of different pacing-sites. Each centre
identified patients eligible for the study by systematically reviewing the institutional database.
The structure of the database affected the time span of inclusion, and therefore also the number
of patients from each centre. The number of LV-paced patients included in this study is relatively
small in respect to the number of patients in the RV-paced groups, since LV pacing (for first
implantation) is only used at a minority of centres. However, patients from several different
centres are included for each pacing group (nine centres for the LV-paced group). Besides,
‘participating centre’ was entered as a covariate in the analysis to correct for potential bias
arising from centre-based differences. 
Future studies with larger numbers of LV-paced patients, more sophisticated
echocardiographic indices and longitudinal follow-up are needed to confirm the conclusions of
this survey, and to explore the effect of pacing-site on parameters other than LV function. 
CONCLUSION
In children with normal cardiac anatomy and AV block, the site of pacing is an important
determinant of LV function, with LVFS being significantly higher in children with chronic LV
pacing than in children with chronic RV pacing. LVFS was subnormal (LVFS <28%) in 14% of the
RV-paced children, whereas LVFS was normal in all LV-paced children. 
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ABSTRACT
Background: We evaluated the effects of the site of ventricular pacing on left ventricular (LV)
synchrony and function in children requiring permanent pacing.
Methods: 178 children (age <18 years) from 21 centers with complete atrioventricular block
and a structurally normal heart undergoing permanent pacing were cross-sectionally studied.
Median age at evaluation was 11.2 (inter-quartile range (IQR) 6.3-15.0) years. Median pacing
duration was 5.4 (IQR 3.1–8.8) years. Data were analyzed in a core lab. Pacing-sites were the free
wall of the right ventricular (RV) outflow tract (RVOT, N=8), lateral RV (RVLat, N=44), RV apex
(RVA, N=61), RV septum (RVS, N=29), LV apex (LVA, N=12), LV mid-lateral wall (LVLat, N=17),
and LV base (LVB, N=7). 
Results: LV synchrony (assessed by 2-dimensional strain), pump function (ejection fraction (EF),
end-systolic volume index, shortening fraction) and contraction efficiency were significantly
affected by pacing-site and were superior in children paced at LVA/LVLat. LV dyssynchrony
correlated inversely with LV EF (R=0.80, P=0.031). Pacing from RVOT/RVLat predicted decreased
LV function (LV EF <45 %; OR 5.19 CI 1.74-15.50, P=0.003) whereas LVA/LVLat pacing was
associated with preserved LV function (LV EF >55 %; OR 6.97, CI 2.21-22.00, P<0.001). Age at
implantation, pre-implantation LV size and function, duration of pacing, DDD mode, QRS
duration, and presence of maternal auto-antibodies had no significant impact on LV EF in a
multivariable analysis.
Conclusion: The site of ventricular pacing has a major impact on LV mechanical synchrony,
efficiency and pump function in children that require life-long pacing. The preferred LVA/LVLat
site can be reached using existing tools, allowing easy prevention of pacing-induced heart
failure. 
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INTRODUCTION
Right ventricular (RV) pacing has been used for decades in both adults and children. Recently,
several large adult studies,1-3 smaller pediatric reports,4-7 and one larger pediatric survey8 have
pointed towards the adverse effects of RV pacing. The incidence of left ventricular (LV)
dysfunction in RV paced children ranged within a medium follow-up of less than a decade from
6.0 to 13.4%.4 The impact of pacing-induced dyssynchrony may be especially important in
children with a prospect of life-long pacing that lasts for decades. This idea is nourished by
findings that dyssynchronous LV activation causes pathologic remodeling and dysfunction.9
Pediatric pacemaker therapy represents an optimal model for the evaluation of the long-term
effects of different pacing-sites because, based on surgical preferences and in contrast to adults,
various pacing-sites are used including LV epicardial pacing. In small single center reports10-14
and one larger retrospective survey8 pacing from the LV apex or free wall was associated with
better preservation of LV function. The purpose of the current multi-center study was to evaluate
the influence of different ventricular pacing-sites on long-term LV function in children with non-
surgical atrioventricular block and a structurally normal heart, and to search for a mechanism for
the difference in pump function between sites, by measuring mechanical synchrony and
efficiency in a cross-sectional echocardiographic evaluation.
PATIENTS AND METHODS
Recruitment and demography
Patients were recruited from 21 centers providing pacemaker therapy for children (17 European and
four North American). According to the study protocol (available online) the patients had to fulfill the
following inclusion criteria: presence of second or third degree atrioventricular (AV) block
necessitating permanent cardiac pacing with >70 % ventricular paced beats, age <18 years at the
time of primary pacemaker implantation, absence of any but trivial structural heart disease and of any
known systemic illness potentially influencing cardiac function, duration of pacing more than one
year, and no change in the ventricular pacing-site during the follow-up period. A total of 178 patients
(female: 96, male: 82) were included in the study with a median age at pacemaker implantation of
3.2, inter-quartile range (IQR) 0.2 – 7.0 years. AV block was congenital in 138 patients and diagnosed
later during childhood in the remaining 40. Maternal auto-antibodies were present in 64 of the 136
mothers tested. Nine of the 178 patients had patent ductus arteriosus which was closed
interventionally using coils prior to (N=3), at the time of (N=3), or after (N=3) pacemaker
implantation. The retrospectively gathered data further included demographic parameters, pre-
implantation LV size and function, New York Heart Association (NYHA) classification, and pacemaker
implantation details (pacing-site as recorded by the implanting physician, lead type: endocardial vs
epicardial, and initial pacing-mode and its change during the follow-up period). 
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Cross-sectional evaluation
After obtaining ethical approval by the hospital review committee and patient consent according
to individual institutional guidelines, eligible patients were evaluated according to a pre-specified
protocol including NYHA class assignment, 12-lead electrocardiogram (ECG), echocardiography,
and, if not available in the patient files, a chest x-ray in the antero-posterior and lateral
projections. The echocardiographic protocol consisted of: 1. two-dimensional grey scale loops of
the parasternal long axis view, parasternal short axis view (at the level of papillary muscles),
apical four-chamber view, and apical two-chamber view. 2. Parasternal long axis and short axis
M-mode. 3. Pulsed Doppler of the RV- and LV-outflow tracts, pulsed transmitral Doppler, and
qualitative assessment of mitral regurgitation (none = 0, mild = 1, moderate = 2 and severe = 3). 
Data analysis
All data were analyzed in a core lab (Children’s Heart Center, Prague, Czech Republic): 1. QRS
duration was measured manually as the maximum value in any lead from ECG printouts with a
sweep speed of 25 or 50 mm/s; 2. Pacing-site assignment was performed using 12-lead ECG
QRS morphology and axis15 and bi-plane chest x-rays from either the cross-sectional evaluation
or any time before; pacing-sites were grouped into seven categories for the purpose of statistical
evaluation: free wall of the RV outflow tract (RVOT), lateral RV wall (RVLat), RV apex (RVA), RV
septum (RVS) (any position), LV apex (LVA), lateral LV wall (LVLat), and LV base (LVB). Details of
the echocardiographic analysis are available on-line. 
Statistics
Data are presented as mean (standard deviation) or as median (25-75 % inter-quartile range)
according to their distribution. Multiple comparisons between different patient groups were
performed by one way analysis of variance followed by pair-wise multiple comparisons using the
Holm-Sidak method for normally distributed data. The Kruskal-Wallis one way analysis of
variance on ranks followed by pair-wise multiple comparisons by the Dunn’s method was used
in the absence of normal distribution. Analysis of covariance was further used to elucidate the
influence of covariates on specific patient group data. For comparisons of categorical variables
the chi-square test was applied. Correlation between two variables was evaluated by linear
regression. Inter-observer variability of two-dimensional strain measurements was tested by the
coefficient of variation.16 Independent variables showing univariate differences (P <0.2) related
to decreased LV function (EF <50 %) were entered into the multiple logistic regression analysis.
SigmaPlot for Windows Version 9.0 (Systat Software Inc., San Jose, California, USA) and PASW
Statistics 18.0.3 (IBM Corporation, New York, USA) were used for statistical analysis. Significance
was accepted at the P <0.05 level.
Chapter 7
114
RESULTS
Cross-sectional evaluation was performed at a median age of 11.2 (IQR 6.3-15.0) years. Median
pacing duration was 5.4 (IQR 3.1–8.8) years.
Pacing-sites
In total, 97 patients were paced epicardially and the remaining 81 from the endocardium.
Patients were not distributed equally with respect to pacing-site, reflecting the historical
preference for RV pacing. Demographic and clinical parameters for the respective pacing-sites
are summarized in Table 1. Patients paced from the LVA were younger and had a shorter follow-
up and QRS duration than those paced from the various RV sites. Also, gender distribution and
the proportion of DDD paced patients were not equal. 
Left ventricular function
Left ventricular shortening fraction, ejection fraction and the end-systolic volume index were
different between pacing-sites, whereas the z-score of the LV end-diastolic dimension and the
end-diastolic volume index did not differ. LVA and LVLat pacing yielded significantly higher
shortening fraction and EF, and lower end-systolic volume index than RV pacing-sites (Figure 1).
LV EF was not significantly different between RVS and RVA pacing. Patients with RVOT and RVLat
pacing had the largest scatter in LV EF with the lower quartile as low as <38 % in the RVOT
group (Figure 1B). Patients with LV EF <50 % were confined to RV pacing-sites whereas all
patients paced from the LV had preserved LV function (Figure 2). As compared to the pre-
implantation values the decrease in LV shortening fraction was significant for all RV pacing-sites
(median -7.8, IQR -12.3 to -2.5 SF units, P <0.001) and absent in the LV paced groups (median
0.3, IQR -6.7 to +4.1 SF units, NS, Figure 3). To elucidate the potential effect of maternal auto-
antibodies on LV function in the respective pacing-site groups, analysis of covariance was used.
Pacing-site was still the most significant predictor of both LV EF and shortening fraction (P
<0.001 for both) whereas antibody status reached marginal significance only for LV EF (P
=0.033). RVOT/RVLat pacing was the only significant independent predictor of decreased LV EF
(<45 %) whereas LVA/LVLat pacing was associated with preservation of LV function (LV EF >55
%, Table 2 and 3). Duration of pacing did not show any significant influence on LV function in
the univariate and multi-variable analysis (Table 2 and 3). QRS duration did not correlate with
either the LV EF or the decrease in LV shortening fraction as compared to pre-implantation values
in the whole cohort, or if evaluated separately in the RV and LV paced subgroups, respectively.
To allow for comparison with a recent multicenter retrospective survey,8 we also analyzed LV
function by whether they were RV epicardial, RV endocardial or LV paced. Results were similar to
the previous findings8 with LV pacing being superior to RV endocardial or epicardial pacing in
terms of LV shortening fraction, LV EF, and change in LV shortening fraction as compared to pre-
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implantation values (P <0.05 for all, Table 4). No difference was found between RV epicardial
and endocardial pacing in this analysis.
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Figure 1. LV function at cross-sectional follow-up.
A. LV shortening fraction. B. LV ejection fraction. C. LV end-systolic volume index. The dashed line shows
the division between normal and subnormal values. LVA = LV apex; LVB = LV base; LVLat = lateral LV wall;
LV EF = LV ejection fraction; LVESVi = LV end-systolic volume index; LV SF = LV shortening fraction; RVA=
RV apex; RVLat = lateral RV wall; RVOT = free wall of the RV outflow tract; RVS = RV septum
Left ventricular dyssynchrony
The inter-ventricular and intra-LV delays were significantly different between pacing-sites (Figure 4).
Segmental strain analysis by speckle tracking confirmed this mechanical dyssynchrony pattern
(Figure 5 and 6A, B). RV pacing consistently produced delayed LV ejection and a mechanical
contraction delay between the septum and LV free wall with least negative effect of the RVA
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Figure 3: Change in LV shortening fraction from pre-implantation to cross-sectional follow-up. 
Dashed line = no change. Abbreviations see Figure 1.
Figure 2. Proportion of patients with decreased left ventricular ejection fraction. 
EF = ejection fraction; for other abbreviations see Figure 1.
pacing-site. In contrast, during LVA and LVLat pacing both inter- and intra- ventricular dyssynchrony
were minimal. Pacing-sites located towards the LVB resulted in a reversed intra-LV dyssynchrony
pattern with early free wall and late septal motion. LV EF was significantly dependent on the
degree of LV dyssynchrony (Figure 6C).
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Table 2: Risk factors for decreased LV function (LV EF <45 %)
Univariate Multi-variable
Variable LV EF <45 % LV EF >45 % P= P= OR (5-95 % CI)
Male gender 50.0 % 45.4 % 0.931 - -
Congenital AV block 75.0 % 77.5 % 0.932 - -
Maternal autoantibodies 61.5 % 43.6 % 0.458 - -
Age at implantation [years, median] 1.80 3.18 0.837 - -
RVOT and RVLat pacing 62.5 % 24.8 % 0.004 0.003 5.19 (1.74-15.50)
DDD pacing 50.0 % 48.2 % 0.897 - -
Pacing duration [years, median]                    4.40 5.39 0.175 0.154 0.89 (0.75-1.05)
QRS duration [ms, median] 145 154 0.689 - -
Abbreviations see Table 1.
Table 3: Factors associated with preservation of LV function (LV EF >55 %)
Univariate Multi-variable
Variable LV EF >55 % LV EF <55 % P= P= OR (5-95 % CI)
Male gender 36.1 % 54.1 % 0.036 0.237 0.66 (0.33-1.32)
Congenital AV block 73.6 % 80.5 % 0.410 - -
Maternal autoantibodies 41.1 % 49.3 % 0.391 - -
Age at implantation [years, median] 3.22 2.89 0.598 - -
LVA and LVLat pacing 4.7 % 29.2 % <0.001 <0.001 6.97 (2.21-22.00)
DDD pacing 45.8 % 50.6 % 0.664 - -
Pacing duration [years, median]                    5.02 5.70 0.304 - -
QRS duration [ms, median] 150 157 0.042 0.080 0.986 (0.97-1.00)
Abbreviations see Table 1.
Contraction efficiency
The proportion of wasted LV contraction due to dyssynchrony (see details of the
echocardiographic analysis as available on-line) was significantly higher during RV pacing than
during LV pacing for both radial and longitudinal systolic function: median 8.3 (IQR 5.7-14.5) vs
3.1 (2.2-3.5), P = 0.002 and 6.2 (IQR 5.0-8.2) vs 2.1 (1.2-3.5) %, P <0.001, respectively. 
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Figure 4: 
A. Inter-ventricular mechanical delay. B. Septal to posterior wall motion delay. To allow for comparisons
between pacing sites statistical significance is calculated for absolute measurement values. Dashed line =
inter-/intraventricular synchrony. IVMD = inter-ventricular mechanical delay; SPWMD = septal to posterior
wall motion delay; for other abbreviations see Figure 1.
Table 4: Differences between RV epicardial, endocardial and LV pacing
Pacing-site P
RV RV LV Overall Between 
epicardial endocardial pacing3 groups
pacing1 pacing2
LVSF [%] 31 33 39 <0.001 3 vs 1,2
median (IQR) (27-35) (29-37) (35-44) <0.05
Change in LVSF [SF units] -9 -6 0 =0.001 3 vs 1,2
median (IQR) (-13- -3) (-13- -2) (-7-4) <0.05
LVEF [%] 53 53 60 <0.001 3 vs 1,2
median (IQR) (49-58) (48-57) (55-65) <0.05
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Figure 5: 
A. Mechanical activation pattern in RV free wall pacing showing early peak negative 2D strain in the basal
and mid-ventricular septum (white arrow) and late negative strain peak in the LV free wall (grey arrow). An
extensive septal to lateral mechanical dyssynchrony with a delay of 300 ms is present. B. Left ventricular
apical pacing with mechanical activation starting at the apex (white arrows) and proceeding to the base
(grey arrows) resulting in almost complete septal to lateral mechanical synchrony.
Figure 6: 
A. Cumulative LV dyssynchrony A. using longitudinal strain
in the apical four- and two-chamber views and B. using
radial strain in the parasternal short axis view. C.
Relationship between the degree of cumulative LV
dyssynchrony using radial strain and LV ejection fraction.
Ant-Inf delay = anterior to inferior delay; As-Post delay =
anteroseptal to posterior delay; Sept-Lat delay = septal to
lateral delay; other abbreviations see Figure 1.
Inter-observer agreement 
Inter-observer agreement (JJ, IvG) was calculated in a total of 28/178 patients. Pacing-site
assignment was equal in 27/28 patients. The following coefficients of variation were achieved in
the parameters tested: biplane LV ejection fraction (EF) = 9.7 %, inter-ventricular mechanical delay
= 5.7 %, septal to posterior wall motion delay = 11.2 %, inter-segmental mechanical delay from
two-dimensional strain = 0.9 %.
DISCUSSION
This is the first cross-sectional multi-center study showing significant differences between various
ventricular pacing-sites in terms of LV synchrony, function and contraction efficiency in a large
group of children that are chronically paced for complete AV block in the absence of structural
heart disease. The results can be summarized as follows: 
1. LV apical and LV lateral wall pacing are associated with the best preservation of LV function,
which appears related to preserved mechanical synchrony and contraction efficiency. 
2. RV pacing-sites carry a high risk for a negative effect on LV performance, coinciding with
significant mechanical asynchrony and contraction inefficiency. This effect is most
pronounced for RV lateral and outflow tract pacing and less with RV apical pacing.
3. Non-targeted RV septal pacing does not show any advantage over RV apical pacing.
4. LV basal pacing produces a significant reversed pattern of LV dyssynchrony and should
probably not be the preferred LV pacing-site.
5. The presence of maternal auto-antibodies is not consistently associated with decreased LV
function and is only a marginal modifier of the response to pacing-induced LV dyssynchrony.
These results strongly support previous findings of a retrospective pediatric study4 showing a
decrease in LV function specifically due to RV free wall pacing. Our results also confirm data on
preservation of LV function with LV apical or LV lateral wall pacing10-14 including a large
retrospective pediatric multi-center survey published recently.8 This report does not show any
superiority of RV septal over RV apical pacing. This is in line with an elegant experimental study
recently published.17 Some studies showed promising results using RV septal lead placement,18
but clear benefit from RV septal pacing has not yet been demonstrated in a randomized study,
except when the lead is positioned in the His-bundle.19 RV pacing (contrary to LV pacing) was
associated with depressed systolic function and induced a consistent decrease in LV systolic
function compared to pre-implantation values. This decrease was functionally well tolerated as
no difference in the NYHA class was observed between the pacing-sites. However, given the
cross-sectional design of the study, patients suffering from symptomatic heart failure may have
been missed because they were upgraded to a biventricular system, were transplanted or died.
The incidence of patients suffering from overt heart failure due to RV pacing has been reported
to range from 6.0 to 13.4 % in previous pediatric reports.4, 6, 7
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Results of this study further indicate that LV pacing may be a substitute for primary biventricular
pacing which has recently been shown to preserve LV function in chronically paced adults.20 As
demonstrated by Tomaske et al. and Vanagt et al. in small descriptive pediatric reports,21, 22 LV
pacing may also be used instead of biventricular pacing to improve LV function which has been
compromised from long-term RV pacing.
QRS duration was not a multivariable predictor of decreased LV function as it reflects the
total electrical activation time but not the sequence of activation. Recently, a sub-analysis of the
MADIT-CRT trial has shown that left bundle branch block morphology rather than QRS duration
is the prerequisite for the efficacy of cardiac resynchronization therapy.23 This implies that a
specific activation pattern is more important than total asynchrony. Our study indicates that the
negative effects of LV dyssynchrony produced by RV pacing, are preventable by LV pacing
irrespective of QRS duration. 
The presence of maternal auto-antibodies in the setting of congenital AV block was not
found to be a strong component of the individual reactivity to the pacing-induced LV
dyssynchrony as opposed to a study showing association of autoimmune AV block with dilated
cardiomyopathy.24 None of the patients who were paced from the LV showed decreased LV
function, despite the presence of maternal auto-antibodies in a significant portion. RV pacing-
induced LV dysfunction has previously been reported in the absence of maternal auto-antibodies
in children with surgical AV block and could be effectively corrected by an upgrade to
biventricular pacing.25, 26 All these findings support our statement that the pacing-site plays a
crucial role in the development of pacing-associated LV dysfunction.
Limitations
This study has limitations related to the unequal number of patients in each pacing-site group,
significant differences in age at primary implantation and duration of pacing, as well as the
accuracy of the retrospective assessment of the pacing-site using surgical records, biplane x-ray
and 12-lead ECG. However, neither age nor duration of pacing was a multi-variable predictor of
LV dysfunction in this study. Pacing-site localization could be performed with acceptable inter-
observer variability. Thus, we do not feel that these limitations significantly skew the results.
Clinical implications and context
Permanent cardiac pacing that starts in childhood will continue for decades. In the current study
mean age was 11 and mean pacing duration 5.5 years, so the observed reduction in LV function
in RV-paced children is only the beginning of a process that will likely develop further over
subsequent decades.9, 27 Thus, the aim to preserve LV synchrony and function should be
mandatory despite a degree of unpredictable individual variability in the response to
electromechanical dyssynchrony. Patients with a systemic LV who are scheduled for epicardial lead
implantation should be paced from the LV apex or free wall, whereas the RV free wall and outflow
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tract should be avoided. Transvenous leads may be placed in the RV apex given the fact, that it
had the least negative hemodynamic influence of all RV pacing-sites. These principles should be
applied to all children with a systemic LV and either spontaneous or surgical AV block. Surgical
access to the LV is possible using existing tools and at no additional costs: the subxiphoid
approach in younger children or, in older ones, a left lateral thoracotomy with an excellent
cosmetic result.28 Care should be taken to place the leads rather at the LV apex than the LV base,
as the inverse pattern of electromechanical dyssynchrony caused by LV basal pacing might be
detrimental in the long term. The results of the present study provide an important clinical
confirmation of previously published experimental research conducted and summarized by the co-
authors of this report.27, 29 The results of this study may also have importance for future strategy
of pacemaker therapy in adults given the fast developments in pacemaker technology and the
expected introduction of leadless pacing systems in the near future with a potential for an easy
application of LV pacing.
CONCLUSION
Pacing-induced deterioration of LV function is easily preventable by pacing the LV apical or mid-
lateral wall. On the other hand RV free wall and outflow tract pacing carry the highest risk of
pacing-induced LV dysfunction and should be avoided. Added to the previously published
experimental and clinical data on the influence of ventricular pacing-sites on LV mechanics and
function this large study will have significant implications on pacemaker therapy in children.
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ABSTRACT
Introduction: Patients treated by atrial redirection surgery (Senning or Mustard procedure) for
transposition of the great arteries (TGA), have an important risk for heart failure caused by
dysfunction of the systemic RV. Conventional non-systemic ventricular pacing (non-systVP) may
even further increase this risk. We investigated whether these patients may benefit from
biventricular pacing (BiVP) and/or single-site systemic ventricular pacing (systVP). 
Methods: During clinically indicated catheterization in 9 patients with TGA and status post atrial
redirection surgery (SenningMustardTGA), endocardial ventricular stimulation (overdrive DDD-
mode, 80-90 bpm) was applied with temporary pacing leads at the non-systemic and the
systemic ventricle. Acute changes in dP/dtmax and systolic pressure of the systemic ventricle, as
induced by non-systVP, systVP and BiVP compared to reference, were assessed with a pressure
wire within the systemic ventricle. Reference was AAI pacing with similar heart rate (n=7), or
non-systVP at a lower heart rate than during stimulation at experimental sites (85 vs. 90 bpm;
n=2).
Results: systemic dP/dtmax and systolic ventricular pressure were significantly higher during
systVP (+15.6% and +5.1%, respectively) and BiVP (+14.3% and +4.9%, respectively, compared
with non-systVP). In 6 out of 7 patients systemic dP/dtmax was even higher during BiVP and
systVP than during AAI pacing. 
Conclusions: In a population of patients with SenningMustardTGA, acute hemodynamic effects
of endocardial systVP and BiVP were significantly and equally better than those of non-systVP.
Single-site systVP and BiVP might also be beneficial in patients with a systemic RV and intrinsic
ventricular dyssynchrony.
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INTRODUCTION
In patients with transposition of the great arteries (TGA) who have undergone atrial redirection
by procedures according to Senning or Mustard (SenningMustardTGA) and in patients with
congenitally corrected TGA (ccTGA), the systemic circulation is supported by the morphological
right ventricle (RV).1 Patients with a systemic RV have an important risk for heart failure caused
by dysfunction of the systemic ventricle.2-4 Conventional left ventricular (LV) pacing (i.e., non-
systemic ventricular pacing; non-systVP) may even further increase the risk for RV failure. Non-
systemic ventricular pacing is associated with decreased exercise capacity and systemic
ventricular function and increased inter- and intraventricular dyssynchrony in both patients with
normal biventricular anatomy (i.e., concordant connections between the ventricles and the great
arteries) and in patients with SenningMustardTGA.5 In patients with structurally normal hearts,
systemic ventricular function is better in patients with chronic LV pacing (i.e., systemic ventricular
pacing; systVP) than in patients with chronic conventional RV pacing.6 Furthermore, if such
patients present with LV dysfunction, an upgrade of conventional RV pacing to biventricular
pacing (BiVP) results in better LV function and a favorable process of reverse remodeling.7, 8
While in these studies the beneficial effect of BiVP could be due to resynchronization, single site
systemic (left) ventricular pacing seems equally beneficial for hemodynamic function as BiVP,
despite a lack of reduction in QRS duration.9-11 The latter observation suggests that pacing the
systemic ventricle creates a better mechanical interaction between the ventricles than pacing the
non-systemic ventricle. We investigated the acute effects of endocardial non-systVP, BiVP and
single-site systVP on cardiac pump function in patients with SenningMustardTGA.
METHODS
Subjects 
The study was performed according to local ethical guidelines. The study included nine patients
with SenningMustardTGA, who underwent a clinically indicated catheterization and gave
informed consent for both catheterization and experimental temporary pacing. Patient
characteristics are indicated in Table 1. 
Pacing protocol
Temporary pacing leads were introduced via the femoral approach and placed across the baffle
in the apex of the non-systemic ventricle and retrograde across the aortic valve against the free
wall of the systemic ventricle. During the study protocol, we enforced a constant heart rate by
atrial overdrive pacing (80-90bpm) to exclude hemodynamic variability induced by spontaneous
changes in heart rate, and to increase the sensitivity of detecting hemodynamic response to
changes in pacing-mode.12 To allow comparison of pacing at the experimental sites with intrinsic
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ventricular activation, atrial pacing only (AAI) was used as reference. In two patients with
blocked atrioventricular (AV) conduction (patients 7 and 9), stimulation by the permanent non-
systemic ventricular lead at a lower heart rate than during stimulation at experimental sites (85
vs. 90 bpm) was used as reference. Hemodynamic changes were induced by changing back-and-
forth from the reference setting to ventricular pacing at the experimental sites; the non-syst
ventricle (non-systVP), the systemic ventricle (systVP) or both ventricles (BiVP) (Figure 1). The AV-
delay during ventricular pacing had a default value of 120ms, ensuring complete capture in all
patients. Transitions to-and-from experimental ventricular pacing were immediately repeated at
least 6 times for each experimental pacing-site. 
Data acquisition 
Whilst changing pacing from reference to an experimental pacing-site (and the other way
around), we recorded continuous systolic blood pressure and dP/dtmax measured invasively from
within the systemic (right) ventricle using a 0.014-inch-diameter high fidelity pressure wire (Radi
wire, St. Jude Medical, Inc., St. Paul, MN, USA). The pressure wire was introduced retrogradely
into the systemic RV via the femoral approach. A continuous ECG signal was recorded using a
Dynascope DS-7100 (Fukuda Denshi USA) monitor. Analogue output signals were taken via a
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Table 1. Patient charateristics
Patient Type of NYHA Age PR QRS QRS RVEF TAPSE RV S’
number surgery functional (years) duration morphology duration (%) (mm) (cm/s)
class (ms) (ms)
1 (f) Senning I 35 195 normal 120 45 14 10
2 (m) Mustard III 39 260 normal 120 50 13 -
3 (f) Senning III 34 240 RBBB 180 40 13 7
4 (m) Senning II 28 160 RBBB 140 50 11 9
5 (m) Mustard III 42 240 RBBB 140 25 8 4
6 (f) Senning III 17 240 (AAI) RBBB 145 40 19 9
7 (m) Senning II 36 150 (DDD) Paced RBBB 200 40 10 6
8 (f) Senning II 25 200 (AAI) RBBB 140 40 15 9
9 (f) Senning II 33 200 (DDD) Paced RBBB 200 40 16 8
Total
(median) II-III 34 200 140* 40 13 8
NYHA functional class = New York Heart Association functional class; RBBB = right bundle branch block; RVEF = right ventricular
ejection fraction; RV S’ = systolic tissue velocity of the right ventricular free wall; TAPSE = tricuspid annular plane systolic excursion. *
median QRS-duration for patients with intrinsic atrioventricular conduction (patients 7 and 9 excluded)
National instruments DAQ-Card AI-16E-4 (National Instruments, Austin, TX), acquired in digital
form using Labview (National Instruments, Austin, TX), and analysed off line with custom
software based on the Matlab platform (MathWorks, Natick, MA).13
Outcome parameters and statistical analysis
Changes in dP/dtmax and systolic pressure of the systemic ventricle were defined as the difference
in these variables between the mean of the last 8 beats prior to transition and the mean of the 8
beats immediately after transition (Figure 1). For the evaluation of the effect of pacing at the
diverse pacing-sites, we used the mean acute change calculated from at least six transitions to
and from the pacing-site tested (three forward transitions to pacing at the site tested and three
backward transitions to the reference setting, reversing the sign for the back transitions). Paired
Student’s T-test was used for comparison of the effects of BiVP, systVP and non-systVP. A p-value
of <0.05 was considered to be significant.
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Figure 1. Schematic representation of the protocol
Hemodynamic changes in systolic blood pressure (not in figure) and dP/dtmax (curve) were induced by
changing back-and-forth from the reference setting to ventricular pacing at the experimental sites
(‘transitions’; dashed vertical line). Hemodynamic changes were defined as the difference between the
mean of the last 8 beats previous to transition (white dots; dashed horizontal line) and the mean of the 8
beats immediately after transition (black dots; solid horizontal line). For the evaluation of the effect of
pacing at the diverse pacing-sites, we used the mean acute change calculated from at least six transitions
to and from the pacing-site tested. 
RESULTS
Pacing protocol and patients
Insertion of temporary pacing leads into the systemic ventricle was achieved without complications
in all patients. Unfortunately, a computer error in data-recording occurred in one experiment
(patient 5). This explains the absence of comparison of systVP versus reference in this patient.
Individual protocol conditions and QRS-duration during the different settings are presented in Table 2.
Non-systVP increased QRS duration in all patients. BiVP and systVP reduced QRS duration in the
patients with prolonged baseline QRS duration (patients 3 and 4) but prolonged it in the other
patients, although to a lesser extent than non-systVP.
Acute hemodynamic effects 
The acute changes in systolic ventricular pressure and dP/dtmax of the systemic ventricle, as
compared to reference, were significantly better with systVP and BiVP than with non-systVP.
Relative changes in dP/dtmax induced by systVP and BiVP were respectively 15.6% and 14.3%
higher, as compared to those induced by non-systVP. Relative changes in systolic ventricular
pressure were 5.1% and 4.9% higher for systVP and BiVP, respectively, than for non-systVP.
Differences between the effects of BiVP and systVP were not significant. Hemodynamic changes
relative to reference and averaged for the study-group, as well as the statistical significance of
differences between pacing-sites, are presented in Table 3. The individual and averaged absolute
hemodynamic differences of non-systVP, BiVP and systVP versus reference are plotted in Figure 2.
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Table 2. Individual protocol conditions and ECG-findings 
QRS duration (ms)
patient reference setting AAI non-systVP BiVP systVP
1 AAI 120 180 140 140
2 AAI 120 240 160 200
3 AAI 170 180 110 120
4 AAI 130 160 120 120
5 AAI 120 160 110 -
6 AAI 120 200 160 160
7 Non-systVP 85bpm - 180 120 140
8 AAI 100 160 110 110
9 Non-systVP 85bpm - 160 120 120
AAI = atrial pacing, with inhibition when atrial activation is sensed; BiVP = biventricular pacing; non-systVP = single-site non-
systemic ventricular pacing; systVP = systolic ventricular pacing.
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Table 3. Averaged acute hemodynamic changes relative to reference
non-systVP BiVP systVP
systemic ventricular systolic vs. reference -2.3 ± 3.6 2.6 ± 4.2 2.8 ± 3.2
pressure change (%) vs. non-systVP * (+4.9; p=0.019) (+5.1; p=0.011)
systemic ventricular vs. reference -6.7 ± 9.9 7.6 ± 10.0 9.0 ± 5.9
dP/dtmax change (%) vs. non-systVP ** (+14.3; p=0.001) (+15.6; p=0.001)
BiVP = biventricular pacing; non-systVP = single-site non-systemic ventricular pacing; systVP = systolic ventricular pacing.
Presented values are mean ± SD. *Difference between BiVP and systVP not significant (p=0.490). **Difference between BiVP
and systVP not significant (p=0.666). 
Figure 2. Acute hemodynamic effects of ventricular pacing
The upper panel shows the acute effects on dP/dtmax of the systemic ventricle (i.e., the right ventricle) of
pacing at the experimental pacing-sites as compared to reference changes. The lower panel shows the
acute effects on systolic pressure of the systemic ventricle. Results for the individual patients are displayed
and indicated by patient number. Large diamonds represent mean±SD for the total study-group. BiVP =
biventricular pacing; non-systVP = non-systolic ventricular pacing (i.e., left ventricular pacing); systVP =
systolic ventricular pacing (i.e., right ventricular pacing).
In 6 out of the 7 patients with intrinsic AV conduction, BiVP and systVP resulted in higher dP/dtmax
than AAI pacing. Systolic pressure was higher as compared to AAI in four of them with BiVP and
in three with systVP.
DISCUSSION
In the current study in patients with a systemic RV, acute effects of endocardial systVP and BiVP
on systolic ventricular pressure and dP/dtmax of the systemic ventricle were significantly and
equally better than those of non-systVP. Besides, in 6 out of the 7 patients with intrinsic AV
conduction, BiVP and systVP resulted in an acute increase in dP/dtmax as compared to AAI pacing
in reference setting. 
Benefit from single-site systemic ventricular pacing and biventricular pacing
in comparison to non-systemic ventricular pacing
Our findings, that both systVP and BiVP are equally superior to non-systVP in terms of acute
hemodynamics, suggest that avoidance of delayed activation of the systemic ventricle is
important, rather than avoidance of asynchronous electrical activation in general. In both
pediatric and adult patients with normal biventricular anatomy (i.e., concordant connections
between the ventricles and the great arteries), single-site LV pacing (i.e., systVP) as well as BiVP
have been extensively investigated and proven to result in better function of the systemic
ventricle, than RV pacing (i.e., non-systVP).6, 8, 14 Also, in cases with systemic RV, beneficial
effects of (upgrade to) BiVP have been observed.15-20 However, single-site systVP has never been
investigated as alternative pacing therapy in these patients. The current findings indicate that
single-site systVP may be at least as good as BiVP for chronic ventricular pacing in patients with
systemic RV. Single-site systVP and BiVP may therefore be the preferred sites, not only in patients
with a systemic left ventricle, but also in those with a systemic right ventricle. This implies that,
in general, pacing should be performed on the ventricle with highest pressure development,
irrespective of its morphological type.
Potential benefit from single-site systemic ventricular pacing and biventricular
pacing in patients who do not require ventricular pacing for rate control
Our patients generally had a wide QRS complex. This is in agreement with the prolonged QRS-
duration (>120  ms) as has been observed in almost half of the patients with
SenningMustardTGA or ccTGA.21 The wide QRS complex in these patients is often associated
with right bundle branch block (RBBB), hence, with delayed activation of the systemic RV.21
Chow et al. found a high prevalence of intra-RV (32%) and interventricular (57%) dyssynchrony
in patients with SenningMustardTGA.22 Therefore, in SenningMustardTGA patients without
chronic non-systVP, failure of the systemic RV may be (partly) related to intrinsic ventricular
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dyssynchrony. Our observation that BiVP is superior to intrinsic activation in 6 out of the 7
patients with intrinsic AV conduction, is in line with the observations of Dubin et al. and
Janousek et al., that patients with either spontaneous or pacing-induced dyssynchrony and RV
failure experience positive effects of BiVP.15, 23 In addition, our experiments indicate that similar
results may be achieved by single-site systVP. The potential beneficial effects of BiVP and single-
site systVP in comparison to intrinsic conduction may have been underestimated by our study,
because AV delay was not individually optimized. Moreover, results of ventricular pacing versus
AAI pacing may have been biased by the influence of differences in AV delay (intrinsic AV delay
in AAI versus a default AV delay of 120 ms in ventricular pacing). Therefore, no statistical analysis
was performed on the observed differences between intrinsic activation and ventricular pacing
at the diverse sites. 
Clinical implications and relevance of the study 
The right ventricle is best suited to function as a low-pressure volume pump, rather than having
to generate high pressures and to face high resistance, which is inherent to the systemic
circulation. Patients with systemic RV are therefore prone to develop heart failure.4, 24
Identification of novel therapeutic strategies to treat systemic RV dysfunction is of major
importance. Moreover, prevention of additional risk factors for heart failure should take first
priority in these patients. In this perspective, chronic ventricular pacing should get attention as it
may be indicated in about 25% of the patients with SenningMustardTGA and seems to increase
risk for cardiac failure when applied to the non-systemic ventricle.4, 5 In pediatric patients with AV
block and normal biventricular anatomy, cardiac dysfunction related to chronic non-systVP occurs
in about 15% of the patients after mid-term follow-up.6, 25 The ability of the systemic RV to adapt
to the stress due to (pacing-induced) dyssynchrony may be limited by its structural abnormality
and by the presence of fibrous areas due to surgical scars or chronic ventricular dilatation.26-28
Hence, long-term adverse effects of non-systVP and their clinical relevance may be even more
important in patients with a systemic RV than in patients with normal cardiac anatomy. 
Practical issues of optimal-site pacing in patients with congenital heart
disease
Besides the potential functional benefits, there are several practical issues that have to be taken
into account in the decision to apply BiVP or single-site systVP. Implantation approach is an
important issue in patients with congenital heart disease. Up to date, (wireless) endocardial pacing
within the systemic ventricle is not yet clinically applicable. Stimulation of the systemic ventricle (for
systVP or BiVP) should therefore be achieved from the epicardium. Transvenous access to the
epicardium of the systemic ventricle via the coronary sinus is difficult to achieve in patients with
ccTGA and impossible to achieve in the majority of patients with SenningMustardTGA. However,
epicardial stimulation of the systemic ventricle and biventricular stimulation could be achieved with
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a surgical procedure either or not combined with a transvenous approach. Jauvert et al. applied
BiVP in seven patients with either ccTGA or SenningMustardTGA and report that BiVP was
technically feasible in these patients and that there were no procedure-related complications.29
Application of cardiac resynchronization therapy may be added to other necessary cardiac surgical
procedures. As suggested by Janousek et al., this may be a good basis for a proactive approach to
the prevention of RV failure in this high-risk population.15
Limitations of the study 
The present study only assessed acute hemodynamic consequences of pacing at different
ventricular endocardial pacing-sites. Studies with permanent pacing and long-term follow-up
should be performed to investigate whether BiVP and systVP are clinically to be preferred in all
patients with either intrinsic dyssynchrony or an indication for chronic ventricular pacing. It has
to be mentioned that the general physical status in the selected study population with clinically
indicated catheterization might have been worse than in the overall SenningMustardTGA
population.30 In the current study we applied endocardial pacing. Recent studies in animals and
adult patients suggest that, for comparable sites, endocardial pacing may even be better than
epicardial pacing.31, 32 For chronic ventricular pacing one difficulty of endocardial pacing lies in
the access to the cavity of the systemic ventricle. Moreover, the presence of a lead in the systemic
ventricle increases the risk of cerebro-vascular accidents by embolism. The application of
endocardial pacing in this study may seem therefore a limitation of the study. However, wireless
pacing with the use of ultrasound-mediated energy to a receiver electrode is quickly developing
and has already been demonstrated in animals and humans in acute studies.33, 34
CONCLUSION
In a population of patients with SenningMustardTGA, acute hemodynamic effects of endocardial
systVP and BiVP were significantly and equally better than those of non-systVP (i.e., conventional
pacing). Single-site systVP and BiVP may therefore be preferred for chronic ventricular pacing in
patients with systemic RV, as these may avoid additional risk for RV failure by pacing in these
patients. Single-site systVP and BiVP might also be beneficial in patients in whom failure of the
systemic RV may be (partly) related to intrinsic ventricular dyssynchrony.
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Part I: 
Toward Optimization of Cardiac Resynchronization Therapy
Part II: 
Toward Prevention of Pacing-Induced Heart Failure
Partly adapted from ‘Chronic Ventricular Pacing in Children: Toward Prevention of Pacing-
Induced Heart Disease’. I.E. van Geldorp et al.
Heart Fail Rev 2011; 16(3):305-314
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INTRODUCTION
The general aim of the research presented in this thesis is to better treat electromechanical
ventricular dyssynchrony and to avoid pacing-induced cardiac deterioration in adults and
children. The motives for the above-mentioned aim are the evident needs for better treatment
and prevention of dyssynchrony and cardiac deterioration originating from either intrinsic or
pacing-induced left bundle branch block (LBBB), as elucidated in the general introduction of this
thesis (chapter 2). These motives are underlined by the studies presented in chapters 3, 5, 6
and 7 showing adverse effects of right ventricular (RV) pacing in patients with normal
biventricular anatomy. Clinically more relevant is that the studies presented in this thesis also
suggest new pacing-strategies by which cardiac function may be improved and/or preserved.
In this general discussion, the results of the studies presented in this thesis are linked and put
in broader perspective. The first part of this chapter discusses optimization of cardiac
resynchronization therapy (CRT) in (adult) patients with dyssynchrony-associated cardiac
dysfunction. Within this field, patient-selection and the reliability of optimization protocols are
discussed in more detail. The second part of the chapter concerns the challenge to prevent
pacing-induced dyssynchrony and cardiac deterioration in pediatric cardiology. Several
alternative sites for chronic ventricular pacing for rate control are reviewed and clinical
implications of the various sites for ventricular pacing in (pediatric) patients with or without
structural congenital heart disease are discussed. 
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GENERAL DISCUSSION PART I
TOWARD OPTIMIZATION OF CARDIAC RESYNCHRONIZATION THERAPY
Over the last decade, it has been proven that in populations with severe heart failure and
electrical dyssynchrony, CRT has the potential to improve left ventricular (LV) function and clinical
status, as well as that it can reduce the risk of heart failure-related hospitalization or death.
However, individual response to CRT varies widely and as much as 30-50% of patients selected
according to current guidelines respond inadequately. It seems therefore that there is still
opportunity for improvement and optimization of this relatively novel therapy. 
“CRT optimization” usually refers to tailoring of atrioventricular (AV) and interventricular (i.e,
ventriculo-ventricular; VV) delay to the individual patient, aiming at increase of the hemodynamic
improvement and long-term benefits induced by CRT. Nonetheless, besides the individual
optimization of device-settings, overall response to CRT is also affected by pre-implantation patient
selection. All approaches to optimize the response to CRT and the methods to guide these
optimizations are currently under debate.
Patient selection affects overall response to CRT
Typically, CRT is indicated in all patients with wide QRS (QRS ≥120ms) and severe heart failure,
the latter defined as severely impaired LV function (LV ejection fraction <35%) and functional
status (New York Heart Association functional class III-IV).1 Patients are defined as ‘responders’ if
the reduction in LV end-systolic volume after six months CRT is above a certain threshold varying
between 10% or 15%. Unfortunately, it seems that an important proportion of the patients with
indication for CRT do not profit from CRT, independent of efforts undertaken to improve
individual response.2 These latter patients may be concerned as ‘real non-responders’.
Withholding application of CRT in real non-responders would obviously increase the success rate
of CRT and reduce unnecessary implantation costs and complications. Apart from the duration
of the QRS complex, its morphology appears also important to identify patients most likely
responding to CRT. Patients with classical LBBB are more likely to respond than those with
atypical intraventricular conduction delay or right bundle branch block.3 Also etiology of heart
failure influences response to CRT with better response observed in patients with non-ischemic
cardiomyopathy when compared to ischemic cardiomyopathy.4, 5 Furthermore, many new indices
of cardiac dyssynchrony have been proposed to refine pre-implantation patient selection. The
clinical value of these indices, however, has not been well established and discussion is going on
while new indices are suggested.6, 7
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On the one hand CRT might be reserved to a more select subgroup of patients complying with
current guidelines, while on the other hand its application might be expanded to other groups
of patients. Cardiac resynchronization therapy aims to reverse the deleterious effects that may
originate from LV dyssynchrony by restoration of a more coordinated contraction pattern. It
seems therefore reasonable to suppose that all patients with LV dyssynchrony associated with
LBBB morphology in the ECG would benefit from resynchronization, irrespective of the level of
heart failure or nature of LBBB morphology (e.g., intrinsic LBBB, RV pacing). In patients with
heart failure following chronic RV pacing, an ‘upgrade’ from RV pacing to biventricular (BiV)
pacing indeed improves clinical presentation, reduces mortality, reverses LV remodeling and
improves LV function to the same extent as ‘de novo’ CRT does in patients with intrinsic LBBB.8-
12 Distinction between pacing-induced and intrinsic LBBB should therefore no longer be made in
the practice of selecting CRT-candidates.1 With respect to heart failure classification and
response to CRT, major studies (REVERSE and MADIT-CRT) have recently shown that CRT in
patients with mild symptoms of heart failure (NYHA I-II) is as effective as in patients with
moderate to severe symptoms of heart failure (NYHA III-IV).13, 14 Although for that reason new
American guidelines are less tenacious to the presence of clinical heart failure symptoms, severe
LV dysfunction is still a strict criterion: it is advised to consider CRT in slightly symptomatic
patients (NYHA II) only if LVEF <35%.1 Our study presented in chapter 3 of this thesis, revealed
that improvement of LV function and reversal of LV remodeling with BiV pacing may occur in
patients with even less severe LV dysfunction than reported in the REVERSE study (mean LVEF
36±10% versus LVEF 27±7%, respectively).13, 15 Additionally, it seems that the response to BiV
pacing is not related to the severity of either LV dysfunction or LV remodeling in the pre-
implantation period.15 These findings indicate that CRT, besides its capability of treatment of
dyssynchrony-induced heart failure, may also prevent or slow the progression to severe heart
failure in patients with (pacing-induced) dyssynchrony.16 However, complication rate and
unnecessary costs are important issues in a mildly symptomatic patient cohort and make
(upgrade to) BiV pacing in every patient with a conventional pacemaker indication or intrinsic
LBBB unfavourable. Until now, neither the long-term effect of (pacing-induced) dyssynchrony,
nor the response to CRT can be predicted for the individual patient. Therefore, the application of
BiV pacing may better be limited to patients presenting overt echocardiographic signs of
remodeling or deterioration of LV function.
Optimization of CRT-response by tailoring of atrioventricular and
interventricular delay
Individual hemodynamic response to CRT and the potential of long-term benefits brought by CRT
may be increased by optimization of AV- and VV-delay.17-20 As optimization of device settings may
increase the individual benefit of CRT, it may indirectly also add to the proportion of ‘responders’.
However, there is lack of consensus on the practice of optimizations of device-settings, as well as
Chapter 9
150
on the methods and parameters to guide these optimization procedures. Consequently, protocols
vary and may not always be well designed.21 Interpretation of both optimization studies and
clinical optimization procedures is therefore difficult. Moreover, suboptimally designed protocols
hamper reliable testing whether or not optimization of device settings is clinically relevant and
whether or not the optimum of settings changes over time or during exercise.
There are two general approaches to optimize AV- and VV-delays. One is ‘qualitative
optimization’, which is based on pattern recognition. For example, in Ritter’s method and the
iterative method for AV optimization, the operator adjusts AV delay until the transmitral Doppler
velocity pattern is judged to have the ideal contour.22, 23 The other approach for optimization of
AV- and VV-delays is ‘quantitative optimization’, in which a physiological variable is measured,
either invasively or noninvasively, while timing is adjusted. Doppler measurements are often used
in this approach, since they can be made noninvasively. However, even with extensive training,
these measurements may be challenging, as they depend on the acoustic window in the patient.
Furthermore, it is very time-consuming to obtain a reliable set of data over a series of heartbeats
for device optimization. Pressure measurements, such as invasive arterial or ventricular pressure,
or its peak slope (dP/dtmax) and non-invasive arterial pressure (chapter 4), are less susceptible for
patient- or investigator-dependent quality and might more easily be automated. 
Reliability of optimization protocols
Choosing a variable that well reflects hemodynamics and that is easily measured, is not the only
thing that matters in the reliability of optimization procedures. Both the amplitude of
hemodynamic response and the measurement variability fundamentally determine the precision
of an optimization procedure. The amplitude of response depends on the physiological
dependence of the variable measured upon changes in device settings, may be very different
between AV- and VV- optimization, and may individually be influenced by heart rate.24
Moreover, for any given patient, there is variability (i.e., scatter or noise) between replicate
measurements at the same setting (Figure 1). This scatter reflects short-term biological variability
of the physiological variable, plus measurement error arising from equipment and imperfect
observer evaluation. Variability in measurements implicates that simply selecting the AV- or VV-
delay at which the highest value is measured (by a single measurement) may not be the optimal
approach to maximize the individual benefit of CRT.21 Until now no systematic way exists to
design optimization protocols to deliver optima to a clinically-desired precision, or even to report
confidence intervals. Arbitrary protocol design is risky, because if the random variation between
repeat measurements at the same setting (scatter) is large in comparison to the genuine
underlying between-setting differences, the protocol may give most patients a wrong
recommendation.21 This makes execution of the protocol at best a waste of clinical resources
and at worst actively harmful. 
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FUTURE PERSPECTIVES IN THE OPTIMIZATION OF CRT
Optimization protocols may be improved 
Improved equipment or improved training may reduce measurement error in optimization
protocols. Physiologic variables will, nevertheless, always be affected by intrinsic biological
variability. Measurement variability implies that simply selecting the AV- or VV-delay at which the
highest value is measured (by a single measurement) is not the optimal approach to maximize
the individual benefit of CRT. To decrease the impact of inevitable biological and measurement
variability, multiple measurements should be taken and averaged for each device-setting. Since
Whinnett et al. demonstrated that the curve of response to BiV pacing at various AV-delays fits closely
to a second order polynomial,20 it may be a good strategy to fit a parabola to the data points and
pick the top of the parabola as the “optimum”. By means of statistics, “parabolic-fitting” decreases
the total number of measurements needed to reliably define the optimum as compared to the “pick-
the-highest” approach. The total number of measurements that should be made to perform a
reliable optimization procedure depends on the scatter-to-curvature ratio of the procedure (i.e., ratio
between amplitude of response and measurement variability) and the desired precision of the
optimization procedure. The highest realistically desirable precision is a 95% confidence interval of ±5
ms. The coarsest precision tabulated is ±30 ms, because poorer precision is very unlikely to be
clinically constructive: a 95% confidence interval of ±40 ms, for example, equates to reporting after
optimization that the patient’s optimum lies “with 95% certainty somewhere between 100 and 180
ms”. If scatter-to-curvature ratio and desired precision are defined, the number of measurements
(combination of settings and repetitions) could be mathematically estimated by the method of Francis
et al.(paper in preparation).
Nowadays, echocardiography is still the most commonly used technique to optimize AV- and VV-
timing,25 yet it is a time-consuming approach and uses significant human resources. The large total
number of measurements essential for a reliable optimization procedure, as demonstrated above,
may implicate that echocardiography may no longer be feasible for such extensive protocols. In this
perspective, non-invasive blood pressure measurements using a finger-cuff, such as Nexfin CO-
Trek® (BMEYE B.V., Amsterdam, Netherlands), are very promising. They are inexpensive easy-to-
use and patient friendly methods that seem highly reliable in the evaluation of hemodynamic
changes and would facilitate the assessment of as many measurements as desired (chapter 4).26
For the sake of application in routine clinics it would however be desirable to have an algorithm
that allows automated execution of the optimization procedure.
Improvement in the delivery of CRT
With reliable and easy optimization protocols, it would be possible to optimize CRT delivery for
all patients. Initially, AV- and VV-delay optimization procedures could be included as part of
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Figure 1.
Observed measurements are composed of underlying true difference between settings (“signal”, top panel)
and beat-to-beat variability (“noise”, middle panel), which may be small (left) or large (right) relative to the
signal. The relative sizes of underlying signal and overlying noise determine whether the observed
measurements (bottom panel) reflect the underlying signal faithfully (left) or not (right). When the noise
variability is relatively large (right), the observed optimum in a single measurement series (arrow) is often not
the true optimum (140 ms in all cases in this figure). (After Pabari et al. Heart Fail Rev. 2011., with permission)21 
routine short-time follow-up after device implantation. Moreover, it would be interesting to
optimize settings at various heart rates and during exercise.27, 28 Furthermore, delivery of CRT
may also be optimized by testing various lead locations for their hemodynamic effects during
CRT implantation. The latter approach might be especially beneficial in patients with abnormal
cardiac anatomy or patients with scar tissue due to cardiac ischemia.29-32 One of the major
advantages of using non-invasive blood pressure measurements is that it can easily be applied in
different body positions and even during exercise. Prospective randomized studies are needed to
clarify the real clinical impact of optimization of CRT-delivery on the patients course. In this
perspective, precision of the protocol is an essential prerequisite for (1) interpreting apparent
optima, (2) interpreting changes over time or apparent differences between alternative
optimization methods, and (3) planning long-term outcome studies.
CONCLUSIONS AND SUGGESTIONS FOR OPTIMIZATION OF CRT
Improvement of clinical condition and improvement in echocardiographically derived variables in
patients with mild heart failure (chapter 3)15 suggest that progression to severe heart failure in
patients with electromechanical dyssynchrony may be prevented or slowed down by CRT.16 Until
now, neither the long-term effect of (pacing-induced) dyssynchrony, nor the response to CRT can
be predicted for the individual patient. Complication rate and unnecessary costs are important
issues in a mildly symptomatic patient cohort and make (upgrade to) BiV pacing in every patient
with a conventional pacemaker indication or intrinsic LBBB debatable. Therefore, careful
monitoring of LV function is advisable and (upgrade to) BiV pacing should be considered when
echocardiographic signs of remodeling or deterioration of LV function occur. 
Individual optimization of the device settings might increase the beneficial response to CRT.
Though, the method for optimization seems to be of critical importance for the reliability of its
outcome. Protocol design with adequate precision is essential to prevent optimization from
wasting clinical resources and harming patients by applying a setting that is far from optimal.
Non-invasive blood pressure measurements using a finger-cuff, such as Nexfin CO-Trek®
(chapter 4),26 may be very useful in the optimization of CRT, in both clinics and research. 
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GENERAL DISCUSSION PART II
TOWARD PREVENTION OF PACING-INDUCED HEART FAILURE
While the majority of patients receiving pacemakers are adults at usually advanced age, a small
group of pacemaker recipients are children, even newborns. Results and conclusions from pacing
studies in adults are not readily transferable to the pediatric population, because diseases and
causes of dyssynchrony and heart failure differ strongly. In adults, indication for pacemaker
therapy or CRT concerns, among others, bradycardia, LV dysfunction, and dyssynchrony due to
partially diseased conduction systems often combined with degenerative diseases and infarctions
of the myocardium. In children and young adults, indication for pacemaker therapy typically
concerns bradycardia due to complete atrioventricular conduction block. This condition may exist
either “isolated” in structurally normal hearts or combined with abnormalities in cardiac anatomy.
In patients that have a perspective of life-long ventricular pacing for AV block, the prevention of
functional as well as structural deterioration seems a major challenge in addition to the
restoration of heart rate.
Recognition of potentially harmful effects of chronic RV pacing (chapter 2)33-35 has prompted
investigation into alternative ventricular pacing-sites. In addition to the traditional RV apex and
free wall sites, several other sites within the RV became accessible by advances in pacemaker-
lead technology and implant approaches and began to be clinically explored. Also, biventricular
pacing has been introduced in children. Surgical approaches are often preferred for all lead
implantations in small children or children undergoing cardiac surgery, implicating a great extent
of freedom to position the lead(s) at the epicardium of either the RV or the LV, or even at both.
Alternative-site RV pacing 
Both terms ‘alternative-site RV pacing’ and ‘selective-site RV pacing’ refer to pacing at sites other
than the RV apex or free wall, though either located within or approached via the RV. These sites
are selected based on the (individual) prospect of a more physiological electrical activation
pattern and a better hemodynamic response with less detrimental remodeling. By lead insertion
through the RV, the His bundle may be paced directly. In patients without distal conduction
abnormalities, His-bundle pacing would obviously induce a normal physiological sequence of
activation and therefore prevent the heart from dyssynchronous activation and associated
harmful effects. Indeed, beneficial effects of successful His-bundle pacing have been reported in
adults with AV-nodal ablation for atrial fibrillation.36, 37 Although technical advances have
improved the success rate of His-bundle pacing,38 implantation in this very small region is a
challenging procedure and seems not very applicable in children. Moreover, especially in children
with surgically induced AV block, but also in children with congenital AV block, the His bundle
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may be involved in the pathological interruption of the conduction system, implicating that there
is no rationale left for direct His-bundle pacing. Within the field of research on alternative RV
pacing sites, also the RV outflow tract has been extensively investigated. Unfortunately, the
term RV outflow tract pacing is not always clearly defined in literature and has been used to
describe a variety of RV pacing sites. Nonetheless, differentiation between the diverse sites
within the conical RV outflow tract is very important, as activation patterns and wave
propagation will differ depending on the exact anatomical position of the lead.39, 40 Not
surprisingly, studies with regard to the effects of RV outflow tract pacing without specification of
exact anatomical definition of the site have shown inconsistent results.41, 42 Beneficial effects for
RV outflow tract pacing have most consistently been found in studies clearly mentioning to pace
from the septal side of the RV outflow tract (also defined as “high septal” or “para-Hisian”
pacing).43-49 Thus, in RV outflow tract pacing, in particular the septal side of the outflow tract
may be a target. Nevertheless, it should be noted that ‘septal RV outflow tract’ is not a good
definition, since the upper part of the ‘septal side’ within the RV outflow tract is located above
the LV. Therefore, only the inferior part of the septal side of the RV outflow tract can be
considered as truly septal and might be the preferred location for lead placement in the RV
outflow tract.39, 40
Biventricular pacing 
Data from large randomized adult CRT trials cannot simply be translated to children with cardiac
failure, because the pediatric population not only includes children with normal cardiac anatomy
and LV failure but also includes children with univentricular hearts (with either RV or LV
morphology), hearts with a systemic RV (i.e., heart with either congenitally corrected
transposition of the great arteries or transposition of the great arteries with atrial redirection
surgery in the past), and hearts with RV failure (e.g., RV failure associated with corrected
Tetralogy of Fallot). In addition, a substantial number of pediatric CRT candidates have
ventricular dyssynchrony and cardiac failure related to conventional pacemaker therapy for
postoperative or congenital AV block. Nonetheless, encouraged by the positive results in adults,
BiV pacing meanwhile has also been applied in children with ventricular dysfunction. In these
children with either isolated AV block or AV block combined with structural heart disease, BiV
pacing (often following chronic RV pacing) improved pump function and reversed ventricular
remodeling. Upgrade from single-site RV pacing to BiV pacing was in children at least as effective
as in adults with heart failure. In some children, even the need for cardiac transplantation was
deferred.50, 51 From the analysis of Janousek et al., the response to BiV pacing seems to depend
on the structural and pathophysiological substrate. The response was most favorable after
upgrades from single-site RV pacing to BiV pacing in patients in whom the LV was the systemic
ventricle.51 Noteworthy, in these studies, resynchronization was mostly indicated for decreased
LV function following chronic conventional RV pacing.51, 52
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Single-site left ventricular pacing versus biventricular pacing
In children with LV dysfunction following chronic RV pacing, functional improvement and reverse
remodeling have also been reported for LV single-site pacing.53, 54 Single-site LV pacing in adult
heart failure patients resulted in the same improvement in LV function as induced by acute or
chronic BiV pacing.55-57 It is argued that single-site LV pacing in LBBB patients results in “hidden
resynchronization” by fusion of the activation front originating from the left lateral pacing
electrode with the impulse traveling through the right bundle. However, because benefits of
single-site LV pacing are also observed during pacing with short AV delays57 as well as in patients
with atrial fibrillation,56 it is very unlikely that the hypothesis of “hidden resynchronization”
applies to all patients. In dogs with experimental complete AV block, Mills and colleagues showed
that LV apical and LV septal pacing resulted in only moderate electric desynchronization as well as
in minor redistribution of mechanical work and perfusion.58 Even after 4 months of pacing in
these dogs, LV pacing induced normal levels of contractility, relaxation, and myocardial efficiency.
Moreover, single-site LV apical and LV septal pacing maintained cardiac function and efficiency at
least as well as BiV pacing.58 Previous to the above-mentioned study, it had already been shown
in laboratory dogs and in children undergoing cardiac surgery that LV pacing acutely increases
pump function when compared with RV pacing.59
Single-site left ventricular pacing may prevent pacing-induced heart failure
Based on surgical preferences, chronic single-site LV pacing has in some centers clinically been
applied in children for already several years. Results of small studies in children of one of these
centers suggested that chronic LV free wall pacing may preserve LV function and dimension at a
normal level (chapter 5).54, 60, 61 Encouraged by these results, we retrospectively and cross-
sectionally evaluated long-term influences of single-site RV and LV pacing sites on LV function
and dyssynchrony in structurally normal hearts in a multi-center study (chapters 6 and 7).62, 63
Results from these evaluations indicate that the site of pacing is indeed an important
determinant of LV function, with LV pacing consistently resulting in better LV function than RV
pacing and with depressed LV function seen in over 10% of the RV-paced patients. In the
individual patient, depressed LV function may indicate that chronic pacing is not well tolerated
and it may impose a higher risk for pacing-induced heart failure. Both LV function and
contraction efficiency were significantly better in children with chronic LV pacing than in children
with chronic RV pacing.62, 64 Interventricular and intra-LV dyssynchrony were minimal in children
undergoing LV apical or LV lateral wall pacing. As suggested by the cross-sectional data (chapter
7), as well as by the retrospective data presented in Figure 2 (unpublished data), LV function is
best preserved in children undergoing LV apical or lateral wall pacing. However, reliable statistical
comparison between all individual pacing-sites is disputable in this study-population, because
data is limited for several pacing-site subgroups.
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The effect of pacing-site and the influence of maternal autoantibodies
Congenital AV block is strongly associated with the presence of maternal IgG autoantibodies
(anti-SSB/La and anti-SSA/Ro). These autoantibodies possibly react with SSB/La and SSA/Ro
antigens, thereby triggering an inflammatory response in the fetus that typically leads to fibrosis
and scarring of the conduction system.65 The inflammatory response may however also lead to
a more diffuse myocardial disease.66, 67 Since most research on the effect of pacing-site has been
done in populations including children with congenital AV block, the question has been raised
whether the outcomes for the effects of pacing-site may have been biased by maternal
autoantibody status.
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Figure 2. Left ventricular fractional shortening for pacing-site subgroups
Left ventricular fractional shortening (LVFS) is displayed for every pacing-site subgroup (the numbers of
patients for each location are indicated between brackets). No statistical analyses were performed on the
differences between these subgroups. Boxplots represent 25th, 50th, and 75th percentiles. Whiskers
represent the minimal and maximal values within the range of [25th percentile - 1.5*InterQuartileRange]
and [75th percentile + 1.5*InterQuartileRange], respectively. Dots represent individual values.
Apex = ventricular apex; Base = base of the ventricle; RVOT = right ventricular outflow tract; Sept =
interventricular septum. Unknown = the precise location of the electrode, within/at the paced ventricle,
was unknown. (Unpublished data from van Geldorp et al.; chapter 6)
In the retrospective part of our multi-center study we did not find any significant influence of
maternal autoantibody status on LV function, while some sub-analyses of the cross-sectional study
suggest an influence of maternal autoantibody status. When considering both the retrospective
and cross-sectional evaluations, it seems that the influence of maternal autoantibody status hangs
in the balance of significance. Theoretically, this might implicate that there is indeed an
association between LV function and maternal autoantibody status, but the study population is
not large enough to strongly indicate this association. Clear is, however, that the influence of
maternal autoantibody status, if there is any, is less important than the influence of the site of
pacing. Pacing the ventricle at the best spot is highly important in the entire population, but is
possibly even more important for those patients having positive maternal autoantibody status.
Optimal pacing in congenital heart disease
The ever-improving survival after surgery for complex congenital heart disease broadens the
variety of anatomical substrates and indications for chronic ventricular pacing. The pediatric
pacing-population is therefore highly hetero-geneous in terms of age and cardiac anatomy. Up to
date, most comparisons of various pacing-sites in children have been made in a population with
structurally normal hearts. Depending on the morphological, electrical and functional anomalies
associated with each congenital heart disease, it is probable that in patients with congenital heart
disease, pacing at a certain site has dissimilar effects than pacing at a comparable site in patients
with isolated AV block.68-71 We assume that the optimal pacing-sites depend on cardiac
substrates, which include cardiac anatomy and the presence of intrinsic dyssynchrony. For
example, in patients with RV failure and intrinsic dyssynchrony from a right bundle branch block
after surgically repaired Tetralogy of Fallot, RV pacing has been proposed as a potential therapy
for RV failure.72-74 It has however been suggested that, when both RV and LV function are
concerned, BiV pacing may be superior to RV pacing.75, 76 Further investigations after the effects
of long-term ventricular pacing are required to confirm these findings and to determine whether
pacing the late-activated ventricle (i.e., RV) or BiV pacing in these patients is worthwhile.77, 78
In patients with congenitally corrected transposition of the great arteries or transposition
and status post atrial redirection surgery, the morphological RV supplies blood-flow to the body,
instead of the morphological LV. In this group of patients LV pacing (i.e., non-systemic ventricular
pacing) is associated with lower functional and exercise capacity, lower systemic ventricular
function and higher degree of inter- and intraventricular dyssynchrony.79 Adverse effects induced
by pacing the non-systemic ventricle may be of major clinical importance since they may induce
additional risk for dysfunction of the systemic RV in these patients who do already have high risk
for cardiac dysfunction. We found in patients with status post Senning or Mustard procedure for
transposition of the great arteries that acute hemodynamic effects of endocardial systemic
ventricular pacing and biventricular pacing were significantly and equally better than those of
non-systemic ventricular pacing (chapter 8). Single-site systemic ventricular pacing and
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biventricular pacing may therefore be preferred for chronic application of ventricular pacing, not
only in patients with a systemic left ventricle, but also in those with a systemic right ventricle.
Why systemic ventricular pacing is superior over non-systemic ventricular pacing 
We postulate that, above and beyond synchrony, the sequence of electrical activation is a major
determinant of cardiac pump function.80, 81 During LV free wall pacing in patients with isolated AV
block, the prolonged duration of total activation is comparable with the delay during RV pacing, as
reflected by a similar prolongation of the QRS duration.60 However, during LV pacing, the LV lateral
wall is activated prior to the septum and RV lateral wall, preventing the septum from paradoxical
movements and resulting in superior hemodynamic performance as compared to RV pacing.82 Left
ventricular apical pacing induces a physiological apex-to-base sequence of activation that results in
synchronous electrical activation and contraction at the circumferential level of the LV.83, 84
Compared with other RV and LV sites, LV apical pacing preserves septal to lateral LV synchrony and
systolic function.63, 64, 85 Our findings in patients with a systemic RV, that both systemic ventricular
pacing and BiV pacing are equally superior to non-systemic ventricular pacing in terms of acute
hemodynamics, again indicate that the sequence of activation is important, rather than avoidance
of asynchronous electrical activation in general. With regard to the activation sequence, all data
point towards the idea that the electrical impulse should start at the chamber with the higher
developed pressure, irrespective of its morphology. This also indicates that mechanical interaction
between the chambers is a major determinant of the hemodynamic effect of ventricular pacing.
Furthermore, optimal single-site pacing may be at least as good as BiV pacing.
Practical considerations with respect to optimal pacing
In patients with (complex) congenital heart defects, restrictions in lead placement could be
introduced by anatomy, prior surgery or scarred myocardium. In older children and adult
patients, leads are often transvenously inserted and endocardially positioned at the apex or
septum of the non-systemic ventricle, because it is technically safe, fast, and reliable. In neonates
and small children, most centers preferably use epicardial lead placement by a surgical approach.
Epicardial lead placement is also preferred in children with an open connection to the systemic
ventricle, because in this condition the presence of endocardial leads increases the risk of
cerebrovascular accidents by embolism. Since possibly successful alternative RV pacing sites
require a transvenous approach for lead implantation, these sites are probably not feasible in
small children. For the purpose of single-site LV pacing, the epicardial LV apex or, alternatively,
the LV free wall can easily be approached through a (limited) sternotomy, sub-xiphoidal incision
or left lateral thoracotomy,86 with good lead stability and pacing performance, as well as
excellent cosmetic results. In larger children and adults, in whom a transvenous approach may be
preferred, single-site LV and BiV pacing may also be achieved by implantation via the coronary
sinus, though for single-site LV pacing it is recommended to position the ventricular lead as far
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to the apex as possible (chapter 5).59, 60 A major practical advantage of single-site pacing,
compared with BiV pacing, is that only one ventricular lead is needed. This will prolong battery
longevity and reduce potential vascular problems and lead-associated complications. Because
every (re)placement of either a lead or generator comes with risks of complications, the number
of replacements should be minimized, especially in children, since they have a perspective of life-
long pacing. Thus, single-lead pacing should be seriously considered. 
Given the absence of a consistent correlation between cardiac function and paced QRS duration
in acute and chronic pacing studies, we discourage the use of QRS duration as a tool for the
selection of an optimal epicardial pacing site in children.59, 60, 87, 88 A better approach in this
respect may be the use of the pattern of activation assessed by non-invasive epicardial
electrocardiographic imaging,89, 90 although the optimal activation pattern for the diverse
anatomical substrates is not known yet. Therefore, and since the intention of optimal-site pacing
is to preserve cardiac function, it may be even better to assess pump function by either
(noninvasive) hemodynamic or echocardiographic measurements while pacing from various
pacing sites, and implant the lead at the site where pacing results in the best pump function.
FUTURE PERSPECTIVES IN THE PREVENTION OF PACING-INDUCED CARDIAC
DETERIORATION
Increase of the level of evidence
Our studies investigating the effect of pacing-site on LV systolic function (chapters 5-7) have shown
that LV pacing is superior to RV pacing in patients with isolated AV block, and that none of the LV-
paced patients was in heart failure.60, 62, 64 Although pacing-duration in our multi-center study was
reasonably long (about 5 years), future studies with very long-term longitudinal follow-up and larger
numbers of LV-paced patients are needed to demonstrate that LV pacing indeed preserves LV systolic
function and prevents pacing-induced heart failure. Additionally, the effect of pacing-site on
parameters other than LV function should be explored. Furthermore, since functional improvement
and reverse remodeling in patients with LV dysfunction following chronic RV pacing have been
reported for both LV single-site pacing53, 54 and BiV pacing,50, 51 it should be investigated whether
or not a clinically relevant difference exists in effect of these pacing-therapies in the treatment of
pacing-induced heart failure. Randomized controlled trials are the most rigorous way of determining
whether a cause-effect relation exists between treatment and outcome. However, practical concerns
such as the relatively low incidence of isolated complete AV block and high number of patients
needed for statistical power, limits controlled randomization. Therefore, controlled randomization
seems not the most feasible design for future studies to compare long-term effects of various pacing
therapies in children. Moreover, at the current level of evidence, it may be debated whether it would
be ethical to randomly apply epicardial RV and LV pacing.
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Differentiation between left ventricular pacing sites: apex versus base. 
It is of clinical importance, once LV epicardial pacing-sites will be more often applied, to know
which site, apex or free wall, should be preferred. Left ventricular apical pacing induces a
physiological apex-to-base sequence of activation, which results in synchronous electrical
activation and contraction at the circumferential level of the LV and seems to preserve septal to
lateral LV synchrony and systolic function.83-85 In the small dog experiment with paired
comparison of LV pacing-sites, described in the ‘discussion’ of chapter 5, the hemodynamic
benefit of LV pacing gradually decreased as compared to LV apical pacing when pacing was
applied at sites closer to the base of the LV free wall.59, 60 A similar trend was observed in the
population of the multi-center survey described in chapters 6 and 7 (Figure 2). These data
suggest that the apex of the LV is indeed the optimal site for ventricular pacing. However, the
optimal site is not always the “preferred site” for chronic ventricular pacing when practical
aspects, such as established minimal surgical techniques, are concerned. Pacing at epicardial LV
mid lateral wall sites, easily accessible through a left lateral thoracotomy, also resulted in good LV
function and may clinically be not inferior to LV apical pacing. It should be further investigated
whether or not there are clinically relevant differences between the various pacing-sites at the LV.
To facilitate the application of “optimal site pacing” in clinical practice, it would be helpful when
a range of functionally “preferred pacing sites” could be defined. 
Endocardial and leadless pacing 
Recent studies in animals and adult patients suggest that, for comparable LV sites, endocardial
pacing may even be better than epicardial pacing.29, 91, 92 One difficulty of endocardial pacing
lies in access to the cavity of the systemic ventricle. So far, in patients with normal biventricular
anatomy, most endocardial leads have been placed with a transseptal approach that accesses the
LV cavity passing from the right atrium through the left atrium. Secondly, the presence of a lead
in the systemic ventricle increases the risk of cerebro-vascular accidents by embolism. Recently,
leadless pacing with the use of ultrasound-mediated energy to a receiver electrode has been
proposed and has already been demonstrated in animals and humans in acute studies.93, 94
Another proposed approach is to use magnetic induction.95 By the use of a “wireless” electrode,
implanted via a trans-aortic access, pacing from any of the diverse endocardial sites in the
systemic ventricle could be achieved. Besides the possible functional advantages of leadless
pacing, elimination of the lead would also exclude lead complications, which nowadays are still
common, especially in growing children.
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CONCLUSIONS AND SUGGESTIONS FOR OPTIMAL PACING
“primum non nocere”; first do not harm
Children are generally paced from a very early age and typically have a perspective of life-long
pacing. Recognizing the adverse effects of dyssynchrony, treatment, or, preferably, prevention of
pacing-induced dyssynchrony, must take high priority in these patients. Concerning preservation
and restoration of pump function, both BiV pacing and single-site systemic ventricular pacing
seem promising in the young. Here raises the question whether or not such pacing therapies
should be applied in all children with an indication for chronic ventricular pacing. When choosing
the optimal pacemaker therapy and pacing-site for the individual patient, one should
discriminate between pacing approaches aiming at the prevention of dyssynchrony and the ones
that resynchronize (treat dyssynchrony). Additionally, practical and functional rationales for
ventricular lead positions should be taken into account.
Optimal pacing in patients with or without structural congenital heart disease
Based on the (patho)physiological background of ventricular pacing, on the current knowledge
regarding the various pacing-sites, as well as on clinical and practical aspects, some
recommendations and suggestions are given for pacing in both patients with normal cardiac
anatomy and patients with structural heart defects. These suggestions are also schematically
displayed in Figure 3A and B, respectively.96
For chronic ventricular pacing in patients with normal biventricular anatomy these suggestions
are the following (Figure 3A); first of all, because by definition, ventricular pacing alters the
physiological pattern of electrical activation, ventricular pacing should be avoided (or minimized)
in patients with (partially) preserved AV conduction and intact His-Purkinje system, such as Sick
Sinus Syndrome.97, 98 In patients with chronic ventricular pacing for surgically induced AV block,
the existence of underlying ventricular rhythm by re-established AV conduction should be
regularly checked, as very late recovery of AV conduction is known to occur.99 In children with
structurally normal hearts without intrinsic dyssynchrony, we advocate the use of single LV apex
and LV free wall sites as the preferred sites for (‘de novo’) chronic ventricular pacing for AV block
(chapters 5-7), especially if a surgical approach is also practically advised.60-62, 64, 100 It is
recommended to preferably avoid pacing from the RV free wall, both endocardially and
epicardially.63, 101 However, in young adults receiving a first pacing system or having a system
replacement, the routine transvenous approach seems justifiable in the context of practical
aspects, because RV apical pacing is well tolerated by most patients.102, 103
General Discussion
163
Chapter 9
164
Figure 3. Recommendations for optimal pacing; a schematic overview
AV block = atrioventricular block; BiV = biventricular = RVx (or RVfw) + LVfw; LBBB = left bundle branch
block; LV = left ventricle/ventricular; LVfw = LV free wall; LVx = LV apex; RBBB = right bundle branch block;
RV = right ventricle/ventricular; RVfw = RV free wall; RVOTsept = the inferior part of the septal side of the
RV outflow tract; RVx = RV apex. (From van Geldorp et al. Heart Fail Rev 2011., with permission)96
A
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B
In children with abnormal cardiac anatomy, influences of different pacing-sites on cardiac function
are less well known. Based on rationale and recent research (chapter 8), we suggest implantation
of the lead for chronic ventricular pacing preferably at the systemic ventricle (Figure 3B). However,
in patients with abnormal cardiac anatomy, it may currently be more correct to investigate various
pacing-sites for their effects on electrical activation and cardiac function, and to implant the
electrode at the site associated with optimal electrical activation pattern and cardiac function.
In general, in the absence of intrinsic dyssynchrony, the systemic ventricle offers the sites where
pacing results in least mechanical dyssynchrony and best cardiac function and should therefore
be considered when chronic ventricular pacing is indicated. Both single-site LV pacing and BiV
pacing may induce reversal of remodeling and reversal of the impaired LV function in
deteriorated hearts after pacing. Changing the site of pacing to either BiV or single-site pacing
at the systemic ventricle should be considered as soon as echocardiography reveals signs of
ventricular dilatation or dysfunction. Regular echocardiographic checkup is therefore warranted
in all (pediatric) patients with pacemaker therapy, and especially in children who are paced at the
non-systemic ventricle. 
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SUMMARY
Improving ventricular pacing in adults and children to treat or to avoid
dyssynchrony-induced cardiac failure
The rationales for the general aim and the studies presented in this thesis are introduced in
chapter 1 and further elucidated in chapter 2. The common background of the research
presented in this thesis is that disturbances in the physiological pattern of electrical ventricular
activation, either due to a partially disrupted conduction system or by pacing of the ventricle, may
be accompanied by dyssynchronous contraction of the left ventricular (LV) myocardium. Both
intrinsic left bundle branch block and conventional right ventricular (RV) pacing are associated
with functional impairment and structural remodeling of the LV, as well as with an increased risk
for heart failure. 
Cardiac resynchronization therapy (CRT) by means of biventricular (BiV) pacing is on
average beneficial in patients with severe LV dysfunction and severe clinical heart failure
associated with either intrinsic or pacing-induced dyssynchrony. However, the individual response
to CRT varies widely between patients, with inadequate response in 30-50% of the patients
receiving CRT. Our research on optimization of CRT in adult patients to improve treatment of
dyssynchrony-induced cardiac failure is presented in chapters 3 and 4.
In patients with congenital or acquired complete atrioventricular (AV) block, ventricular
pacing is indicated when the intrinsic rhythm of the ventricles is inadequate. The awareness of
the potentially deleterious effects of conventional RV pacing has initiated the search for
alternative approaches for chronic ventricular pacing. The general objective of the studies
presented in chapters 5-8 was to define better pacing strategies in the young, aiming at
prevention of pacing-induced cardiac deterioration. 
Upgrade to biventricular pacing may also be considered in chronically paced
patients with relatively mild cardiomyopathy
By restoration of a more coordinated contraction pattern, CRT aims to reverse the deleterious
effects that may originate from LV dyssynchrony. It seems therefore reasonable to suppose that
all patients with LV dyssynchrony may benefit from resynchronization, irrespective of the level of
heart failure or etiology of dyssynchrony. In the study presented in chapter 3, we compared the
effects of BiV pacing and RV pacing in previously chronically RV paced patients with relatively
mild cardiomyopathy (LV ejection fraction 36±10%) and, hence, no established indication for
CRT. Biventricular pacing resulted in better LV function, less LV dilatation and less clinical
symptoms. Furthermore, the response to BiV pacing did not correlate to the severity of either LV
dysfunction or LV remodeling. Hence, upgrade to BiV pacing should be considered in chronically
paced patients with relatively mild cardiomyopathy, in whom it may serve to prevent rather than
to treat heart failure.
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In the optimization of cardiac resynchronization, assessment of stroke volume
changes using a non-invasive arterial pulse contour technique is promising
Hemodynamic and long-term benefits brought by CRT may be improved by tailoring of device-
settings to the individual patient. However, procedures to optimize device-settings, as well as
measurements to guide these optimization procedures, are still under debate. We sought for a
patient-friendly non-invasive measurement to guide optimization procedures. Nexfin CO-Trek®
(BMEYE B.V., Amsterdam, Netherlands) is such a non-invasive system, as it uses a finger-cuff with
an arterial pulse contour technique for continuous measurement of stroke volume. In the study
presented in chapter 4, we investigated the accuracy and feasibility of this non-invasive arterial
pulse contour technique in optimization of AV delay in CRT, through comparisons with echo
Doppler aortic velocity-time integral at 1) the measurement of beat-to-beat stroke volume
changes, 2) the assessment of relative effects of CRT at various AV delays, and 3) the
determination of an optimal AV delay. Nexfin CO-Trek® had a good precision at all three points.
Therefore, and because of its easy and patient-friendly use, we judged the non-invasive arterial
pulse contour technique as a promising tool to evaluate hemodynamic changes for individualized
optimization of CRT. 
In children with isolated atrioventricular block, chronic left ventricular pacing, as
compared with right ventricular pacing, results in a better left ventricular function 
Given the acute beneficial hemodynamic effects of single-site LV pacing shown by earlier studies
of our group, we investigated whether chronic LV pacing is superior to RV pacing in children with
AV block and structurally normal hearts. In chapter 5, a small study is presented in which we
retrospectively evaluated echocardiographic data on LV function from healthy children (control
subjects) and from children with isolated AV block undergoing chronic epicardial pacing at either
the RV or LV. After chronic LV pacing, LV diameter, geometry and function (fractional shortening)
were at the level of healthy children, whereas chronic RV pacing was associated with a decrease
in LV fractional shortening and a higher LV systolic eccentricity index.
Subsequently, we evaluated long-term influences of chronic ventricular pacing in children
with isolated AV block in a large observational multi-center study, carried out at 27 centers. In this
study, presented in chapter 6, we retrospectively investigated the impact of ventricular pacing site
on LV function in almost 300 children with permanent ventricular pacing for isolated AV block.
The results indicated that the site of pacing is an important determinant of LV function, with LV
fractional shortening being significantly higher in children with chronic LV pacing than in children
with chronic RV pacing. Furthermore, LV fractional shortening was subnormal (<28%) in 14% of
the RV-paced children, whereas it was normal in all LV-paced children.
The retrospective nature of our gathered data, however, limited the evaluation to the
measurement of LV shortening fraction. The purpose of the cross-sectional multi-center study
presented in chapter 7 was therefore to evaluate the influence of different ventricular pacing
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sites on long-term LV function and synchrony in children with isolated AV block, using cross-
sectional assessment of multiple echocardiography parameters of LV function and dyssynchrony.
Echocardiography data of 178 chronically paced children from 21 centers were systematically
analyzed in a core lab. Left ventricular synchrony, pump function and contraction efficiency were
significantly affected by pacing site and were best in children paced at the LV apex or lateral wall.
Pacing from the RV free wall was related with decreased LV function, whereas LV apical and LV
lateral wall pacing were associated with preserved LV function. In both the retrospective and
cross-sectional evaluation, age at implantation, pre-implantation LV size and function, duration
of pacing, DDD mode, QRS duration and presence of maternal auto-antibodies had no
significant impact on long-term outcomes.
Patients with a systemic right ventricle may benefit from single-site systemic
ventricular pacing or biventricular pacing
The study presented in chapter 8 concerns ventricular pacing in patients in whom the RV
instead of the LV supports the systemic circulation. In these patients, having a high risk for
dysfunction of the systemic ventricle, conventional non-systemic ventricular pacing (i.e. LV pacing
in these patients) may even further increase the risk to develop RV dysfunction. In our study
population of nine patients with a transposition of the great arteries treated by atrial redirection
surgery (Senning or Mustard procedure), acute hemodynamic effects of endocardial systemic
ventricular pacing and BiV pacing were significantly and equally better than those of non-
systemic ventricular pacing. As such, systemic ventricular pacing and BiV pacing may avoid
additional pacing-induced risk for cardiac failure in patients with a systemic RV, and may
therefore be the preferred strategies for chronic ventricular pacing in these patients.
In the last chapter of this thesis (chapter 9), the findings of above-mentioned studies are linked
and put in broader perspective. Discussions are accompanied by recommendations for ‘optimal
pacing’ and suggestions for related future research.
Cardiac resynchronization therapy can be improved by better patient
selection and more reliable optimization protocols 
The first part of the general discussion concerns optimization of CRT. On the one hand CRT
might be reserved to a select subgroup of patients complying with current guidelines. On the
other hand, since it may prevent or slow the progression to severe heart failure, the application
of CRT might also be expanded to patients with only mild cardiomyopathy associated with
dyssynchrony. However, complication rate and unnecessary costs are important issues in a mildly
symptomatic patient cohort and make (upgrade to) BiV pacing in every patient with a
conventional pacemaker indication or an intrinsic LBBB unfavorable. Until now, neither the long-
term effect of (pacing-induced) dyssynchrony, nor the response to CRT can be predicted for the
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individual patient. The application of BiV pacing may better be limited to patients presenting
overt echocardiographic signs of remodeling or deterioration of LV function. This recommen-
dation is supported by the observation that adverse remodelling may be reversed by BiV pacing.
The method of optimization and its accuracy seem to be of critical importance for the
reliability of the outcome of CRT-optimization. Variability of measurements used (the sum of
biological and technical variability) is in the same range as the size of the effect to be measured.
This implies that simply selecting the setting at which the highest single value is measured, is not
the optimal approach to maximize the individual benefit of CRT. To decrease the impact of
inevitable biological and measurement variability, multiple measurements should be taken and
averaged for each device setting. Prospective, randomized studies, using adequate optimization
protocols, are needed to clarify the real clinical impact of individual optimization on the patient’s
course.
“Primum non nocere”: optimal-site pacing may prevent pacing-induced
cardiac dysfunction 
In the second part of the general discussion, several sites for chronic ventricular pacing are
reviewed and clinical implications of these sites are discussed. Based on rationale and research,
we suggest implantation of the lead for chronic ventricular pacing at the systemic ventricle,
especially so when a surgical approach is also practically advised. Future studies with very long-
term longitudinal follow-up and parameters other than those for systemic ventricular function
are needed to investigate the hypothesis that systemic ventricular pacing indeed prevents
pacing-induced heart failure. To facilitate the application of “optimal-site pacing” in clinical
practice, it would be helpful when a range of functionally preferred pacing sites could be
defined. It should therefore be investigated whether or not clinically relevant differences exist
between pacing at different sites of the systemic ventricle. Future studies are also needed to
investigate whether the difference between single-site systemic ventricular pacing and
biventricular pacing is clinically relevant. 
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SAMENVATTING
Verbeteren van ventriculaire pacemakertherapie bij volwassenen en kinderen
ter behandeling of voorkoming van hartfalen geïnduceerd door
dyssynchronie 
De motieven voor bovengenoemde algemene intentie van het proefschrift en de daarin
beschreven studies worden kort uiteengezet in hoofdstuk 1 en verder onderbouwd in
hoofdstuk 2. De gemeenschappelijke achtergrond van het in dit proefschrift beschreven
onderzoek betreft het feit dat een abnormaal elektrisch activatiepatroon van het hart kan
samengaan met een slecht gecoördineerde, dyssynchrone samentrekking van het linker ventrikel
(LV). Een abnormaal activatiepatroon kan niet alleen veroorzaakt worden door een gedeeltelijke
onderbreking van het speciale elektrische geleidingssysteem, maar ook door kunstmatige
elektrische stimulatie met behulp van een pacemaker. Zowel elektrisch stimuleren (i.e., pacen)
van het rechter ventrikel (RV) als een onderbreking van het geleidingssysteem naar het LV,
oftewel een linker bundeltakblok, zijn zowel geassocieerd met functionele achteruitgang en
structureel remodelleren van het hart, alsook met een verhoogd risico op hartfalen. 
Biventriculair (BiV) pacen, het kunstmatig stimuleren van beide ventrikels, kan de synchronie
tussen beide ventrikels herstellen. Deze zogenoemde cardiale resynchronisatietherapie (CRT) is
effectief gebleken in patiënten met ernstige dysfunctie van het LV geassocieerd met intrinsieke
dyssynchronie of met door pacen geïnduceerde dyssynchronie. De individuele respons op CRT
varieert echter in grote mate, hetgeen blijkt uit het feit dat 30-50% van de patiënten die CRT
krijgen een inadequate respons hebben. Om het behandelingseffect te vergroten zou CRT in
verschillende opzichten verbeterd kunnen worden. Ons onderzoek in relatie tot de optimalisatie
van CRT, met het streven dyssynchronie-geïnduceerd hartfalen in volwassenen te behandelen,
wordt beschreven in de hoofdstukken 3 en 4.
Bij patiënten met een aangeboren of verworven blokkade van de elektrische geleiding
tussen atria en ventrikels, een atrioventriculair (AV) blok, is ventriculair pacen geïndiceerd indien
het spontane ventriculaire ritme te laag is. De bewustwording van de potentieel nadelige effecten
van conventionele RV-stimulatie heeft een zoektocht geïnitieerd naar alternatieve methoden voor
chronisch ventriculair pacen. In de hoofdstukken 5-8 worden de studies gepresenteerd die
betrekking hebben op het streven naar preventie van de functionele en structurele verslechtering
van het hart die geassocieerd is met chronisch pacen in jonge patiënten.
De overstap naar biventriculair pacen zou overwogen kunnen worden bij
chronisch gestimuleerde patiënten met relatief milde cardiomyopatie. 
Cardiale resynchronisatietherapie probeert de negatieve effecten die het gevolg zijn van
dyssynchronie van het LV ongedaan te maken door het bewerkstelligen van een beter
gecoördineerd contractiepatroon. Het lijkt daarom aannemelijk dat alle patiënten met
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dyssynchronie van het LV baat zouden kunnen hebben bij CRT, ongeacht de mate van hartfalen
of de oorsprong van de dyssynchronie. In de studie die wordt gepresenteerd in hoofdstuk 3
hebben we de effecten van BiV-pacen en RV-pacen vergeleken in een groep chronisch RV-
gestimuleerde patiënten die vanwege hun relatief milde cardiomyopathie (LV ejectiefractie
36±10%) buiten de gebruikelijke criteria voor CRT vielen. Biventriculaire stimulatie resulteerde in
een betere LV functie, minder LV dilatatie en minder klinische symptomen dan RV-pacen.
Bovendien leek de respons op BiV-pacen niet gerelateerd aan de ernst van de LV-dysfunctie, noch
aan de mate van de structurele veranderingen van het LV. Bij chronisch RV-gestimuleerde
patiënten met relatief milde cardiomyopathie zou de toepassing van BiV-pacen dus overwogen
kunnen worden, waarbij CRT niet zozeer dient als therapie voor hartfalen maar meer gebruikt
wordt ter preventie van hartfalen.
Voor de optimalisatie van cardiale resynchronisatietherapie kan gebruik
gemaakt worden van non-invasief gemeten contouren van de arteriële drukgolf
Acute en lange-termijn effecten van CRT zouden verder verbeterd kunnen worden door het
afstemmen van de pacemakerinstellingen op de individuele patiënt. Maar zowel de procedures
om de instellingen te optimaliseren, als de parameters die daarbij gebruikt worden, zijn nog
steeds onderwerp van discussie. Bij optimalisatieprocedures heeft een patiëntvriendelijke, non-
invasieve meting de voorkeur. Nexfin CO-Trek® (BMEYE B.V., Amsterdam, Nederland) is een
techniek die veranderingen in het slagvolume kan bepalen uit non-invasief gemeten contouren
van de arteriële drukgolf in de vinger. In hoofdstuk 4 onderzochten we de precisie en de
toepasbaarheid van deze techniek in de optimalisatie van het AV-interval, door het met de
arteriële drukgolfmetingen bepaalde slagvolume op drie manieren te vergelijken met de
snelheid-tijd integraal van de aorta bloedvolumestroom gemeten met echo Doppler; de meting
van slag-tot-slag veranderingen in slagvolume, de bepaling van relatieve effecten van CRT bij
verschillende AV-intervallen, en de vaststelling van een optimaal AV-interval. Nexfin CO-Trek®
had een goede precisie op alle drie niveaus. Daarom, en omdat het een makkelijke en
patiëntvriendelijke methode betreft om hemodynamische veranderingen te evalueren, vinden wij
dat het gebruikmaken van non-invasief gemeten contouren van de arteriële drukgolf in de
vinger veelbelovend is in de individuele optimalisatie van CRT. 
In kinderen met een geïsoleerd atrioventriculair blok resulteert chronisch
links ventriculair pacen, in vergelijking met rechts ventriculair pacen, in een
betere functie van het linker ventrikel
Gezien de gunstige hemodynamische effecten van LV-pacen in de acute situatie die in eerdere
studies van onze groep werden aangetoond, onderzochten we of ook chronisch pacen op het LV
in kinderen met een structureel normaal hart beter is dan RV-pacen. Hoofdstuk 5 betreft een
kleine studie waarin we retrospectief, met behulp van bestaande echocardiografische data, de
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LV-functie evalueerden in kinderen met een compleet AV-blok die chronisch op het LV of RV
gestimuleerd werden. Ook beoordeelden we de LV-functie in een controlegroep met gezonde
kinderen. In kinderen met chronische LV-stimulatie waren de LV-diameter, geometrie en functie
op het niveau van gezonde kinderen, terwijl chronische RV-stimulatie geassocieerd was met een
verminderde verkortingsfractie van het LV en een hogere systolische wandspanning van het LV. 
Vervolgens evalueerden we de effecten van chronisch ventriculair pacen in kinderen met
een geïsoleerd AV-blok in een grote, in 27 centra uitgevoerde, observationele studie. In deze in
hoofdstuk 6 beschreven multicenter studie werd het belang van de paceplaats op LV-functie
retrospectief onderzocht in bijna 300 kinderen met chronisch ventriculair pacen voor een
geïsoleerd AV-blok. De resultaten van deze studie lieten zien dat de plaats waar gestimuleerd
wordt een belangrijke invloed heeft op LV-functie, met een significant betere functie in kinderen
met chronisch LV-pacen dan in kinderen met chronisch RV-pacen. Verder bleek dat de
verkortingsfractie van het LV in 14% van de kinderen met RV-pacen subnormaal (<28%) was,
terwijl deze goed was in alle kinderen met LV-pacen.
Door het retrospectieve karakter van de studie waren vooral echografische data
voorhanden waarmee de verkortingsfractie van het LV bepaald kon worden. Derhalve werd de
multicenter studie die wordt gepresenteerd in hoofdstuk 7, zo opgezet dat middels een cross-
sectionele echocardiografische evaluatie meerdere parameters van LV-functie en dyssynchronie
bepaald konden worden. Daarmee onderzochten we in kinderen met een geïsoleerd AV-blok de
lange-termijn invloed van de paceplaats op de functie, synchronie en effectiviteit in contractie
van het LV. Echocardiografische data van 178 chronisch gestimuleerde kinderen van 21 centra
werden systematisch geanalyseerd in één laboratorium. Synchronie, pompfunctie en effectiviteit
in contractie van het LV werden significant beïnvloed door paceplaats en waren het best in
kinderen die werden gestimuleerd op de apex of laterale wand van het LV. Pacen van de vrije
wand van het RV was sterk geassocieerd met een verminderde functie, terwijl pacen van de apex
en vrije wand van het LV geassocieerd was met intacte LV-functie. Zowel in de retrospectieve als
in de cross-sectionele evaluatie hadden leeftijd bij implantatie, grootte en functie van het LV vóór
implantatie, duur van pacen, manier van pacen (DDD-mode), QRS-duur en aanwezigheid van
maternale auto-antistoffen, geen significante impact op lange termijn uitkomsten. 
Patiënten met een systemische rechter ventrikel zouden profijt kunnen
hebben van systemisch ventriculair of biventriculair pacen
De studie die in hoofdstuk 8 wordt gepresenteerd, heeft betrekking op pacen in patiënten met
een ondersteuning van de systemische circulatie door het RV, in plaats van het LV. Bij deze
patiënten, die sowieso een verhoogd risico hebben op dysfunctie van het systemische RV, kan LV-
pacen (i.e., non-systemisch ventriculair pacen) het risico op RV-dysfunctie verder vergroten. In
onze studiepopulatie van negen patiënten met een transpositie van de grote vaten behandeld
met atriale redirectionele chirurgie (procedure volgens Senning of Mustard), waren de acute
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hemodynamische effecten van endocardiaal systemisch ventriculair en BiV-pacen significant
beter dan die van endocardiaal non-systemisch ventriculair pacen. Daarom zou in patiënten met
een systemische RV het additionele risico voor hartfalen dat wordt geïnduceerd door pacen,
mogelijk voorkomen kunnen worden door systemisch ventriculair of BiV te pacen. 
In het laatste hoofdstuk van dit proefschrift (hoodstuk 9) worden de bevindingen van
bovengenoemde studies met elkaar verbonden en in een breder perspectief geplaatst. Discussies
worden vergezeld door aanbevelingen voor de beste strategie voor pacen en door suggesties
voor gerelateerd toekomstig onderzoek.
Cardiale resynchronisatietherapie kan verbeterd worden door betere
patiëntselectie en door betrouwbaardere optimalisatieprotocollen
Het eerste deel van de algemene discussie behandelt de optimalisatie van CRT. Aan de ene kant
zou CRT gereserveerd dienen te blijven voor een selecte subgroep van patiënten die voldoen aan
de richtlijnen. Maar aangezien CRT de progressie naar ernstig hartfalen zou kunnen voorkomen
of vertragen, zou aan de andere kant de toepassing van CRT misschien uitgebreid moeten
worden naar patiënten met slechts milde dyssynchronie-geassocieerde cardiomyopathie. In een
mild symptomatische patiëntengroep zijn het risico op complicaties en onnodige kosten echter
belangrijke aspecten die het niet wenselijk maken om BiV-pacen toe te passen in iedere
individuele patiënt met een indicatie voor conventioneel pacen of een intrinsiek linker
bundeltakblok. Tot nu toe zijn noch de lange termijn effecten van dyssynchronie, noch de
respons op CRT voor de individuele patiënt te voorspellen. Daarom, en omdat de negatieve
effecten van dyssynchronie (deels) omkeerbaar zijn, zou de toepassing van BiV-pacen vooralsnog
het beste gereserveerd kunnen worden voor patiënten die zich presenteren met duidelijke
tekenen van remodelleren of dysfunctie van het LV. 
Voor de betrouwbaarheid van de uitkomst van de optimalisatie van CRT lijken de
optimalisatiemethode en zijn precisie van kritisch belang. De variabiliteit in de gebruikte
metingen (de som van biologische en technische variabiliteit) is in dezelfde orde van grootte als
het effect dat gemeten moet worden. Dit houdt in dat het eenvoudig selecteren van de instelling
waarbij de beste waarde gemeten wordt niet de optimale aanpak is om het individuele voordeel
van CRT te maximaliseren. Om het effect van onvermijdbare biologische variabiliteit en
meetfouten te verminderen zouden voor iedere instelling meerdere metingen moeten worden
gedaan en worden gemiddeld. Prospectieve gerandomiseerde studies die gebruik maken van
adequate optimalisatieprotocollen die aan bovengenoemde voorwaarde voldoen, zijn nodig om
de daadwerkelijke klinische impact van CRT-optimalisatie te bepalen.
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“Primum non nocere”; pacen op de optimale paceplaats zou pacen-
geïnduceerd hartfalen kunnen voorkomen 
In het tweede deel van de algemene discussie worden verschillende locaties voor chronisch
ventriculair pacen besproken en worden de klinische implicaties van deze locaties bediscussieerd.
Uitgaand van logica en de uitkomsten van wetenschappelijk onderzoek, adviseren wij om voor
de toepassing van chronisch ventriculaire stimulatie de pacemakerdraad te implanteren op de
systemische ventrikel. Dit advies geldt vooral indien een chirurgische benadering ook om
praktische redenen wordt geadviseerd. Om de veronderstelling te onderzoeken dat stimulatie
van het systemische ventrikel pacen-geïnduceerd hartfalen kan voorkomen, zijn vervolg studies
nodig met langere follow-up en andere parameters dan alleen die voor de functie van de
systemische ventrikel. Om de klinische toepasbaarheid van pacen op de optimale paceplaats te
vergroten, zou het van voordeel zijn als een groter gebied van functioneel te prefereren
paceplaatsen gedefinieerd zou kunnen worden. Het zou daarom onderzocht moeten worden of
er klinisch-relevante verschillen bestaan tussen stimulatie van verschillende paceplaatsen op het
systemische ventrikel. Ook zijn er toekomstige studies nodig om te onderzoeken of het verschil
tussen biventriculair pacen en pacen op een enkele paceplaats op het systemische ventrikel
klinisch relevant is.
Samenvatting
189

D
an
kw
o
o
rd
 &
 A
ck
n
o
w
le
d
g
em
en
ts
Dankwoord & Acknowledgements
192
Dit proefschrift is tot stand gekomen mede door de inspanningen en kennis, en bovendien het
enthousiasme, van vele anderen. Ik ben iedereen die in welke vorm dan ook heeft bijgedragen
aan dit werk, heel erg dankbaar. 
Graag wil ik allereerst nadrukkelijke dank uit laten gaan naar die mensen zonder wie dit
proefschrift niet had kunnen bestaan.
Mijn promotores prof.dr. Tammo Delhaas en prof.dr. Frits W. Prinzen wil ik graag heel
hartelijk bedanken voor hun onvoorwaardelijke en onuitputtelijke inzet om me te begeleiden in
mijn werk en me op te leiden tot een kritisch, nauwkeurig en veelzijdig onderzoeker. Beste
Tammo en Frits, ik zie het als groot geluk dat ik in de afronding van de studie Geneeskunde bij
jullie terecht ben gekomen voor de invulling van mijn wetenschappelijke stage. Naast mijn eigen
interesse in de kindercardiologie, zijn vooral jullie enthousiasme en de ongedwongen sfeer die
uitging van besprekingen met jullie, motiverend geweest om de stage te vervolgen met een
promotietraject. In dit traject hebben jullie het beste begeleiders-duo gevormd dat ik me had
kunnen wensen! 
Mijn derde promotor, prof.dr. Jan Janousek (University Hospital Motol, Prague) ben ik zeer
erkentelijk voor een prettige en inspirerende samenwerking met betrekking tot een zeer
aanzienlijk deel van dit proefschrift. Dear Jan, I thank you for our successful collaboration, which
has been very inspiring to me. I look forward to working together in the future. I’m very
honoured that you are one of my promotores.
Prof.dr. U. Schotten, prof.dr.ir. T. Arts, prof.dr. N. Blom, prof.dr. H.P. Brunner-La Rocca en
prof.dr. L.J.I. Zimmermann, leden van de beoordelingscommissie, wil ik graag hartelijk
bedanken voor de kritische beoordeling van mijn proefschrift. 
Prof.dr. H.J.G.M. Crijns, is steeds zeer betrokken geweest bij de totstandkoming van mijn
proefschrift. Beste prof. Crijns, bedankt voor het in mij en mijn promotores gestelde vertrouwen,
de praktische steun, de waardevolle feedback op de manuscripten van onze studies, en de
getoonde interesse. 
Dr. W.Y.R. Vanagt was vanaf mijn eerste schreden in de wetenschappelijke wereld een
voorbeeld en coach. Beste Ward, bedankt voor alle uitleg, praktische hulp en emotionele steun
die je me de afgelopen jaren in mijn promotietraject hebt geboden. Dat ons beider werk
“bekroond” werd met een ‘Dr. E. Dekker beurs’ van de Nederlandse Hartstichting was het
summum. Ik hoop dat we de komende jaren nog veel zullen samenwerken en dat ik daarbij nog
veel van je mag leren!
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Prof.dr. U. Bauersfeld† en dr. M. Tomaske (University Children’s Hospital, Zürich), ben ik veel
dank verschuldigd voor hun gastvrijheid in Zürich tijdens het eerste deel van mijn
wetenschappelijke stage en voor de verdere samenwerking die resulteerde in mijn eerste
wetenschappelijke publicatie (hoofdstuk 5). Dear Maren, I’m thankful for your hospitality and
your collaboration in my first scientific project, as well as for your contribution to our multi-
center studies on ventricular pacing in children.
Dr. K. Vernooy en dr. B. Dijkman wil ik bedanken voor het bieden van een lopend project (de
“rijdende BiV-RV trein”, hoofdstuk 3) waar ik in mocht stappen. Daarmee kon ik reeds aan het
begin van mijn promotietraject aan de slag met de analyses van eerder verzamelde data. 
Prof.dr. A. Auricchio (Fondazione Cardiocentro Ticino, Lugano), dr.ir. J. Settels (BMEYE B.V.,
Amsterdam), dr. R. Cornelussen en dr. B. Gerritse (Medtronic Bakken Research Center,
Maastricht) en drs. B. Broers, wil ik bedanken voor de enorme inspanningen voor onze
zogenaamde ‘Nexfin-studie’ (hoofdstuk 4). De intensieve brainstormsessies en discussies die
gepaard gingen met deze studie, zijn steeds weer inspirerend en leerzaam geweest. Caro
Angelo, I would like to thank you and your colleagues for the collaboration on the Nexfin-
project. Moreover, our meetings at several international conferences were inspiring to me. I’m
honoured with your participation in the corona. Beste Jos, bedankt voor je praktische en
wetenschappelijke input. Beste Richard, bedankt voor je betrokkenheid en het in contact
brengen met de juiste mensen. Beste Bart, bedankt voor je statistische adviezen. Beste Bernard,
zowel het enthousiasme waarmee jij patiënten wist te motiveren mee te doen, als je eindeloze
echografische inspanningen voor deze studie verdienen hier een eervolle vermelding. 
Dr. D. Francis en dr. Z.I. Whinnett (St. Mary’s Hospital and Imperial College, London) ben ik
dankbaar voor de tips-‘n-tricks met betrekking tot CRT-optimalisatie. Dear Darrel, I would like to
thank you for the inspiring (email)-discussions on “how (not) to optimize CRT”. Dear Zach, ‘un
grand merci’ for your help and enthusiasm in Bordeaux. 
Dr. J.B. Thambo, dr. P. Bordachar, prof.dr. M. Haïssaguerre, drs. Ph. Ritter, drs. X. Iriart,
drs. M. de Guillebon et collègues, de l’Hôpital Cardiologique du Haut-Lévêque, (Pessac-
Bordeaux) ben ik zeer dankbaar voor hun gastvrijheid en hun enthousiasme om een jaar lang
samen te werken aan het project waarvoor ik de beurs van de Nederlandse Hartstichting
ontving. Je vous remercie de m’avoir accordée votre confiance en m’offrant l’opportunité de
faire mes travaux de recherche chez vous. Merci de votre soutien. J’ai eu un grand plaisir à
travailler à vos côtés et de profiter de votre savoir.
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Alle coauteurs van de multi-center studies (hoofdstukken 6 en 7) ben ik zeer erkentelijk voor
hun bijdragen. We could never have gathered so many data without the enthusiastic (financially
unrewarded) participation of so many colleagues from all over the world. Their efforts for
collecting data as well as their constructive feedback to the manuscripts are very much
appreciated.
Alle patiënten die hebben geparticipeerd in de studies beschreven in dit proefschrift ben ik veel
dank verschuldigd.  
De Nederlandse Hartstichting ben ik zeer erkentelijk voor de ‘Dr. E. Dekker beurs’ voor
kindercardiologisch onderzoeker, die ik ontving voor de uitvoering van de studie naar de effecten
van ventriculair pacen in jongvolwassenen met een systemische rechter ventrikel (hoofdstuk 8).
Dit project is in veel opzichten verrijkend geweest voor mijn onderzoekstraject.
Zonder goede collegae, vrienden en familie, zou het voor mij niet mogelijk zijn geweest
onderzoek te doen. Daarom wil ik hier graag diegenen noemen die op andere (in)directe wijze
hebben bijgedragen aan de totstandkoming van dit proefschrift.
Alle collegae van de vakgroepen Fysiologie, Biomedische Technologie, en Kinder-
geneeskunde wil ik bedanken voor de getoonde interesse, de kritische inbreng en praktische
hulp, en bovenal voor de bemoedigende woorden en het bieden van de mogelijkheid om
frustraties te delen wanneer dat nodig was. Een speciaal woord van dank aan diegenen met wie
ik de afgelopen jaren het meeste onderzoekslief en -leed heb gedeeld: Joost Lumens en Wilco
Kroon. Beste Wilco en Joost, bedankt voor de grote portie humor die jullie me de afgelopen
jaren hebben gebracht. Ik hoop dat WIJ (i.e., Wilco, Irene, Joost) tot in de verre toekomst nog
vaak met elkaar zullen lachen! Marc Strik, mijn steun en toeverlaat voor de steeds complexer
wordende excel-bestanden en mijn favoriete congresmaatje. Beste Marc, je bent in de afgelopen
jaren een goede vriend geworden. Met jou als paranimf voel ik me gesterkt in alle opzichten!
Daarnaast wil ik jou, en mijn andere kamergenootjes Marloes Gelissen, Ilka Lorenzen-
Schmidt, Caroline van Deursen, Patrick Houthuizen, Sandra Eliautou en Sylvain Ploux
bedanken voor de fijne samenwerking en het delen van vreugdes en frustraties. 
Student Ben Hermans ben ik ook veel dank verschuldigd: zonder zijn MathLab hulp had ik de
Nexfin studie (hoofdstuk 4) wellicht niet tot een goed einde weten te brengen. Onze goede en
leuke samenwerking heeft ertoe bijgedragen dat het doen van onderzoek me ook in die periode
(waarin ‘de flow’ iets minder voortvarend was) voldoening gaf. Ook de samenwerking met de
studenten Michel Janssen, Loes de Vaan en Guusje Vugts heb ik als heel inspirerend ervaren! 
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Zonder vrienden en familie zou ik ongelukkig zijn geweest. Ik ben jullie allen meer dan
dankbaar voor de getoonde interesse in mijn onderzoek, maar vooral voor het doen vergeten
van de onderzoeksperikelen en het samen genieten van het leven. 
Lieve papa en mama, ik ben jullie enorm dankbaar voor het feit dat jullie me van jongs af aan
hebben gestimuleerd om mijn talenten zo goed mogelijk te ontplooien en mijn best te doen om
mijn ‘non-talenten’ te verbeteren. Het heeft me gevormd tot de persoon die ik nu ben, en het
heeft bijgedragen aan alles wat ik tot nu toe heb bereikt. Bedankt voor alle kansen, de steun en
de onvoorwaardelijke liefde die jullie me bieden. 
Lieve Martijn en Marie-Sophie, broer en zusje, ik heb het getroffen met jullie! Een leven
zonder jullie is niet voor te stellen. Lieve Martijn, ik heb groot respect voor jouw
doorzettingsvermogen! Het betekent veel voor me dat je mijn paranimf wil zijn. Lieve Marie-
Sophie, jij bent de enige in ons gezin die niet werkt in de gezondheidszorg, maar zich juist richt
op de uiterlijke verzorging van de mens. Ik vind het mooi dat jij zo anders bent dan ik, omdat je
juist daardoor mijn leven verrijkt! Ik ben trots op je.
Lieve Joost, het is onmogelijk om in woorden uit te drukken wat jij voor mij betekent. De
bijdragen die jij hebt geleverd om mijn promotietraject en -boekje tot een goed einde te
brengen, zijn talloos. Ik ben je daarvoor meer dan dankbaar. Bovenal ben ik blij dat mijn
promotietraject er ook toe heeft geleid dat wij elkaar gevonden hebben. Jij hebt de gave om
altijd, in welke gemoedstoestand ik ook ben, een lach op mijn gezicht te toveren. Mijn wereld is
veel mooier en leuker met jou!
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From 1993 until 1999, she attended secondary education at “Stedelijk Gymnasium” in Breda
where she obtained her Gymnasium diploma. In 1999, she started her medical training at the
Faculty of Health and Life Sciences at Maastricht University. In parallel to her medical training, she
attended courses of psychology and completed a facultative internship in pediatric cardiology at
“Ospedale Bambin’ Gesú” in Rome (Italy), from September 2003 until February 2004. She
became ‘doctorandus’ in Medicine (equivalent of Master of Science) in 2004 and graduated as
Medical Doctor in July 2006. Subsequently, she gained clinical experience in pediatrics at Orbis
Medisch Centrum in Sittard and as of November 2006, she was a resident in pediatrics at
Maastricht University Medical Center. From July 2007 until 2012, she worked as a PhD-student at
Cardiovascular Research Institute Maastricht (Maastricht University) under supervision of prof.dr.
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rewarded with a grant of the Dutch Heart
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